0001126234-18-000140.txt : 20181102 0001126234-18-000140.hdr.sgml : 20181102 20181102170817 ACCESSION NUMBER: 0001126234-18-000140 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181102 DATE AS OF CHANGE: 20181102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEWLINK GENETICS CORP CENTRAL INDEX KEY: 0001126234 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421491350 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35342 FILM NUMBER: 181157948 BUSINESS ADDRESS: STREET 1: 2503 SOUTH LOOP DRIVE STREET 2: SUITE 5100 CITY: AMES STATE: IA ZIP: 50010 BUSINESS PHONE: 515-296-5555 MAIL ADDRESS: STREET 1: 2503 SOUTH LOOP DRIVE STREET 2: SUITE 5100 CITY: AMES STATE: IA ZIP: 50010 10-Q 1 nlnk-20180930.htm 10-Q Document
NEWLINK GENETICS CORP0001126234Accelerated Filer10-Q9/30/20182018Q3falseTRUEFALSE37,224,606--12-310.010.015,000,0005,000,000————0.010.0175,000,00075,000,00037,305,62637,168,12237,216,89237,109,55688,73458,566P3YP3Yfive yearsP5YP5Y2.62.9—76.279.24P7Y10M24D4.908,371,0057,314,00689,053181,3361.3800,000500,00000011262342018-01-012018-09-30xbrli:shares00011262342018-10-30iso4217:USD00011262342018-09-3000011262342017-12-31iso4217:USDxbrli:shares0001126234us-gaap:GrantMember2018-07-012018-09-300001126234us-gaap:GrantMember2017-07-012017-09-300001126234us-gaap:GrantMember2018-01-012018-09-300001126234us-gaap:GrantMember2017-01-012017-09-300001126234us-gaap:LicenseAndServiceMember2018-07-012018-09-300001126234us-gaap:LicenseAndServiceMember2017-07-012017-09-300001126234us-gaap:LicenseAndServiceMember2018-01-012018-09-300001126234us-gaap:LicenseAndServiceMember2017-01-012017-09-3000011262342018-07-012018-09-3000011262342017-07-012017-09-3000011262342017-01-012017-09-300001126234us-gaap:CommonStockMember2017-12-310001126234us-gaap:AdditionalPaidInCapitalMember2017-12-310001126234us-gaap:TreasuryStockMember2017-12-310001126234us-gaap:RetainedEarningsMember2017-12-310001126234us-gaap:AdditionalPaidInCapitalMember2018-01-012018-09-300001126234us-gaap:CommonStockMember2018-01-012018-09-300001126234us-gaap:TreasuryStockMember2018-01-012018-09-300001126234us-gaap:RetainedEarningsMember2018-01-012018-09-300001126234us-gaap:CommonStockMember2018-09-300001126234us-gaap:AdditionalPaidInCapitalMember2018-09-300001126234us-gaap:TreasuryStockMember2018-09-300001126234us-gaap:RetainedEarningsMember2018-09-3000011262342016-12-3100011262342017-09-300001126234us-gaap:IPOMember2011-01-012011-12-310001126234nlnk:FollowOnOfferingMember2013-01-012013-12-310001126234nlnk:ATMOfferingMember2015-01-012015-12-310001126234nlnk:ATMOfferingMember2017-01-012017-12-310001126234nlnk:PublicOfferingMember2017-10-012017-10-3100011262342018-03-122018-03-120001126234nlnk:ATMOfferingMember2018-09-302018-09-300001126234us-gaap:ComputerEquipmentMembersrt:MinimumMember2018-01-012018-09-300001126234us-gaap:ComputerEquipmentMembersrt:MaximumMember2018-01-012018-09-300001126234us-gaap:EquipmentMember2018-01-012018-09-300001126234nlnk:ContractManufacturingOrganizationEquipmentMember2018-01-012018-09-300001126234us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2018-01-0100011262342018-01-010001126234us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2017-12-310001126234us-gaap:AccountingStandardsUpdate201409Memberus-gaap:GrantMemberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2018-07-012018-09-300001126234us-gaap:GrantMemberus-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member2018-07-012018-09-300001126234us-gaap:AccountingStandardsUpdate201409Memberus-gaap:GrantMemberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2018-01-012018-09-300001126234us-gaap:GrantMemberus-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member2018-01-012018-09-300001126234us-gaap:AccountingStandardsUpdate201409Memberus-gaap:LicenseAndServiceMemberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2018-07-012018-09-300001126234us-gaap:LicenseAndServiceMemberus-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member2018-07-012018-09-300001126234us-gaap:AccountingStandardsUpdate201409Memberus-gaap:LicenseAndServiceMemberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2017-01-012017-09-300001126234us-gaap:LicenseAndServiceMemberus-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member2018-01-012018-09-300001126234us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2018-07-012018-09-300001126234us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member2018-07-012018-09-300001126234us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2018-01-012018-09-300001126234us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member2018-01-012018-09-300001126234us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2018-09-300001126234us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2017-12-310001126234nlnk:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2014-01-012014-12-310001126234nlnk:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2018-07-012018-09-300001126234nlnk:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2018-01-012018-09-300001126234nlnk:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2017-07-012017-09-300001126234nlnk:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2017-01-012017-09-300001126234nlnk:MerckSharpeandDohmeCorpMemberus-gaap:CollaborativeArrangementMember2014-12-012014-12-310001126234nlnk:MerckSharpeandDohmeCorpMemberus-gaap:CollaborativeArrangementMember2015-02-012015-02-280001126234us-gaap:LicenseAndServiceMembernlnk:MerckSharpeandDohmeCorpMemberus-gaap:CollaborativeArrangementMember2018-07-012018-09-300001126234us-gaap:LicenseAndServiceMembernlnk:MerckSharpeandDohmeCorpMemberus-gaap:CollaborativeArrangementMember2018-01-012018-09-300001126234us-gaap:LicenseAndServiceMembernlnk:MerckSharpeandDohmeCorpMemberus-gaap:CollaborativeArrangementMember2017-07-012017-09-300001126234us-gaap:LicenseAndServiceMembernlnk:MerckSharpeandDohmeCorpMemberus-gaap:CollaborativeArrangementMember2017-01-012017-09-300001126234nlnk:A2009EquityIncentivePlanMember2018-09-300001126234nlnk:A2009EquityIncentivePlanMember2010-05-152010-05-150001126234nlnk:A2009EquityIncentivePlanMember2011-01-072011-01-070001126234nlnk:A2009EquityIncentivePlanMember2013-01-012013-01-010001126234nlnk:A2009EquityIncentivePlanMember2014-01-012014-01-010001126234nlnk:A2009EquityIncentivePlanMember2015-01-012015-01-010001126234nlnk:A2009EquityIncentivePlanMember2016-01-012016-01-010001126234nlnk:A2009EquityIncentivePlanMember2017-01-012017-01-010001126234nlnk:A2009EquityIncentivePlanMember2018-01-012018-01-01xbrli:pure0001126234nlnk:A2009EquityIncentivePlanMember2018-01-012018-09-300001126234nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember2011-11-100001126234nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember2013-05-092013-05-090001126234nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember2018-09-300001126234nlnk:A2010EmployeeStockPurchasePlanMember2011-11-100001126234nlnk:A2010EmployeeStockPurchasePlanMember2013-05-092013-05-090001126234nlnk:A2010EmployeeStockPurchasePlanMember2018-09-300001126234us-gaap:EmployeeStockOptionMember2018-09-300001126234us-gaap:EmployeeStockOptionMember2018-01-012018-09-300001126234us-gaap:EmployeeStockOptionMember2017-12-310001126234us-gaap:EmployeeStockOptionMember2017-01-012017-12-310001126234us-gaap:PerformanceSharesMember2018-01-012018-09-300001126234us-gaap:RestrictedStockMember2017-12-310001126234us-gaap:RestrictedStockMember2018-01-012018-09-300001126234us-gaap:RestrictedStockMember2018-09-300001126234srt:MinimumMemberus-gaap:EmployeeStockOptionMember2018-01-012018-09-300001126234us-gaap:EmployeeStockOptionMembersrt:MaximumMember2018-01-012018-09-300001126234us-gaap:EmployeeStockOptionMember2018-01-012018-09-300001126234us-gaap:RestrictedStockMember2018-01-012018-09-300001126234us-gaap:EmployeeStockOptionMember2017-01-012017-09-300001126234us-gaap:RestrictedStockMember2017-01-012017-09-3000011262342018-07-012018-07-310001126234us-gaap:GeneralAndAdministrativeExpenseMember2018-01-012018-09-300001126234us-gaap:ResearchAndDevelopmentExpenseMember2018-01-012018-09-3000011262342017-07-012017-07-3100011262342017-01-012017-12-310001126234us-gaap:GeneralAndAdministrativeExpenseMember2017-01-012017-09-300001126234us-gaap:ResearchAndDevelopmentExpenseMember2017-01-012017-09-300001126234us-gaap:EmployeeSeveranceMember2017-12-310001126234us-gaap:EmployeeSeveranceMember2018-01-012018-09-300001126234us-gaap:EmployeeSeveranceMember2018-09-300001126234us-gaap:GeneralAndAdministrativeExpenseMember2018-07-012018-09-300001126234us-gaap:ResearchAndDevelopmentExpenseMember2018-07-012018-09-30
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
ý Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
For the quarterly period ended September 30, 2018.
o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
For the transition period from                       to                     .
Commission File Number
001-35342
NEWLINK GENETICS CORPORATION
(Exact name of Registrant as specified in Its Charter)
Delaware
42-1491350
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
2503 South Loop Drive
Ames, Iowa 50010
(515) 296-5555
(Address, including zip code, and telephone number, including area code, of principal executive offices)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes ý    No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý    No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o
Accelerated filer x
Non-accelerated filer o
Smaller reporting company x
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o    No ý

As of October 30, 2018, there were 37,224,606 shares of the registrant’s Common Stock, par value $0.01 per share, outstanding.



nlnk-20180930_g1.jpg

NewLink Genetics Corporation
FORM 10-Q
Table of Contents
Page
Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2018 and 2017
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017


2
PART I

 NewLink Genetics Corporation
and Subsidiaries
Condensed Consolidated Balance Sheets
(unaudited)
(In thousands, except share data)
September 30,December 31,
20182017
Assets
Current assets:
Cash and cash equivalents
$122,061 $158,708 
Prepaid expenses and other current assets
4,920 6,226 
Income tax receivable
7,398 356 
Other receivables
700 10,176 
Total current assets
135,079 175,466 
Property and equipment, net
4,096 5,091 
Income tax receivable
140 140 
Total non-current assets
$4,236 5,231 
Total assets $139,315 $180,697 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$1,238 $9,256 
Accrued expenses
8,736 12,467 
Current portion of unearned revenue
— 56 
Current portion of deferred rent
84 92 
Current portion of notes payable and obligations under capital leases
74 160 
Total current liabilities
10,132 22,031 
Long-term liabilities:
Royalty obligation payable to Iowa Economic Development Authority
6,000 6,000 
Notes payable and obligations under capital leases
59 111 
Deferred rent
929 998 
Total long-term liabilities
6,988 7,109 
Total liabilities 17,120 29,140 
Stockholders' equity:
Blank check preferred stock, $0.01 par value: Authorized shares — 5,000,000 at September 30, 2018 and December 31, 2017; issued and outstanding shares — 0 at September 30, 2018 and December 31, 2017
— — 
Common stock, $0.01 par value: Authorized shares — 75,000,000 at September 30, 2018 and December 31, 2017; issued 37,305,626 and 37,168,122 at September 30, 2018 and December 31, 2017, respectively, and outstanding 37,216,892 and 37,109,556 at September 30, 2018 and December 31, 2017, respectively
373 372 
Additional paid-in capital
403,674 389,786 
Treasury stock, at cost: 88,734 and 58,566 shares at September 30, 2018 and December 31, 2017, respectively
(1,409)(1,142)
Accumulated deficit
(280,443)(237,459)
Total stockholders' equity
122,195 151,557 
Total liabilities and stockholders' equity
$139,315 $180,697 
See accompanying notes to condensed consolidated financial statements. 

3
NewLink Genetics Corporation
and Subsidiaries
Condensed Consolidated Statements
of Operations
(unaudited)
(In thousands, except share and per share data)

Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Grant revenue
$— $5,379 $11,268 $18,279 
Licensing and collaboration revenue
120 103 1,004 334 
Total operating revenues
120 5,482 12,272 18,613 
Operating expenses:
Research and development
7,570 18,480 39,972 52,405 
General and administrative 7,588 7,907 23,792 25,038 
Total operating expenses
15,158 26,387 63,764 77,443 
Loss from operations
(15,038)(20,905)(51,492)(58,830)
Other income and expense:
Miscellaneous (expense) income
(18)12 16 (101)
Interest income 664 151 1,510 353 
Interest expense (2)(3)(51)(116)
Other income, net 644 160 1,475 136 
Net loss before taxes
(14,394)(20,745)(50,017)(58,694)
Income tax benefit
6,991 119 6,991 429 
Net loss
$(7,403)$(20,626)$(43,026)$(58,265)
Basic and diluted loss per share
$(0.20)$(0.69)$(1.16)$(1.98)
Basic and diluted average shares outstanding 37,214,363 29,939,823 37,178,542 29,462,226 
See accompanying notes to condensed consolidated financial statements.







4


NewLink Genetics Corporation
and Subsidiaries
Condensed Consolidated Statement of Stockholders' Equity
(unaudited)
(In thousands, except share data)
Number of
Common
Shares
Outstanding
Common
Stock
Additional
Paid-in
Capital
Treasury Stock
Accumulated Deficit
Total
Stockholders' Equity
Balance at December 31, 2017
37,109,556 $372 $389,786 $(1,142)$(237,459)$151,557 
Share-based compensation
— — 13,620 — — 13,620 
Exercise of stock options and restricted stock vested
105,393 1 138 — — 139 
Sales of shares under stock purchase plan
32,111 — 130 — — 130 
Repurchase of common stock
(30,168)— — (267)— (267)
Cumulative effect of accounting change
— — — — 42 42 
Net loss — — — — (43,026)(43,026)
Balance at September 30, 2018 37,216,892 $373 $403,674 $(1,409)$(280,443)$122,195 

See accompanying notes to condensed consolidated financial statements.


5

NewLink Genetics Corporation
and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(unaudited)
(In thousands)
Nine Months Ended September 30, 
20182017
Cash Flows From Operating Activities
Net loss $(43,026)$(58,265)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation 13,620 14,938 
 Depreciation and amortization
901 1,064 
 (Gain) Loss on sale of fixed assets
(16)102 
Changes in operating assets and liabilities: 
Prepaid expenses and other current assets 842 3,220 
Other receivables 9,982 13,856 
Accounts payable and accrued expenses (11,749)(11,500)
Income taxes receivable (7,042)5,861 
Unearned revenue (56)(279)
Deferred rent (78)(67)
Net cash used in operating activities
(36,622)(31,070)
Cash Flows From Investing Activities 
Purchase of equipment (7)(43)
Proceeds on sale of equipment 118 185 
Net cash provided by investing activities
111 142 
Cash Flows From Financing Activities 
Issuance of common stock, net of offering costs 269 20,585 
Repurchase of common stock (267)(260)
Payments under capital lease obligations and principal payments on notes payable (138)(185)
Net cash (used in) provided by financing activities
(136)20,140 
Net decrease in cash and cash equivalents
(36,647)(10,788)
Cash and cash equivalents at beginning of period 158,708 131,490 
Cash and cash equivalents at end of period $122,061 $120,702 
Supplemental disclosure of cash flows information: 
Cash paid for interest
$6 $11 
Cash refunds received for taxes, net $4 $(6,261)
See accompanying notes to condensed consolidated financial statements.

6
NewLink Genetics Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(unaudited)
1.     Description of Business
On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000.
NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs.
The accompanying condensed consolidated financial statements as of September 30, 2018 and for the three and nine months ended have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of $37.6 million from its initial public offering in 2011, completed a follow-on offering of its common stock raising net proceeds of $49.0 million in 2013, and raised an additional $58.7 million in net proceeds from an at the market (ATM) offering completed in 2015.
During 2017, the Company sold 1,940,656 shares of its common stock under an ATM offering, with aggregate net proceeds of $19.3 million after commissions of $398,000 paid to Cantor Fitzgerald & Co. (Cantor) as the placement agent, and other costs of $163,000. In October 2017, the Company sold 5,750,000 of its shares of common stock in a public offering for aggregate net proceeds of $55.2 million after underwriters' discounts, commissions and other expenses of $3.7 million. On March 12, 2018, the Company entered into a new Sales Agreement with Cantor under which the Company may sell up to $60.0 million of its common stock in one or more placements at prevailing market prices in an ATM offering (the 2018 ATM Offering). As of September 30, 2018, no shares have been sold under the 2018 ATM Offering.
The Company's cash and cash equivalents as of September 30, 2018 are expected to be adequate to satisfy the Company's liquidity requirements into the second half of 2021. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include selling additional shares of common stock, alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.
2. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management’s opinion, reflect all adjustments necessary to present fairly the Company’s interim condensed financial information.
Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K. The financial results for any interim period are not necessarily indicative of financial results for the full year.
3.     Significant Accounting Policies
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
7
NewLink Genetics Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(unaudited)
Principles of Consolidation
The condensed consolidated financial statements include the financial statements of NewLink and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Financial Instruments and Concentrations of Credit Risk
Cash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable and capital lease obligations was $133,000 and $271,000 as of September 30, 2018 and December 31, 2017, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain. 
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.
Property and equipment
Property and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of $7.1 million and $6.6 million as of September 30, 2018 and December 31, 2017, respectively. Equipment under capital leases is stated at the present value of minimum lease payments. Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of three to five years, lab equipment has a useful life of five years and contract manufacturing organization equipment has a useful life of five years.
Recently Issued Accounting Pronouncements not yet adopted 
In February 2016, the Financial Accounting Standards Board, or the FASB, issued ASU No. 2016-02, Leases, to improve financial reporting for leasing transactions. The new standard requires lessees to recognize on the balance sheet a right of use asset and related lease liability for all leases with terms greater than twelve months. The ASU also requires disclosures about the amount, timing, and uncertainty of cash flows arising from leases. The effective date for public entities is fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company does not currently have any material leases and therefore does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures.
Recently Adopted Accounting Pronouncements

On May 28, 2014, the FASB issued ASU No. 2014-09 (Topic 606), Revenue from Contracts with Customers. Topic 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (Topic 605), and requires entities to recognize revenue when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted Topic 606 as of January 1, 2018 and as a result changed its accounting policy for revenue recognition, as discussed in Note 4.
4.     Revenues
Adoption of ASC Topic 606, "Revenue from Contracts with Customers"
On January 1, 2018, we adopted Topic 606 using the modified retrospective method by recognizing the cumulative effect of initially applying Topic 606 as an adjustment to the opening balance of equity as of January 1, 2018. Therefore results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting policy under Topic 605. The change in accounting policy from Topic 605 to Topic 606 impacted how the Company recognizes revenue from government grants, and did not impact license and collaboration revenues due to the nature of those services in the period leading up to and after the adoption of Topic 606.

8
NewLink Genetics Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(unaudited)
The Company recorded an immaterial net reduction to the opening accumulated deficit within equity as of January 1, 2018 due to the cumulative impact of adopting Topic 606 with respect to grants from government entities which were not completed as of the date of adoption.  As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to accounts on the Condensed Consolidated Balance Sheet as of January 1, 2018 (in thousands):
As Reported December 31, 2017 Adjustments Adjusted January 1, 2018 
Balance Sheet 
Assets: 
Prepaid expenses and other current assets $6,226 $(464)$5,762 
Other receivables $10,176 $506 $10,682 
Total assets $180,697 $42 $180,739 
Equity: 
Accumulated deficit $(237,459)$42 $(237,417)
Total liabilities and stockholders' equity $180,697 $42 $180,739 

The impact of adoption on the Company’s Condensed Consolidated Statement of Operating Loss for the three and nine months ended September 30, 2018 was as follows (in thousands):

Three Months Ended September 30, Nine Months Ended September 30, 
As Reported
Adjustments
Balance without Adoption of Topic 606
As Reported
Adjustments
Balance without Adoption of Topic 606
Statement of Operating Loss
Grant Revenues
$— $— $— $11,268 $346 $11,614 
Licensing and collaboration revenue $120 $18 $138 $1,004 $164 $1,168 
Research and Development $7,570 $18 $7,588 $39,972 $468 $40,440 
Net Loss $(7,403)$— $(7,403)$(43,026)$42 $(42,984)

The impact of adoption on the Company’s Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2018 was as follows (in thousands):
As Reported
Adjustments
Balance without Adoption of Topic 606
Statement of Cash Flows
Net Loss
$(43,026)$42 $(42,984)
Changes in operating assets and liabilities:
Other receivables
$9,982 $(492)$9,490 
Accounts payable and accrued expenses
$(11,749)$450 $(11,299)
Net cash used in operating activities
$(36,622)$— $(36,622)
9
NewLink Genetics Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(unaudited)
Revenue Recognition
Revenues are recognized under Topic 606 when control of the promised goods or services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company receives payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services, or HHS. These agreements provide the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues are recognized over time and measured using the input method. The Company uses labor costs and subcontractor fees as inputs to measure progress towards satisfying its performance obligations under these agreements. This is the most faithful depiction of the transfer of goods and services to the government entities due to the government entities’ control over the research and development activities. Under this method, the Company recognizes revenue generally in the period during which the related costs are incurred, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.
The Company had $320,000 and $9.3 million of receivables relating to the government contracts recorded in other receivables and zero and $465,000 of unbilled expenses relating to the government contracts recorded in prepaid expenses and other current assets on the balance sheet as of September 30, 2018 and December 31, 2017, respectively. The Company had $81,000 and $1.8 million of accrued expenses for subcontractor fees incurred under the government contracts as of September 30, 2018 and December 31, 2017, respectively. 
5.   License and Research Collaboration Agreements
Genentech, a Member of the Roche Group
In October 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Genentech, or the Genentech Agreement, for the development and commercialization of NLG919, one of the Company's clinical stage IDO pathway inhibitors and for the discovery of next generation IDO/TDO compounds to be developed and commercialized under this agreement. Under the terms of the Genentech Agreement, the Company received a nonrefundable upfront cash payment of $150.0 million from Genentech in 2014. On June 6, 2017, the Company received a formal notice of Genentech’s intent to terminate the Genentech Agreement with respect to NLG919. As part of the partial termination, worldwide rights to NLG919 reverted to us, and Genentech granted to us an exclusive, royalty-bearing license under certain Genentech intellectual property to develop and commercialize NLG919. If NLG919 is commercialized, we will be obligated to pay to Genentech royalties as a low single-digit percentage of net sales of NLG919.
Additionally, on May 9, 2018 the Company received formal notice that Genentech would not continue the collaboration with respect to next generation IDO/TDO inhibitors identified through the research program. The Genentech Agreement will terminate in its entirety no later than November 6, 2018.
For the three and nine months ended September 30, 2018, the Company recognized license and collaboration revenue under the Genentech Agreement of zero and $56,000, respectively, for providing an alliance manager. For the three and nine months ended September 30, 2017, the Company recognized license and collaboration revenue under the Genentech Agreement of $56,000 and $279,000, respectively, for providing an alliance manager. All of the deliverables identified within the collaboration and license agreement were completed in their entirety and all of the $150.0 million upfront payment was recognized as of March 31, 2018.
10
NewLink Genetics Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(unaudited)
Merck Sharp & Dohme Corp.
In November 2014, the Company entered into a licensing and collaboration agreement with Merck, or the Merck Agreement, to develop, manufacture and commercialize rVSV-ZEBOV GP, an Ebola vaccine the Company licensed from the Public Health Agency of Canada, or PHAC. Under the terms of the Merck Agreement, the Company granted Merck an exclusive, royalty bearing license to rVSV-ZEBOV GP and related technology. Under the Merck Agreement, the Company received a $30.0 million non-refundable, upfront payment in December 2014, and a one-time $20.0 million non-refundable milestone payment in February 2015 upon the initiation of the pivotal clinical trial using the current rVSV-ZEBOV GP vaccine product as one arm of the trial. In addition, the Company can receive escalating royalties on potential commercial sales by Merck of the current product candidate ranging from single digit to double digits on the rVSV-ZEBOV GP license agreement product sales and escalating royalties on potential commercial sales by Merck of products other than current products within the Company’s patent rights ranging from low to high single digit, on increasing levels of annual net sales worldwide. Merck will lead the development of rVSV-ZEBOV GP and any other rVSV-based viral hemorrhagic fever vaccine product candidates in order to create a marketable product safe for human use.
The Merck Agreement was amended on December 5, 2017 in connection with our entry into an amended and restated PHAC license on December 5, 2017. The amended Merck Agreement absolves our subsidiary, BioProtection Systems Corporation, or BPS, from any future obligation to negotiate or amend the terms of the PHAC license, converts the scope of Merck's sublicense under PHAC’s intellectual property rights to be non-exclusive in the Ebola Sudan field of use, and requires Merck to reimburse us in certain circumstances where we may be obligated to pay royalties to PHAC as a result of Merck’s product sales but Merck would not otherwise be obligated to pay a royalty to us. On April 26, 2018 the Company entered into an agreement with Merck, DTRA and BARDA to transfer the government grants from BARDA and DTRA to Merck. The transfer was completed in June 2018 and Merck has replaced the Company as the prime contractor on all such grants. As a result grant revenues for the three and nine months ended September 30, 2018 have decreased as compared to the three and nine months ended September 30, 2017 and the Company does not expect to recognize additional revenue from government contracts for the development of the rVSV∆G-ZEBOV GP vaccine product candidate subsequent to September 30, 2018.
The Company completed all deliverables under the Merck Agreement in their entirety during the year ended December 31, 2016. For the three and nine months ended September 30, 2018, the Company recognized license and collaboration revenues under the Merck Agreement of $120,000 and $949,000, respectively, for the reimbursement of costs not covered under government contracts. For the three and nine months ended September 30, 2017, the company recognized license and collaboration revenue under the Merck Agreement of $48,000 and $55,000, respectively, for the reimbursement of costs not covered under government contracts. 
6.   Common Stock Equity Incentive Plan
2009 Equity Incentive Plan
In April 2000, the stockholders approved the Company's 2000 Equity Incentive Plan, or the 2000 Plan, and in July 2009, the stockholders approved the Company's 2009 Equity Incentive Plan, or the 2009 Plan. Following the approval of the 2009 Plan, all options outstanding under the 2000 Plan are effectively included under the 2009 Plan. Under the provisions of the 2009 Plan, the Company may grant the following types of common stock awards:
• Incentive Stock Options
• Nonstatutory Stock Options
• Restricted Stock Awards
• Stock Appreciation Rights
Awards under the 2009 Plan, as amended, may be made to officers, employees, members of the Board of Directors, advisors, and consultants to the Company. As of September 30, 2018, there were 11,722,602 shares of common stock authorized for the 2009 Plan and 1,489,402 shares remained available for issuance.
11
NewLink Genetics Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(unaudited)
The following table summarizes the authorized increases of common stock under the 2009 Plan:
Date Authorized
Authorized Shares Added
May 15, 20101,238,095 
January 7, 2011714,286 
January 1, 2013838,375 
January 1, 20141,066,340 
January 1, 20151,119,255 
January 1, 20161,152,565 
January 1, 20171,166,546 
January 1, 20181,484,382 
The increases in the authorized shares of common stock under the 2009 Plan in 2010 and 2011 were approved by the Company’s stockholders. The increases in the authorized shares of common stock under the 2009 Plan in 2013 through 2018 were made pursuant to an “evergreen provision,” in accordance with which, on January 1 of each year, from 2013 to (and including) 2019, a number of shares of common stock in an amount equal to 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan.
2010 Non-Employee Directors' Stock Award Plan
Under the terms of the Company’s 2010 Non-Employee Directors’ Stock Award Plan, or the Directors’ Plan, which became effective on November 10, 2011, 238,095 shares of common stock were reserved for future issuance. On May 9, 2013, an additional 161,905 shares of common stock were added to the shares reserved for future issuance under the Directors' Plan. As of September 30, 2018, no shares remained available for issuance under the Directors' Plan.
2010 Employee Stock Purchase Plan
Under the terms of the Company’s 2010 Employee Stock Purchase Plan, or the 2010 Purchase Plan, which became effective on November 10, 2011, 214,285 shares of common stock were reserved for future issuance. On May 9, 2013, an additional 185,715 shares of common stock were added to the shares reserved for future issuance under the 2010 Purchase Plan. As of September 30, 2018, 69,885 shares remained available for issuance under the 2010 Purchase Plan.
Share-based Compensation
Share-based compensation expense for the three months ended September 30, 2018 and 2017 was $4.6 million and $4.4 million, respectively. Share-based compensation expense for the nine months ended September 30, 2018 and 2017 was $13.6 million and $14.9 million, respectively. Share-based compensation expense is allocated between research and development and general and administrative expenses within the condensed consolidated statements of operations.
As of September 30, 2018, the total compensation cost related to nonvested option awards not yet recognized was $11.8 million and the weighted-average period over which it is expected to be recognized is 2.1 years.
12
NewLink Genetics Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(unaudited)
Stock Options and Performance Stock Options
The following table summarizes the stock option activity, including options with market and performance conditions, for the nine months ended September 30, 2018:
Number
of options
Weighted
average
exercise
price
Weighted average
remaining contractual
term (years)
Outstanding at beginning of period
7,202,221 $13.72 5.3
Options granted
1,632,523 6.92 
Options exercised
(32,946)4.24 
Options forfeited
(317,359)13.59 
Options expired
(118,097)21.96 
Outstanding at end of period
8,371,005 $12.32 5.1
Options exercisable at end of period
6,264,767 $13.03 3.8
The Company estimates the fair value of each stock option grant on the date of grant using a Black-Scholes option pricing model. For stock option grants issued with a market condition, the Company used a Monte Carlo simulation valuation model to determine the grant date fair value.
The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the nine months ended September 30, 2018:
Risk-free interest rate
2.6% to 2.9% 
Expected dividend yield
—%  
Expected volatility
76.2% to 79.2% 
Expected term (in years)
4.0 to 7.9 
Weighted-average grant-date fair value per share
$4.90 
The intrinsic value of options exercised during the nine months ended September 30, 2018 was $77,788. The fair value of awards vested during the nine months ended September 30, 2018 was $10.2 million.
During the nine months ended September 30, 2018, the Company’s Board of Directors approved and granted 466,750 shares of equity awards to certain executives with either market or performance conditions. The equity awards had a weighted-average grant date fair value per share of $5.33. The equity awards will vest upon the achievement of certain performance conditions. Certain performance conditions relating to the equity awards granted in 2018 and 2017 were met during the nine months ended September 30, 2018 and 213,725 shares were vested.
Restricted Stock and Performance Restricted Stock
Restricted stock is common stock that is subject to restrictions, including risks of forfeiture, determined by the plan committee of the Board of Directors in its sole discretion, for as long as such common stock remains subject to any such restrictions. A holder of restricted stock has all rights of a stockholder with respect to such stock, including the right to vote and to receive dividends thereon, except as otherwise provided in the award agreement relating to such award. Restricted stock awards are classified as equity within the consolidated balance sheets. The fair value of each restricted stock grant is estimated on the date of grant using the closing price of the Company's common stock on the NASDAQ Stock Market on the date of grant.
A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at September 30, 2018 and changes during the nine months ended September 30, 2018 are as follows:
13
NewLink Genetics Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(unaudited)
Number of restricted stock shares
Weighted average grant date fair value
Unvested at beginning of period
168,221 $35.82 
Granted
— — 
Vested
(72,447)35.40 
Forfeited/cancelled
(6,721)40.99 
Unvested at end of period
89,053 $35.76 
As of September 30, 2018, the total remaining unrecognized compensation cost related to restricted stock was approximately $1.6 million and is expected to be recognized over a weighted-average period of 1.0 years.
The Company does not have a formal policy regarding the source of shares issued upon exercise of stock options or issuance of restricted stock. The Company expects shares issued to be issued from treasury shares or new shares.
7.   Income Taxes
For the three and nine months ended September 30, 2018, the Company recorded a $7.0 million income tax benefit. The income tax benefit for the three and nine months ended September 30, 2018 differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due a refund received as a result of amendments filed to change the allocation of income for certain states for the years ending December 31, 2014 and 2015. We received the full refund subsequent to September 30, 2018. For the nine months ended September 30, 2017, the Company recorded an income tax benefit of $429,000. For the three months ended September 30, 2017, the Company recorded $119,000. Additionally, the Company has a noncurrent income tax receivable as of September 30, 2018 for $140,000 which was recorded as an income tax benefit in 2017 and is for the receipt of AMT Credit carryovers. The Tax Cuts and Jobs Act of 2017, or the Tax Act, provides that the AMT credit carryovers are partially refundable beginning in 2018 as an offset to a tax liability. The Company expects the amount to be fully refunded by 2021.
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected taxable income, and tax planning strategies in making this assessment. Valuation allowances have been established for the entire amount of the net deferred tax assets as of September 30, 2018 and December 31, 2017, respectively, due to the uncertainty of future recoverability.
The Company has a reserve for uncertain tax positions related to state tax matters of $653,000 as of September 30, 2018 recorded within Accrued Expenses in the condensed consolidated balance sheet, which includes the accrual of interest and penalties. The Company does not expect the amount to change significantly within the next 12 months.
8.   Net Loss per Common Share
Basic loss per share is based upon the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common stock equivalents during the period when the effect is dilutive.

The following table presents the computation of basic and diluted loss per common share (in thousands, except share and per share data):
 
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Loss attributable to common stockholders
$(7,403)$(20,626)$(43,026)$(58,265)
Basic and diluted weighted-average shares outstanding
37,214,363 29,939,823 37,178,542 29,462,226 
Basic and diluted loss per share
$(0.20)$(0.69)$(1.16)$(1.98)

14
NewLink Genetics Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(unaudited)
All common stock equivalents are excluded from the computation of diluted loss per share during periods in which losses are reported since the result would be anti-dilutive. As of September 30, 2018, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled 8,371,005 and 89,053, respectively. As of September 30, 2017, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled 7,314,006 and 181,336, respectively. 

9. Restructuring Charges
The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee severance costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. The Company also records costs incurred with contract terminations associated with restructuring activities.
In July 2018, the Company completed an organizational review of its clinical programs and reduced its headcount by approximately 30% as compared to June 30, 2018 and made several changes to senior leadership effective July 26, 2018 in order to conserve resources to further advance its clinical development programs. Restructuring charges of $1.3 million were recorded during the three and nine months ended September 30, 2018 of which $800,000 is included within general and administrative expenses and $500,000 is included within the research and development expenses in the condensed consolidated statement of operations.
The Company undertook an organizational realignment in July 2017 to refocus its clinical development efforts and align the Company's resources to focus on the Company's highest value opportunities. The Company's restructuring activities included a reduction of its workforce by approximately 50%, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus. The Company recorded total restructuring charges of $1.7 million during the nine months ended September 30, 2017 of which $1.1 million is included within general and administrative expenses and $600,000 is included within the research and development expenses in the condensed consolidated statement of operations.
The following table shows the amount accrued for restructuring activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet (in thousands):
Employee Severance Cost
Total
Balance as of December 31, 2017
207 207 
Expensed
1,323 1,323 
Cash Payments
511 511 
Balance as of September 30, 2018 1,019 1,019 

10. Commitments and Contingencies
From time to time, claims are asserted against the Company arising in the ordinary course of business. In the opinion of management, liabilities, if any, arising from existing claims are not expected to have a material effect on the Company's earnings, financial position, or liquidity.

On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York, or the Court, captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545, or the Securities Action.  Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick & Foti, LLC as lead counsel in the Securities Action.  On October 31, 2016, the lead plaintiffs filed an amended complaint asserting claims under the federal securities laws against the Company, the Company’s Chief Executive Officer Charles J. Link, Jr., and the Company’s Chief Medical Officer and President Nicholas Vahanian, or collectively, the Defendants.  The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company’s investors. In particular, the lead plaintiffs allege that the Defendants made material
15
NewLink Genetics Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(unaudited)
misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L. The lead plaintiffs did not quantify any alleged damages in the amended complaint but, in addition to attorneys’ fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company’s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the amended complaint on July 14, 2017. The lead plaintiffs filed an opposition to the motion to dismiss on September 12, 2017. The Defendants filed a reply in support of the motion to dismiss on September 26, 2017. Oral argument was held on October 19, 2017, after which the Court reserved decision. On March 29, 2018, the Court dismissed the amended complaint for failure to state a claim, without prejudice, and gave the lead plaintiffs until May 4, 2018 to file any amended complaint attempting to remedy the defects in their claims.  On May 4, 2018, the lead plaintiffs filed a second amended complaint asserting claims under the federal securities laws against the Defendants. Like the first amended complaint, the second amended complaint alleges that the Defendants made material false and/or misleading statements or omissions relating to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L that caused losses to the Company’s investors. The lead plaintiffs did not quantify any alleged damages in the second amended complaint but, in addition to attorneys’ fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company’s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the second amended complaint on July 31, 2018. The lead plaintiffs filed an opposition to the motion to dismiss the second amended complaint on September 14, 2018. The Defendants filed a reply in support of the motion to dismiss the second amended complaint on October 9, 2018. Oral argument was held on October 19, 2018, after which the Court reserved decision. The Company intends to continue defending the Securities Action vigorously.

On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company’s Chief Executive Officer Charles J. Link, Jr., the Company’s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth, or collectively, the Morrow Defendants, captioned Morrow v. Link., et al., Case 1:17-cv-03039, or the Morrow Action.  The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation of federal securities law.  The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.  The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company’s shareholders.  The language for such proposals is not specified in the complaint.  The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.  On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.  Also on May 19, 2017, plaintiffs’ counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.  The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.  By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise finally resolved.  Under the terms of the stay, the plaintiff in the Ely Action will be provided with any discovery that is provided in the Securities Action, and given an opportunity to participate in any mediation or settlement efforts in the Securities Action.  The Company disputes the claims in the Ely Action and intends to defend against them vigorously.
16
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and such statements are subject to the “safe harbor” created by those sections.  Forward-looking statements are based on our management’s beliefs and assumptions and on information available to our management as of the date hereof. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: our ongoing and planned preclinical studies and clinical trials; the timing of the release of the results of data from ongoing preclinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; the clinical utility of our product candidates; our plans to leverage our existing technologies to discover and develop additional product candidates; our ability to quickly and efficiently identify and develop product candidates; our intellectual property position; the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; plans to develop, commercialize, market and manufacture our product candidates; and other risks and uncertainties, including those described in Part II, Item 1A, “Risk Factors” of this Quarterly Report and in our other periodic reports filed from time to time with the Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K for the year ended December 31, 2017.  Our actual results could differ materially from those discussed in our forward-looking statements for many reasons, including those risks. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form 10-Q. You should read this Quarterly Report on Form 10-Q completely. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The following discussion and analysis should be read in conjunction with the unaudited financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Overview
NewLink Genetics Corporation (the "Company", "NewLink", "we", "our" or "us") is a clinical-stage immuno-oncology company focused on developing novel immunotherapeutic products for the treatment of patients with cancer. Our leading small-molecule product candidates currently in clinical development target the indoleamine-2, 3-dioxygenase, or IDO, pathway, which is one of the key pathways for cancer immune escape. These lead product candidates, indoximod and NLG802 (a prodrug of indoximod), are IDO pathway inhibitors with mechanisms of action that center around breaking the immune system’s tolerance to cancer.

Based on early clinical data from our Phase 1b clinical trials, our indoximod clinical program is focused on front-line acute myeloid leukemia (AML) and malignant pediatric brain tumors. These targeted indications are those with great unmet need where indoximod has produced encouraging early data. The Company plans to provide data updates at medical conferences in fourth quarter of 2018 for AML and in the first half of 2019 for malignant pediatric brain tumors. We also have a Phase 1 clinical trial for NLG802, the prodrug of indoximod, and we plan to present data in the fourth quarter of 2018 relating to this trial.
IDO Pathway Inhibitors
In cancer, the IDO pathway regulates immune response by suppressing T-cell activation, which enables cancer to avoid immune response. IDO is overexpressed in many cancers, both within tumor cells as a direct defense against T-cell attack, and also within antigen presenting cells in tumor-draining lymph nodes, thereby promoting peripheral tolerance to tumor associated antigens, or TAAs. When hijacked by developing cancers in this manner, the IDO pathway may facilitate the survival, growth, invasion and metastasis of malignant cells whose expression of TAAs might otherwise be recognized and attacked by the immune system. 
The IDO pathway refers to a series of reactions initiated by the IDO enzyme that result in the reduction of the amino acid tryptophan in the local tumor environment. We believe the local presence of tryptophan in adequate concentrations promotes antitumor T-cells, and the local reduction of tryptophan combined with the presence of the break-down product of tryptophan metabolism, kynurenine, is understood to suppress the activation of T-cells. Preclinical data has suggested that IDO pathway
17
inhibitors may also enhance the anti-tumor effects of other immunotherapies, chemotherapies and radiation when used as a combination therapy for patients with cancer.
We have a clinical development program focused on the IDO pathway. Our small-molecule IDO pathway inhibitor product candidates in clinical development include indoximod and NLG802. Our product candidates are designed to counteract immunosuppressive effects of the IDO pathway, a fundamental mechanism regulating immune response. Indoximod targets the IDO pathway through different mechanisms of action from enzymatic IDO inhibitors and therefore could represent a differentiated clinical and commercial opportunity. We believe indoximod acts as a tryptophan mimetic, thereby signaling the activation of antitumor T-cells by the up regulation of mTOR, acts directly on T-cells, and modulates AhR-mediated effects.
We have observed an encouraging safety profile for our IDO pathway inhibitors. They are orally bioavailable and we believe they offer the potential to be synergistic with other therapies such as radiation, chemotherapy, vaccination and immunotherapies involving other checkpoint inhibitors such as anti-PD-1, anti-PD-L1 or anti-CLTA4. Clinical data suggests an increase in activity without adding significant toxicity.
Indoximod
Indoximod, our lead IDO pathway inhibitor, has been studied in more than 800 patients to date and has been generally well-tolerated, including in combination with PD-1 checkpoint inhibitors, various chemotherapy agents and a cancer vaccine. Indoximod has a differentiated mechanism of action (MOA) which may demonstrate clinical benefit for patients compared to direct enzymatic inhibitors. Indoximod is currently in clinical development in combination with other cancer therapeutics for patients with AML and pediatric brain tumors.
We have finalized the dose for the salt formulation of indoximod for adult patients. Data from recent clinical trials suggest that the maximum plasma concentration levels and half-life observed after oral dosing of the new salt formulation of indoximod are modestly higher than those observed with the free base formulation.
A U.S. patent covering salt and prodrug formulations of indoximod was issued to us on August 15, 2017 providing exclusivity until at least 2036. We are currently pursuing international patent coverage for these formulations.
NLG802
NLG802 is a prodrug of indoximod. NLG802 is intended to increase bioavailability and exposure to indoximod above the levels currently achievable by direct oral administration. We filed an Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or FDA, in the first quarter of 2017 and the first patient was dosed with NLG802 in a Phase 1 clinical trial in July 2017. The purpose of this Phase 1 trial is to assess preliminary safety and to determine the recommended dose for subsequent Phase 2 evaluations. NLG802 is a new chemical entity with patent coverage into 2036. We are also pursuing international patent coverage for NLG802.
NLG919
NLG919, a direct enzymatic inhibitor, was previously in clinical development as part of our collaboration with Genentech. NLG919 seeks to inhibit the IDO enzyme directly and thereby prevent the metabolism of tryptophan into kynurenine. In October 2014, we entered into an exclusive worldwide license and collaboration agreement with Genentech, or the Genentech Agreement. The Genentech Agreement provided for the development and commercialization of NLG919. On June 6, 2017, we received a formal notice of Genentech’s intent to terminate the Genentech Agreement with respect to NLG919, and such termination was effective December 6, 2017. As part of the partial termination, worldwide rights to NLG919 reverted back to the Company and Genentech granted us a license under certain of Genentech’s intellectual property to develop and commercialize NLG919.
Under the Genentech Agreement, we conducted a two-year pre-clinical research program with Genentech to discover novel next generation IDO/tryptophan-2,3-dioxygenase, or TDO, inhibitors. The research program ended in November 2016, and we received notice on May 9, 2018 that Genentech would not continue the collaboration with respect to next generation IDO/TDO inhibitors identified through the research program. The Genentech Agreement will terminate in its entirety no later than November 6, 2018.
Additional Product Candidates
Additional clinical-stage product candidates in our pipeline include two small molecules we acquired in 2017 from Daré Bioscience, Inc. (previously Cerulean Pharma Inc.) and two product candidates that utilize our HyperAcute® Cellular Immunotherapy technology. Our small molecule product, NLG207 (formerly CRLX101), is being evaluated in early clinical
18
development for patients with advanced solid malignancies. We have substantially reduced our financial commitment for CRLX301, the second asset acquired from Daré Bioscience, Inc., and have no future plans for the development of CRLX301. Additionally, we have substantially reduced our financial commitment for the HyperAcute Cellular Immunotherapy product candidates and have no plans to conduct additional clinical trials for such product candidates.
Ebola Vaccine Candidate
In November 2014, we entered into an exclusive, worldwide license and collaboration agreement, or the Merck Agreement, with Merck to develop and potentially commercialize our rVSV∆G-ZEBOV GP vaccine product candidate and other aspects of our vaccine technology. The rVSV∆G-ZEBOV GP vaccine product candidate was originally developed by the Public Health Agency of Canada, or PHAC, and is designed to utilize the rVSV vector to induce immunity against Ebola virus when replacing the VSV glycoprotein with corresponding glycoproteins from filoviruses. Under the Merck Agreement, we received an upfront payment of $30.0 million in October 2014, and in February 2015 we received a milestone payment of $20.0 million. We have the potential to earn royalties on sales of the vaccine in certain countries, if the vaccine is approved and if Merck successfully commercializes it. rVSV∆G-ZEBOV GP is also eligible to receive a priority review voucher and we are entitled to a portion of the value of the voucher if it is granted. In addition to milestone payments from Merck, we were awarded contracts for development of the rVSV∆G-ZEBOV GP from the U.S. BioMedical Advanced Research & Development Authority, or BARDA, and the Defense Threat Reduction Agency, or DTRA, totaling $52.1 million during 2016 and $67.0 million during 2014 and 2015. Funds of $2.1 million were de-obligated from the DTRA grant awards in 2017. We have received total awards of $118.8 million. 
On April 26, 2018 we entered into an agreement with Merck, DTRA and BARDA to transfer the government grants from BARDA and DTRA to Merck. The transfer was completed in June 2018 and Merck has replaced us as the prime contractor on all such grants. As a result our grant revenues for the three and nine months ended September 30, 2018 have decreased as compared to the three and nine months ended September 30, 2017 and we expect to recognize no additional revenue from government contracts for the development of the rVSV∆G-ZEBOV GP vaccine product candidate subsequent to September 30, 2018.
Restructuring Charges
In July 2018, the Company completed an organizational review of its clinical programs and reduced its headcount by approximately 30% as compared to June 30, 2018 and made several changes to senior leadership effective July 26, 2018 in order to conserve its resources. Restructuring charges of $1.3 million were recorded during the three and nine months ended September 30, 2018 relating to this reorganization.
Our organizational realignment in July 2017 included a reduction of our workforce by approximately 50%, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus. Refer to Note 9 of the “Notes to Condensed Consolidated Financial Statements” of this Form 10-Q for more information.
Corporate Information
Founded in 1999, our principal executive office is located in Ames, Iowa, with additional offices located in Austin, Texas and Wayne, Pennsylvania. We have a clinical, research and development team dedicated to our pipeline of product candidates for patients with cancer and other diseases.
We incurred a net loss of $43.0 million for the nine months ended September 30, 2018. We expect to continue to incur losses over the next several years as we incur expenses to complete our clinical trial programs for our product candidates, develop our pipeline and pursue regulatory approval of our product candidates.
Critical Accounting Policies and Significant Judgments and Estimates
We have prepared our financial statements in accordance with U.S. GAAP which requires us to make estimates, assumptions and judgments that affect the reported amount of assets, liabilities, expenses and related disclosures at the date of the financial statements, as well as revenues and expenses during the reporting periods. As such, to understand our financial statements, it is important to understand our critical accounting policies. A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operation and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Actual results could therefore differ materially from these estimates under different assumptions or conditions.
19
Our Annual Report on Form 10-K for the year ended December 31, 2017, discusses our most critical accounting policies. Since December 31, 2017, there have been no material changes in the critical accounting policies discussed in our 2017 Annual Report.
Recent Accounting Pronouncements
We adopted ASC Topic 606 on January 1, 2018 and have disclosed the impact adoption had on our condensed consolidated financial statements within Note 4 of the “Notes to Condensed Consolidated Financial Statements” of this Form 10-Q. We do not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

Results of Operations

Comparison of the Three Months Ended September 30, 2018 and 2017

Revenues. Revenues for the three months ended September 30, 2018 were $120,000, a decrease of $5.4 million from $5.5 million for the same period in 2017. The decrease in revenue was due to a decrease in grant revenue of $5.4 million, primarily due to a decrease in billings under the government grant contracts which were fully transferred to Merck in June 2018, offset by an increase of $17,000 in licensing revenue, due to higher billings to Merck.

Research and Development Expenses. Research and development expenses for the three months ended September 30, 2018 were $7.6 million, a decrease of $10.9 million from $18.5 million for the same period in 2017.  The decrease was primarily due to reductions of $7.3 million in contract research and manufacturing spend, $2.5 million in clinical trial expense, $570,000 in personnel-related and stock compensation expense, $560,000 in supplies and licensing, and a $100,000 decrease in restructuring expense, offset by an increase of $70,000 in legal and consulting expense.
General and Administrative Expenses. General and administrative expenses for the three months ended September 30, 2018 were $7.6 million, a decrease of $320,000 from $7.9 million for the same period in 2017. The decrease was due primarily to reductions of $300,000 in restructuring expense, a decrease of $240,000 in legal and consulting expense, and a decrease of $10,000 in personnel-related and stock compensation expense, offset by an increase of $230,000 in supplies and other expense.
Income Tax Benefit. We recorded a $7.0 million and $119,000 income tax benefit for the three months ended September 30, 2018 and 2017, respectively. The increase in the benefit is due to amendments filed to change the allocation of income for certain states for the years ending December 31, 2014 and 2015. We received the full refund subsequent to September 30, 2018.
Net Loss. The net loss for the three months ended September 30, 2018 was $7.4 million compared to net loss of $20.6 million for the same period in 2017. The basic and diluted weighted-average common shares outstanding for the three months ended September 30, 2018 were 37,214,363, resulting in a basic and diluted loss per share of $0.20. For the three months ended September 30, 2017, the basic and diluted weighted-average common shares outstanding were 29,939,823, resulting in basic and diluted loss per share of $0.69.
Comparison of the Nine Months Ended September 30, 2018 and 2017
Revenues. Revenues for the nine months ended September 30, 2018 were $12.3 million, a decrease of $6.3 million from $18.6 million for the same period in 2017. The decrease in revenue was due to a decrease in grant revenue of $7.0 million, primarily due to a decrease in billings under the government grant contracts as a result of the transfer of the government grant contracts which was completed in its entirety in June 2018, and an increase of $670,000 in licensing revenue.
Research and Development Expenses. Research and development expenses for the nine months ended September 30, 2018 were $40.0 million, a decrease of $12.4 million from $52.4 million for the same period in 2017. The decrease was primarily due to reductions in contract research and manufacturing spend of $4.4 million, a decrease in supplies and other expense of $2.9 million, a decrease in personnel-related and stock compensation expense of $2.8 million, a decrease of $1.5 million in clinical trial expense, a decrease in licensing expense of $1.3 million, and a decrease in restructuring charges of $100,000, offset by a $646,000 increase in legal and consulting expenses.
General and Administrative Expenses. General and administrative expenses for the nine months ended September 30, 2018 were $23.8 million, a decrease of $1.2 million from $25.0 million for the same period in 2017. The decrease was due primarily to a reduction in personnel-related spend of $1.5 million, a decrease in restructuring charges of $300,000, and a decrease in legal and consulting expense of $163,000, offset by increases in supplies and other expenses of $755,000.
20
Income Tax Benefit. There was $7.0 million in income tax benefit recorded for the nine months ended September 30, 2018, increased as compared to income tax benefit of $429,000 for the same period in 2017. The change of $6.6 million is primarily due to an amendment filed to change the allocation of income for certain states for the years ending December 31, 2014 and 2015. We received the full refund subsequent to September 30, 2018.
Net Loss. The net loss for the nine months ended September 30, 2018 was $43.0 million compared to net loss of $58.3 million for the same period in 2017. The basic and diluted weighted average common shares outstanding for the nine months ended September 30, 2018 were 37,178,542, resulting in a basic and diluted loss per share of $1.16. For the nine months ended September 30, 2017, the basic and diluted weighted average common shares outstanding were 29,462,226, resulting in basic and diluted loss per share of $1.98.

Liquidity and Capital Resources

As of September 30, 2018, we had cash and cash equivalents of $122.1 million. We have funded our operations principally through the private placement of equity securities and public offerings of common stock. To date, we have raised aggregate proceeds, net of offering costs, of $76.3 million from the issuance of convertible preferred stock prior to our IPO, and $145.3 million in net proceeds through our IPO and other public follow-on offerings through 2015. Additionally, we raised aggregate proceeds, net of offering costs, of $19.3 million through public at the market sales of common stock in 2017. In October 2017, we sold 5,750,000 shares of common stock in a public offering for aggregate net proceeds of $55.2 million after underwriters' discounts, commissions and other expenses of $3.7 million. We entered into a Sales Agreement with Cantor in March 2018 under which we may sell up to $60.0 million of our common stock in one or more placements at prevailing market prices in an ATM offering (the 2018 ATM Offering). As of September 30, 2018, no shares have been sold under the 2018 ATM Offering.

With the exception of the 2014 fiscal year, we have incurred operating losses and an accumulated deficit as a result of ongoing research and development spending since inception. We anticipate that we will continue to generate operating losses as we incur expenses to complete our clinical trial programs for our product candidates, develop our pipeline and pursue regulatory approval of our product candidates.
We may seek to sell additional equity or debt securities or obtain a credit facility if our available cash and cash equivalents are insufficient to satisfy our liquidity requirements or if we develop additional opportunities to do so. The sale of additional equity and debt securities may result in additional dilution to our stockholders. If we raise additional funds through the issuance of debt securities or preferred stock, these securities could have rights senior to those of our common stock and could contain covenants that would restrict our operations. We may require additional capital beyond our currently forecasted amounts. Any such required additional capital may not be available on reasonable terms, if at all. If we were unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned research and development activities, which could harm our business.
Because of the numerous risks and uncertainties associated with the research and development of biopharmaceutical products, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:
• the scope, progress, results and costs of clinical trials for our product candidates, and discovery and development activities related to new product candidates;
• the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;
• the cost of commercialization activities if any of our product candidates are approved for sale, including marketing, sales, facilities, and distribution costs;
• the cost of manufacturing our product candidates and any products we commercialize;
• our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;
• whether, and to what extent, we are required to repay our outstanding government provided loans;
• the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and
• the timing, receipt and amount of sales of, or royalties on, our future products, if any.
We believe that our cash and cash equivalents on hand will be sufficient to fund our operations into the second half of 2021.
21
Cash Flows
The following table sets forth the primary sources and uses of cash for each of the periods set forth below:
Nine Months Ended September 30, 
20182017
Net cash used in operating activities
$(36,622)$(31,070)
Net cash provided by investing activities
111 142 
Net cash (used in) provided by financing activities
(136)20,140 
Net decrease in cash and cash equivalents
$(36,647)$(10,788)
 

For the nine months ended September 30, 2018 and 2017, we used cash of $36.6 million and $31.1 million, respectively, for our operating activities. The increase in cash used in operating activities was primarily due to the decrease in research and development activity and changes in working capital for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017.
For the nine months ended September 30, 2018 and 2017, our investing activities provided cash of $111,000 and $142,000, respectively. The cash provided by investing activities during the nine months ended September 30, 2018 was due to proceeds received from sales of property and equipment of $118,000, offset by the purchase of equipment of $7,000. The cash provided by investing activities during the nine months ended September 30, 2017 was due to the purchase of equipment of $43,000 offset by $185,000 in proceeds received from sales of property and equipment.
For the nine months ended September 30, 2018 and 2017, our financing activities used cash of $136,000 and provided cash of $20.1 million, respectively. The cash used in financing activities during the nine months ended September 30, 2018 was due to the issuance of common stock for net proceeds of $269,000 offset by net payments on long-term obligations and notes payable of $138,000 and repurchases of common stock of $267,000. The cash provided by financing activities during the nine months ended September 30, 2017 was primarily due to the sale and issuance of common stock for net proceeds of $20.6 million, offset by net payments on long-term obligations and notes payable of $185,000, and repurchase of common stock of $260,000.
Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk related to changes in interest rates. As of September 30, 2018 and December 31, 2017, we had cash and cash equivalents of $122.1 million and $158.7 million, respectively, consisting primarily of money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United States interest rates. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio.

Our long-term debt and our capital lease obligations bear interest at fixed rates. Any change in interest rates would have an immaterial impact on our financial statements.

22
ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation required by the Securities Exchange Act of 1934, as amended, or the Exchange Act, under the supervision and with the participation of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act, as of September 30, 2018. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of September 30, 2018, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and to provide reasonable assurance that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosures.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
23
PART II. OTHER INFORMATION

Item 1A.  RISK FACTORS
RISK FACTORS
Investing in our common stock involves significant risks, some of which are described below. In evaluating our business, investors should carefully consider the following risk factors. These risk factors contain, in addition to historical information, forward-looking statements that involve substantial risks and uncertainties. Our actual results could differ materially from the results discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below. The order in which the following risks are presented is not intended to reflect the magnitude of the risks described. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.
Business Risks
Risks Relating to Clinical Development and Commercialization of Our Product Candidates
If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them. We have not completed testing of any of our product candidates in controlled clinical trials.
The clinical development and regulatory approval process is expensive and time-consuming. The timing of any future product approval cannot be accurately predicted. If we fail to obtain regulatory approval for our current or future product candidates, we will be unable to market and sell them and therefore we may never be profitable.
As part of the regulatory process, we must conduct clinical trials for each product candidate to demonstrate safety and efficacy to the satisfaction of the FDA and other regulatory authorities abroad. The number and design of clinical trials that will be required varies depending on the product candidate, the condition being evaluated, the trial results and regulations applicable to any particular product candidate. Any inability to successfully complete preclinical and clinical development could result in additional costs to us.
Prior clinical trial program designs and results are not necessarily predictive of future clinical trial designs or results. Initial results may not be confirmed upon full analysis of the detailed results of a trial. Product candidates in later-stage clinical trials may fail to show the desired safety and efficacy despite having progressed through initial clinical trials with acceptable endpoints. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products.
We are heavily dependent on the success of the clinical development of indoximod, and if we fail to complete clinical trials, fail to demonstrate safety and efficacy in those clinical trials, fail to obtain regulatory approval or fail to successfully commercialize indoximod, our business, financial condition and results of operations would be harmed.
The indoximod clinical development program currently encompasses a number of Phase 1 and 2 combination trials across multiple cancer indications. If we fail to complete any of these trials or fail to obtain regulatory approval, our ability to commercialize indoximod will be materially and adversely affected and our business, financial condition and results of operations would be harmed.
If we make changes to any of our product candidates, additional clinical trials may be required resulting in additional costs and delays. 
We have an ongoing research program to investigate potential opportunities to improve the potency, efficacy and/or safety profile of some of our product candidates through modifications to their formulations or chemical compositions.  These efforts may not be successful.  If a new formulation or composition appears promising, we may decide to undertake clinical development of such formulation or composition even if an existing product candidate has shown acceptable safety and efficacy in clinical trials.  The nature and extent of additional clinical trials that might be required for a new formulation or composition would depend on many factors.  If we were to decide to pursue clinical development of a new formulation or composition, we
24
would incur additional costs and the timeline for potential commercialization would be delayed.  There can be no assurance that any new formulation or composition would prove to be safe or effective or superior to an existing product candidate.  Any delay in commercialization of a new formulation or composition may adversely affect our competitive position.
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and managerial resources, we must focus on research programs and product candidates for the specific indications that we believe are the most scientifically and commercially promising. As a result, we have in the past determined to let certain of our development projects remain idle, including by allowing Investigational New Drug applications to lapse into inactive status, and we may in the future decide to forego or delay pursuit of opportunities with other product candidates or other indications that later prove to have greater scientific or commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable scientific or commercial products or profitable market opportunities. In addition, we may spend valuable time and managerial and financial resources on research programs and product candidates for specific indications that ultimately do not yield any scientifically or commercially viable products. Furthermore, our resource allocation decisions and our decisions about whether and how to develop or commercialize any particular product candidate may be based on evaluations of the scientific and commercial potential or target market for the product candidate that later prove to be materially inaccurate. If we enter into collaborations, licensing or other royalty arrangements to develop or commercialize a particular product candidate, we may relinquish valuable rights to that product candidate in situations where it would have been more advantageous for us to retain sole rights to development and commercialization.
We may face delays in completing our clinical trials, or we may not be able to complete them at all.
We have not completed all of the clinical trials necessary to support an application with the FDA for approval to market any of our product candidates. Our current and future clinical trials may be delayed or terminated as a result of many factors, including:

• we may experience delays or failure in reaching agreement on acceptable clinical trial contracts or clinical trial protocols with prospective sites;
• regulators or institutional review boards may not authorize us to commence a clinical trial;
• regulators or institutional review boards may suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or concerns about patient safety;
• we may suspend or terminate our clinical trials if we believe that they expose the participating patients to unacceptable health risks;
• we may need to reformulate or change the dosing of our product candidates;
• our clinical trials may have slower than expected patient enrollment or lack of a sufficient number of patients that meet their enrollment criteria;
• patients may not complete clinical trials due to safety issues, side effects, dissatisfaction with the product candidate, or other reasons;
• we may experience difficulty in maintaining contact with patients after treatment, preventing us from collecting the data required by our clinical trial protocol;
• product candidates may demonstrate a lack of efficacy during clinical trials;
• our third-party contractors, including those manufacturing our product candidates or components of ingredients thereof or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner or at all;
• the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply;
• we may experience governmental or regulatory delays, failure to obtain regulatory approval or changes in regulatory requirements, policy and guidelines;
25
• enrollment in and conduct of our clinical trials may be adversely affected by the regulatory approval of competing agents in this class, competition with ongoing clinical trials or scheduling conflicts with participating clinicians; and
• we may experience delays in achieving clinical trial endpoints and completing data analysis for a trial.
In addition, we rely on academic institutions, physician practices and clinical research organizations to conduct, supervise or monitor some or all aspects of clinical trials involving our product candidates. We have less control over the timing and other aspects of these clinical trials than if we conducted the monitoring and supervision entirely on our own. Third parties may not perform their responsibilities for our clinical trials on our anticipated schedule or consistent with a clinical trial protocol or applicable regulations. We also may rely on clinical research organizations to perform our data management and analysis. They may not provide these services as required or in a timely or compliant manner.
Moreover, our development costs will increase if we are required to complete additional or larger clinical trials for our product candidates prior to FDA approval. If the delays or costs are significant, our financial results and ability to commercialize our product candidates will be adversely affected.
If we encounter difficulties enrolling patients in our clinical trials, our clinical trials could be delayed or otherwise adversely affected.
Clinical trials for our product candidates require us to identify and enroll a large number of patients with the disease under investigation, or healthy volunteers willing to participate in certain trials. We may not be able to enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a clinical trial, to complete our clinical trials in a timely manner. Patient enrollment is affected by factors including:
• severity of the disease under investigation;
• design of the trial protocol;
• size of the patient population;
• eligibility criteria for the clinical trial in question;
• perceived risks and benefits of the product candidate under study;
• changes in the standard of care that make the trial as designed less attractive to clinicians and patients;
• availability of competing therapies and clinical trials, including announced clinical trials evaluating potentially competing IDO pathway inhibitors in clinical settings similar to our clinical trials;
• the results of clinical trials of other IDO pathway inhibitors;
• efforts to facilitate timely enrollment in clinical trials;
• patient referral practices of physicians;
• ability to monitor patients adequately during and after treatment; and
• proximity and availability of clinical trial sites for prospective patients.
Regulatory authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials.
We have discussions with and obtain guidance from regulatory authorities regarding certain aspects of our clinical development activities. These discussions are not binding commitments on the part of regulatory authorities. Under certain circumstances, regulatory authorities may revise or retract previous guidance during the course of our clinical activities or after the completion of our clinical trials. A regulatory authority may also disqualify a clinical trial in whole or in part from consideration in support of approval of a potential product for commercial sale or otherwise deny approval of that product. Prior to regulatory approval, a regulatory authority may elect to obtain advice from outside experts regarding scientific issues and/or marketing applications under a regulatory authority review. In the United States, these outside experts are convened through the FDA’s Advisory Committee process, which would report to the FDA and make recommendations that may differ from the views of the FDA. The FDA is not bound by the recommendations of an Advisory Committee, but it typically follows such recommendations. In addition, should an Advisory Committee be convened, it would be expected to lengthen the time for obtaining regulatory approval, if such approval is obtained at all.
26
The FDA and other foreign regulatory agencies can delay, limit or deny marketing approval for many reasons, including:
• a product candidate may not be considered safe or effective;
• our manufacturing processes or facilities may not meet the applicable requirements; and
• changes in their approval policies or adoption of new regulations may require additional work on our part.
Any delay in, or failure to receive or maintain, approval for any of our product candidates could prevent us from ever generating meaningful revenues or achieving profitability in future years.
Our product candidates may not be approved even if they achieve their endpoints in clinical trials. Regulatory agencies, including the FDA, or their advisors may disagree with our trial design and our interpretations of data from preclinical studies and clinical trials. Regulatory agencies may change requirements for approval even after a clinical trial design has been approved. Regulatory agencies also may approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.
Under the Merck Agreement, we have ongoing obligations related to the development of our Ebola vaccine product candidate, which may result in greater costs and a longer timeframe for regulatory approval than we estimate, yet we will receive limited revenues, if any, from any future sales of our Ebola vaccine product candidate.

Under the Merck Agreement, we have ongoing obligations related to the development of our Ebola vaccine product candidate, including obligations related to clinical trials, government contracting and licensing of the vaccine technology, which may cause us to incur costs or losses materially larger than we expect. However, because we have exclusively licensed the right to research, develop, manufacture and distribute our Ebola vaccine product candidate to Merck and we are only entitled to certain royalty and other payments under the Merck Agreement, we will receive limited revenues, if any, even if we or Merck are successful in developing and commercializing our Ebola vaccine product candidate.

The time and cost of product development and the timeframe for regulatory approval of any Ebola vaccine product candidate are uncertain and may be longer and more costly than we estimate. Our Ebola vaccine product candidate is a live virus based on vesicular stomatitis virus, or VSV. There are no commercial vaccines based upon this virus, and unforeseen problems related to the use of our live virus vaccine may prevent or materially increase costs and delays of further development or approval of our Ebola vaccine product candidate. There may be unknown safety risks associated with the vaccine, and regulatory agencies such as the FDA may require us to conduct extensive safety testing prior to approval to demonstrate a low risk of rare and severe adverse events caused by the vaccine.

Public perception of vaccine safety issues, including adoption of novel vaccines based upon VSV, may adversely influence willingness of subjects to participate in clinical trials, or if approved, of physicians to prescribe, and of patients to receive, novel vaccines. For example, our Ebola vaccine product candidate is currently being developed for prevention of, and may later be developed for treatment of patients infected with, Ebola, and public aversion to vaccines for Ebola or vaccines in general may adversely influence later-stage clinical trials of this product candidate or, if approved, its commercial success.
Even if approved, a number of factors may adversely affect commercial sales. Lack of familiarity with the viral vaccine and potential adverse events associated with vaccination may adversely affect physician and patient perception and uptake of our potential product. Furthermore, there are no assurances that the vaccine will be approved for inclusion in government stockpile programs, which may be material to the commercial success of the product candidate, either in the United States or abroad. If our Ebola vaccine product candidate eventually is approved and sold commercially, we will receive limited revenues under the Merck Agreement. Finally, in certain cases, our obligations to pay royalties to PHAC may exceed the royalties we receive from Merck.
We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed.
Clinical trials must be conducted in accordance with the FDA’s Good Clinical Practice, or GCP, requirements, or other applicable foreign government guidelines and are subject to oversight by the FDA, other foreign governmental agencies and Institutional Review Boards at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates produced under current Good Manufacturing Practice, or cGMP, requirements and may require large numbers of test subjects. Clinical trials may be suspended by the FDA, other foreign governmental agencies, or us for various reasons, including:
27
• deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or clinical protocols;
• inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;
• the product candidate may have unforeseen adverse side effects;
• the time required to determine whether the product candidate is effective may be longer than expected;
• fatalities or other adverse events arising during a clinical trial due to medical problems that may not be related to clinical trial treatments;
• failure to demonstrate a benefit from using a drug;
• the quality or stability of the product candidate may fall below acceptable standards; or
• insufficient quantities of the product candidate to complete the trials.
In addition, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to Institutional Review Boards for reexamination, which may impact the costs, timing or successful completion of a clinical trial. Due to these and other factors indoximod, NLG802, NLG919, and other product candidates could take significantly longer to gain regulatory approval than we expect or we may never gain approval for additional indications, which could reduce our revenue by delaying or terminating their commercialization.
Some of our product candidates have been studied, or in the future may be studied, in clinical trials co-sponsored by organizations or agencies other than us, or in investigator-initiated clinical trials, which means we have little control over the conduct of such trials.
We are currently supplying indoximod, our lead IDO pathway inhibitor product candidate, in support of a Phase 2 investigator-initiated clinical trial, and we provided clinical supply of dorgenmeltucel-L in support of a Phase 2 investigator-initiated clinical trial. Our Ebola vaccine product candidate was studied in clinical trials in West Africa. We may continue to supply and otherwise support similar trials in the future. However, because we are not the sponsors of these trials, we do not control the protocols, administration or conduct of these trials, including follow-up with patients and ongoing collection of data after treatment, and, as a result, are subject to risks associated with the way these types of trials are conducted, in particular should any problems arise. These risks include difficulties or delays in communicating with investigators or administrators, procedural delays and other timing issues and difficulties or differences in interpreting data.
If we cannot demonstrate the safety of our product candidates in preclinical and/or other non-clinical studies, we will not be able to initiate or continue clinical trials or obtain approval for our product candidates.
In order to move a product candidate not yet being tested in humans into a clinical trial, we must first demonstrate in preclinical testing that the product candidate is safe. Furthermore, in order to obtain approval, we must also demonstrate safety in various preclinical and non-clinical tests. We may not have conducted or may not conduct in the future the types of preclinical and other non-clinical testing ultimately required by regulatory authorities, or future preclinical tests may indicate that our product candidates are not safe for use in humans. Preclinical testing is expensive, can take many years and can have an uncertain outcome. In addition, success in initial preclinical testing does not ensure that later preclinical testing will be successful. We may experience numerous unforeseen events during, or as a result of, the preclinical testing process, which could delay or prevent our ability to develop or commercialize our product candidates, including:
• our preclinical testing may produce inconclusive or negative safety results, which may require us to conduct additional preclinical testing or to abandon product candidates that we believed to be promising;
• our product candidates may have unfavorable pharmacology, toxicology or carcinogenicity;
• our product candidates may cause undesirable side effects; and
• the FDA or other regulatory authorities may determine that additional safety testing is required.
Any such events would increase our costs and could delay or prevent our ability to commercialize our product candidates, which could adversely impact our business, financial condition and results of operations.
28
Even if ultimately approved, indoximod, NLG802, NLG919, our Ebola vaccine product candidate or any other potential product we or our collaborators may commercialize and market may be later withdrawn from the market or subject to promotional limitations.
We or our collaborators may not be able to obtain the labeling claims necessary or desirable for the promotion of any potential future products. We or our collaborators may also be required to undertake post-marketing clinical trials. If the results of such post-marketing studies are not satisfactory, the FDA or a comparable agency in a foreign country may withdraw marketing authorization or may condition continued marketing on commitments from us or our collaborators that may be expensive and/or time consuming to fulfill. In addition, if we or others identify adverse side effects after any of our potential products are on the market, or if manufacturing problems occur, regulatory approval may be withdrawn and reformulation of our potential products, additional clinical trials, changes in labeling of our potential products and/or additional marketing applications may be required. Any reformulation or labeling changes may limit the marketability of our potential products.
We will need to develop or acquire additional capabilities in order to commercialize any product candidates that obtain FDA approval, and we may encounter unexpected costs or difficulties in doing so.
We will need to acquire additional capabilities and effectively manage our operations and facilities to successfully pursue and complete future research, development and commercialization efforts. Currently, we have limited experience in preparing applications for marketing approval, commercial-scale manufacturing, managing large-scale information technology systems or managing a large-scale distribution system. We will need to add personnel and expand our capabilities, which may strain our existing managerial, operational, regulatory compliance, financial and other resources.
To do this effectively, we must:
• train, manage and motivate a growing employee base;
• accurately forecast demand for our products; and
• expand existing operational, financial and management information systems.
We will need to increase our manufacturing capacity, which may include negotiating and entering into additional third-party agreements to meet our commercial manufacturing requirements.
If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate significant product revenue.

We do not have a sales organization and have no experience in the sales and distribution of pharmaceutical products. There are risks involved with establishing our own sales capabilities and increasing our marketing capabilities, as well as entering into arrangements with third parties to perform these services. Developing an internal sales force is expensive and time consuming and could delay any product launch. On the other hand, if we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues to us could potentially be lower than if we market and sell these products ourselves.

We entered into the Merck Agreement in November 2014 for the research, development, manufacture and distribution of our Ebola vaccine product candidate. Even if our Ebola vaccine product candidate is approved by regulators for marketing and sale, Merck may be unsuccessful in its efforts to commercialize our Ebola vaccine product candidate, respectively, or may devote fewer resources to such efforts than we would consider optimal.
We may establish our own specialty sales force and/or engage other biopharmaceutical or other healthcare companies with established sales, marketing and distribution capabilities to sell, market and distribute any future products. We may not be able to establish a specialty sales force or establish sales, marketing or distribution relationships on acceptable terms. Factors that may inhibit our efforts to commercialize any future products without strategic collaborators or licensees include:
• our inability to recruit and retain adequate numbers of effective sales and marketing personnel;
• the inability of sales personnel to obtain access to an adequate number of physicians to educate them about the attributes of any future products;
• the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and
29
• unforeseen costs and expenses associated with creating an independent sales and marketing organization.
Because the establishment of sales, marketing and distribution capabilities depends on the progress toward commercialization of our product candidates, and because of the numerous risks and uncertainties involved with establishing those capabilities, we are unable to predict when, if ever, we will establish our own sales, marketing and distribution capabilities. If we are not able to collaborate with third parties and are unsuccessful in recruiting sales, marketing and distribution personnel or in building the necessary infrastructure, we will have difficulty commercializing our product candidates, which would adversely affect our business and financial condition.
Failure to attract and retain key personnel could impede our ability to develop our products and to obtain new collaborations or other sources of funding.
Because of the specialized scientific nature of our business, our success is highly dependent upon our ability to attract and retain qualified scientific and technical personnel, consultants and advisors. We are highly dependent on the principal members of our scientific and management staff. The long-term loss of services of key executives might significantly delay or prevent the achievement of our research, development, and business objectives. We do not maintain key-man life insurance with respect to any of our employees, nor do we intend to secure such insurance.
We will need to recruit additional personnel in order to achieve our operating goals. In order to pursue product development and marketing and sales activities, if any, we will need to hire additional qualified scientific personnel to perform research and development, as well as personnel with expertise in clinical testing, government regulation, manufacturing, marketing and sales. We also rely on consultants and advisors to assist in formulating our research and development strategy and adhering to complex regulatory requirements. We face competition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities and other research institutions. There can be no assurance that we will be able to attract and retain such individuals on acceptable terms, if at all. Additionally, our only significant facility is located in Iowa, which may make attracting and retaining qualified scientific and technical personnel from outside of Iowa difficult. The failure to attract and retain qualified personnel, consultants and advisors could have a material adverse effect on our business, financial condition and results of operations.
Risks Relating to Manufacturing Activities
We rely on third-party manufacturers to produce our preclinical and clinical product candidate supplies and we intend to rely on third parties to produce commercial supplies of any product candidates that may be approved in the future. Any failure by a third-party manufacturer to produce supplies for us may delay or impair our ability to complete our clinical trials or commercialize our product candidates.
We do not possess all of the capabilities to fully commercialize any of our product candidates on our own. If we are unable to arrange for third-party manufacturing sources, or to do so on commercially reasonable terms, we may not be able to complete development of such product candidates or market them. In addition, we currently rely on our partner Merck for the supply of our Ebola vaccine product candidate and other third party manufacturers for our supply of indoximod, NLG802, and NLG919 for preclinical and clinical studies. Problems with any of our facilities or processes, or our contract manufacturers’ facilities or processes, could prevent or delay the production of adequate supplies of indoximod, NLG802, NLG919, our Ebola vaccine product candidate or other finished products.

Any prolonged delay or interruption in the operations of our current or future contract manufacturers’ facilities could result in cancellation of shipments, loss of components in the process of being manufactured or a shortfall in availability of a product. A number of factors could cause interruptions, including the inability of a supplier to provide raw materials, equipment malfunctions or failures, damage to a facility due to natural disasters, changes in international or U.S. regulatory requirements or standards that require modifications to our manufacturing processes, action by regulatory authorities or by us that results in the halting or slowdown of production of components or finished product due to regulatory issues, a contract manufacturer going out of business or failing to produce product as contractually required or other similar factors. Because manufacturing processes are highly complex and are subject to a lengthy regulatory approval process, alternative qualified production capacity and sufficiently trained or qualified personnel may not be available on a timely or cost-effective basis or at all. Difficulties or delays in our contract manufacturers’ production of product candidates could delay our clinical trials, increase our costs, damage our reputation and cause us to lose revenue and market share if we are unable to meet market demand for any products that are approved for sale on a timely basis.

30
Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control, failure of the third party to accept orders for supply of drug substance or drug product and the possibility of termination or nonrenewal of the agreement by the third-party based on its own business priorities and at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates be manufactured according to cGMP and similar foreign standards. Any failure by our third-party manufacturers to comply with cGMP or failure to scale-up manufacturing processes as needed, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be the basis for action by the FDA to withdraw approvals for product candidates that may have been granted to us and for other regulatory action, including recall or seizure, fines, imposition of operating restrictions, total or partial suspension of production or injunctions.

We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical studies. There are a small number of suppliers for certain capital equipment and raw materials that are used to manufacture our product candidates. Such suppliers may not sell this capital equipment or these raw materials to our manufacturers at the times we need them or on commercially reasonable terms. We do not have any control over the process or timing of the acquisition of this capital equipment or these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Any significant delay in the supply of a product candidate or the raw material components thereof for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.

Because of the complex nature of many of our early stage compounds and product candidates, our manufacturers may not be able to manufacture such compounds and product candidates at a cost or in quantities or in a timely manner necessary to develop and commercialize related products. If we successfully commercialize any of our product candidates, we may be required to establish or access large-scale commercial manufacturing capabilities. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical trial and commercial manufacturing capacity. To meet our projected needs for commercial manufacturing in the event that one or more of our product candidates gains marketing approval, third parties with whom we currently work will need to increase their scale of production or we will need to secure alternate suppliers.
Furthermore, we do not currently have experience with the management of relationships related to commercial-scale contract manufacturing, and we may incur substantial costs to develop the capability to negotiate and enter into relationships with third-party contract manufacturers.
We and our contract manufacturers are subject to significant regulation with respect to manufacturing of our products.
All entities involved in the preparation of a therapeutic drug for clinical trials or commercial sale, including our Company, our existing contract manufacturers and those we may engage in the future, and Merck in its capacity as our licensee, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Our facilities and quality systems and the facilities and quality systems of some or all of our third party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of any of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of any of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. In addition, to the extent that we rely on foreign contract manufacturers, as we do currently for our Ebola vaccine product candidate, we are or will be subject to additional risks including the need to comply with export and import regulations.
31
If our current or future contract manufacturers are not in compliance with regulatory requirements at any stage, including post-marketing approval, we may be fined, forced to remove a product from the market and/or experience other adverse consequences, including delays, which could materially harm our business.
Our costs for the manufacture and clinical development of our Ebola vaccine product candidate may exceed our current or any future funding for development efforts of our Ebola vaccine product candidate.
We have entered into certain manufacturing and clinical trial management agreements for our Ebola vaccine product candidate, and we expect to enter into additional agreements and incur additional costs related to our obligations under the Merck Agreement and our agreements with government agencies that are providing funding to us for the development of our Ebola vaccine product candidate. The total costs that we are likely to incur to fulfill our contractual obligations under agreements with third parties for the development of our Ebola vaccine product candidate may exceed our total amount of funding from all sources for such activities. In addition, we are likely to incur operating expenses related to our Ebola vaccine product candidate in addition to our direct contractual costs of administering clinical and other studies.  Our failure to obtain sufficient grants or other funding for our Ebola vaccine development efforts will not relieve us of our obligations under our current or future contract manufacturing and other agreements for the Ebola vaccine product candidate.
Our facility is located in areas where floods and tornados are known to occur, and the occurrence of a flood, tornado or other catastrophic disaster could damage our facilities and equipment, which could cause us to curtail or cease operations.
Our primary facility is located in Ames, Iowa, which is susceptible to floods and tornados, and our facility is therefore vulnerable to damage or disruption from floods and tornados. We are also vulnerable to damage from other types of disasters, such as power loss, fire and similar events. If any disaster were to occur, our ability to operate our business could be seriously impaired. We currently carry business insurance (real, personal and business income) of nearly $11.6 million in the aggregate, but this policy does not cover disasters such as floods and earthquakes. We may not have adequate insurance to cover our losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business and financial condition.
Significant disruptions of information technology systems or breaches of data security could adversely affect our business.
We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have also outsourced elements of our information technology infrastructure, and as a result we manage a number of third-party vendors who may or could have access to our confidential information. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches and other cyber-attacks. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent the adverse effect of such events. Significant disruptions of our information technology systems or breaches of data security could adversely affect our business.
Risks Relating to Regulation of Our Industry
The industry within which we operate and our business are subject to extensive regulation, which is costly and time consuming and which may subject us to unanticipated delays.
The research, development, testing, manufacturing, labeling, packaging, marketing, distribution, promotion and advertising of biologic and pharmaceutical products such as our product candidates are subject to extensive regulation by governmental regulatory authorities in the United States and other countries. The drug development and approval process is generally lengthy, expensive and subject to unanticipated delays. Data obtained from preclinical and clinical testing are subject to varying interpretations that could delay, limit or prevent regulatory approval. In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of development and regulatory review of each submitted application for approval. To obtain approval for a product candidate, we must demonstrate to the satisfaction of the regulatory authorities that the product candidate is safe and effective in the case of a small-molecule pharmaceutical product, or
32
is safe, pure and potent in the case of a biologic, which typically takes several years or more depending upon the type, complexity and novelty of the product and requires the expenditure of substantial resources.
There can be no assurance that we will not encounter problems in clinical trials that would cause us or the regulatory authorities to delay or suspend clinical trials. Any such delay or suspension could have a material adverse effect on our business, financial condition and results of operations. There can be no assurance that we will not encounter problems in clinical trials that would cause us or the regulatory authorities to delay or suspend clinical trials. Any such delay or suspension could have a material adverse effect on our business, financial condition and results of operations. There can be no assurance that clinical trials for any of our product candidates currently under development will be completed successfully or within any specified time period, if at all. Further, there can also be no assurance that such testing will show any product to be safe, pure, potent or effective. We cannot predict when, if ever, we might submit for regulatory review our product candidates currently under development. In addition, regardless of how much time and resources we devote to development of a product candidate, there can be no assurance that regulatory approval will be obtained for that product candidate.
Even if such regulatory approval is obtained, we, our products and any contract manufacturers or commercial collaborators of ours will be subject to continual regulatory review in both the United States and other countries. Later discovery of previously unknown problems with regard to a product, distributor or manufacturer may result in restrictions, including withdrawal of the product from the market and/or disqualification or decertification of the distributor or manufacturer. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with regulatory requirements of the FDA and/or non-U.S. regulatory authorities, we could be subject to administrative or judicially imposed sanctions, including:
• warning letters;
• civil or criminal penalties;
• injunctions;
• suspension of or withdrawal of regulatory approval;
• total or partial suspension of any ongoing clinical trials or of production;
• voluntary or mandatory product recalls and publicity requirements;
• refusal to approve pending applications for marketing approval of new products or supplements to approved applications filed by us;
• restrictions on operations, including costly new manufacturing requirements; or
• seizure or detention of our products or import bans.
The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of new biologic and pharmaceutical products through lengthy and detailed preclinical and clinical testing procedures, sampling activities and other costly and time-consuming compliance procedures. Clinical trials are vigorously regulated and must meet requirements for FDA review and oversight and requirements under GCP guidelines. A new drug may not be marketed in the United States until the FDA has approved it. There can be no assurance that we will not encounter delays or rejections or that the FDA will not make policy changes during the period of product development and FDA regulatory review of each submitted BLA and NDA. A delay in obtaining, or failure to obtain, such approvals would have a material adverse effect on our business, financial condition and results of operations. Even if regulatory approval were obtained, it would be limited as to the indicated uses for which the product may be promoted or marketed. A marketed product, its manufacturer and the facilities in which it is manufactured are subject to continual review and periodic inspections. If marketing approval is granted, we would be required to comply with FDA requirements for manufacturing, labeling, advertising, record-keeping and reporting of adverse experiences and other information. In addition, we would be required to continue to comply with federal and state anti-kickback and other healthcare fraud and abuse laws that pertain to the marketing of pharmaceuticals, among other things. Failure to comply with regulatory requirements and other factors could subject us to regulatory or judicial enforcement actions, including product recalls or seizures, injunctions, withdrawal of the product from the market, civil penalties, criminal prosecution, refusals to approve new products and withdrawals of existing approvals, as well as enhanced product liability exposure, any of which could have a material adverse effect on our business, financial condition and results of operations. Sales of our products outside the United States will be subject to foreign regulatory requirements governing clinical trials, marketing approval, manufacturing and pricing. Noncompliance with these requirements could result in enforcement actions or penalties or could delay introduction of our products in certain countries.

The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement outside the United States vary greatly from country to country. The time required to obtain approvals outside the United States may differ from
33
that required to obtain FDA approval. We may not obtain foreign regulatory approvals on a timely basis, or at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA. Foreign regulatory authorities could also require additional testing. Failure to comply with these regulatory requirements or obtain required approvals could impair our ability to develop foreign markets for our products and may have a material adverse effect on our results of operations and financial condition.
We are also subject to laws generally applicable to businesses including, but not limited to, federal, state and local regulations relating to wage and hour matters, employee classification, mandatory healthcare benefits, unlawful workplace discrimination and whistleblowing. Any actual or alleged failure to comply with any regulation applicable to our business or any whistleblowing claim, even if without merit, could result in costly litigation or regulatory action or otherwise harm our business, results of operations, financial condition, cash flow and future prospects.
The availability of coverage and amount of reimbursement for our product candidates, if approved, and the manner in which government and private payers may reimburse for our potential products, are uncertain.

In both the United States and foreign markets, sales of our proposed products will depend in part on the availability of coverage and reimbursement from third-party payers such as government health administration authorities, private health insurers and other organizations. In addition, the process for determining whether a third party payer will provide coverage for a pharmaceutical typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payers are increasingly challenging the price and cost-effectiveness of medical products and services.
Significant uncertainty exists as to the reimbursement status of newly approved healthcare products. There can be no assurance that our proposed products will be considered cost-effective or that adequate third-party reimbursement will be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.
Our future levels of revenues and profitability may be affected by the continuing efforts of governmental and third-party payers to contain or reduce the costs of healthcare. We cannot predict the effect that private sector or governmental health care reforms may have on our business, and there can be no assurance that any such reforms will not have a material adverse effect on our business, financial condition and results of operations. Legislation and regulations affecting the pricing of pharmaceuticals may change before any of our proposed products are approved for marketing. Adoption of such legislation could further limit reimbursement for medical products and services. As a result, we may elect not to market future products in certain markets.
Moreover, while we are in clinical trials, we will not be reimbursed for any of our materials used during the clinical trials, however, certain services rendered to clinical trial participants may be reimbursable by third-party payors for standard of care treatment if not otherwise reimbursed under the applicable clinical trial study budget.

34
The biopharmaceutical industry is subject to significant regulation and oversight in the United States, in addition to approval of products for sale and marketing; our failure to comply with these laws could harm our results of operations and financial condition.
In addition to FDA restrictions on marketing of biopharmaceutical products, our operations may be directly, or indirectly through our relationships with healthcare providers, customers and third-party payers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute. These laws may impact, among other things, our proposed sales, and education programs, and these laws have been applied to restrict certain marketing practices in the biopharmaceutical industry. In addition, we may be subject to patient privacy regulation by both the U.S. federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, among others, the following:
• The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any health care item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Moreover, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.
• The federal civil False Claims Act prohibits any person or entity from knowingly presenting, or causing to be presented, to the federal government a claim for payment or approval that is false or fraudulent or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Several pharmaceutical and other health-care companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of off-label promotion. Private parties may initiate qui tam whistleblower lawsuits against any person or entity under the federal civil False Claims Act in the name of the government and share in the proceeds of the lawsuit.
• The federal Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the federal Anti- Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. 
• HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization on covered entities, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information.
• The federal Food, Drug and Cosmetic Act, or FDCA, prohibits, among other things, the adulteration or misbranding of drugs and medical devices.
• The federal Physician Payments Sunshine Act, and its implementing regulations require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services, or CMS, information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment interests held by physicians and other healthcare providers and their immediate family members.
35
• Analogous state laws and regulations include: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information and that require tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. It is possible that some of our business activities could be subject to challenge under one or more of these laws, which could have a material adverse effect on our business, financial condition and results of operations.
We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA’s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. Notably, on January 30, 2017, President Trump issued an Executive Order, applicable to all executive agencies, including the FDA, that required that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the “two-for-one” provisions. This Executive Order included a budget neutrality provision that required the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the Executive Order requires agencies to identify regulations that can be repealed to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within OMB on February 2, 2017, the administration indicates that the “two-for-one” provisions may apply not only to agency regulations, but also to significant agency guidance documents. Further, on February 24, 2017, President Trump issued an Executive Order requiring each agency to designate a regulatory reform officer and create a regulatory reform task force to evaluate existing regulations and make recommendations regarding their repeal, replacement, or modification. It is difficult to predict how these requirements will continue to be enforced, the extent to which they will continue to impact the FDA’s ability to exercise its regulatory authority, and the negative impact they may have on our business.
Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
The U.S. and some foreign jurisdictions are considering or have enacted a number of additional legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. For example, in the United States, the pharmaceutical industry has been affected by the passage of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, which, among other things, imposed new fees on entities that manufacture or import certain branded prescription drugs and expanded pharmaceutical manufacturer obligations to provide discounts and rebates to certain government programs. There have been judicial and congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Act includes a provision repealing, effective
36
January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole”. More recently, in July 2018, CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Congress may consider other legislation to repeal and replace elements of the ACA.
In addition, there has been particular and increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices in recent years, particularly with respect to drugs that have been subject to relatively large price increases over relatively short time periods. There have been several recent U.S. Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. The Trump administration’s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. While any proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Additionally, the Trump administration released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. HHS, has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January 1, 2018, and in October 2018, CMS proposed a new rule that would require direct-to-consumer television advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the “Wholesale Acquisition Cost”, or list price, of that drug or biological product.  Any of these initiatives could harm our ability to generate revenues.
In the future, there will likely continue to be proposals relating to the reform of the U.S. healthcare system, some of which could further limit coverage and reimbursement of drug products, including our product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
Individual states are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures and to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payers or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which pharmaceutical products and suppliers will be included in their prescription drug and other healthcare programs. This could reduce ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.
Furthermore, regulatory authorities’ assessment of the data and results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable to our business prospects. For example, average review times at the FDA for marketing approval applications have fluctuated over the last 10 years, and we cannot predict the review time for any of our submissions with any regulatory authorities. In addition, review times can be affected by a variety of factors, including budget and funding levels and statutory, regulatory and policy changes.
Additionally, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 ("Right to Try Act") was signed into law. The law, among other things, provides a federal framework for certain
37
patients to access certain investigational new drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program.

We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislative or administrative action, either in the United States or abroad.
We use hazardous materials in our business and must comply with environmental laws and regulations, which can be expensive.
Our research and development involves the controlled use of hazardous materials, chemicals, various active microorganisms and volatile organic compounds, and we may incur significant costs as a result of the need to comply with numerous laws and regulations. We are subject to laws and regulations enforced by the FDA, the Drug Enforcement Agency, foreign health authorities and other regulatory requirements, including the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Food, Drug and Cosmetic Act, the Resource Conservation and Recovery Act, and other current and potential federal, state, local and foreign laws and regulations governing the use, manufacture, storage, handling and disposal of our products, materials used to develop and manufacture our product candidates, and resulting waste products. Although we believe that our safety procedures for handling and disposing of such materials, and for killing any unused microorganisms before disposing of them, comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages that result and any such liability could exceed our resources.
Failure to comply with existing or future data protection laws and regulations related to privacy or data security could lead to government enforcement actions (which could include civil or criminal fines or penalties), private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, could limit their use or adoption, and could otherwise negatively affect our operating results and business.
Regulation of data processing is evolving, as federal, state, and foreign governments continue to adopt new, or modify existing, laws and regulations addressing data privacy and security, and the collection, processing, storage, transfer, and use of data. We and our partners may be subject to current, new, or modified federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). These new or proposed laws and regulations are subject to differing interpretations and may be inconsistent among jurisdictions, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data. These and other requirements could require us or our partners to incur additional costs to achieve compliance, limit our competitiveness, necessitate the acceptance of more onerous obligations in our contracts, restrict our ability to use, store, transfer, and process data, impact our or our partners’ ability to process or use data in order to support the provision of our products or services, or affect our or our partners’ ability to offer our products and services in certain locations.
In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to civil and/or criminal penalties including if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. 
International data protection laws, including, without limitation, the European Union Directive 95/46/EC, or the Directive, and the European Union’s General Data Protection Regulation, or the GDPR, that took effect in May 2018, and member state data protection legislation, may also apply to health-related and other personal information obtained outside of the United States. These laws impose strict obligations on the ability to process health-related and other personal information of data subjects in the European Union, including in relation to use, collection, analysis and transfer of such personal information. These laws include several requirements relating to the consent of the individuals to whom the personal data relates, limitations on data processing, establishing a legal basis for processing, notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects, the security and confidentiality of the personal data and various rights that data subjects may exercise.
38
The Directive and the GDPR prohibits, without an appropriate legal basis, the transfer of personal data to countries outside of the European Economic Area, or EEA, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions.
Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United States, uncertainty about compliance with European Union data protection laws remains. For example, ongoing legal challenges in Europe to the mechanisms allowing companies to transfer personal data from the EEA to the United States could result in further limitations on the ability to transfer personal data across borders, particularly if governments are unable or unwilling to reach new or maintain existing agreements that support cross-border data transfers, such as the European Union-U.S. and Swiss-U.S. Privacy Shield framework. Additionally, other countries have passed or are considering passing laws requiring local data residency.
Under the GDPR, regulators may impose substantial fines and penalties for non-compliance. Companies that violate the GDPR can face fines of up to the greater of 20 million Euros or 4% of their worldwide annual turnover (revenue). The GDPR has increased our responsibility and liability in relation to personal data that we process, requiring us to put in place additional mechanisms to ensure compliance with the GDPR and other EU and international data protection rules.
Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals’ privacy rights, failed to comply with data protection laws, or breached our contractual obligations related to security or privacy, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. Compliance with data protection laws may be time-consuming, require additional resources and could result in increased expenses, reduce overall demand for our products and services and make it more difficult to meet expectations of or commitments to customers or partners.
Any of these matters could materially adversely affect our business, financial condition, or operational results.
Financial Risks
We have a history of net losses. We incurred a net loss for the years ended December 31, 2016 and 2017 and expect to continue to incur net losses for the foreseeable future, and we may never achieve or maintain profitability in the future.
We were profitable in the year ended December 31, 2014, primarily as a result of upfront payments under the Genentech Agreement and the Merck Agreement. We are not entitled to receive any additional upfront payments under these licensing or collaboration agreements. We do not expect any milestone or royalty payments under these or other agreements, if any, to be sufficient to make us profitable in future years. We incurred a loss of $43.0 million for the nine months ended September 30, 2018 and we do not expect to be profitable for the foreseeable future. We anticipate that we will continue to incur operating losses over the next several years as we continue our clinical development programs.
Because of the numerous risks and uncertainties associated with biopharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of future expenses or when, or if, we will be able to achieve or maintain profitability. Currently, we have no products approved for commercial sale, and to date we have not generated any product revenue. We have financed our operations primarily through the sale of equity securities, government grants, economic development loans and capital lease and equipment financing. The size of our future net losses will depend, in part, on the rate of growth or contraction of our expenses and the level and rate of growth, if any, of our revenues. Our ability to achieve profitability in future years is dependent on our ability, alone or with others, to complete the development of our products successfully, obtain the required regulatory approvals, manufacture and market our proposed products successfully or have such products manufactured and marketed by others and gain market acceptance for such products. There can be no assurance as to whether or when we will achieve profitability.
We may require substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.
Development of our product candidates will require substantial additional funds to conduct research, development and clinical trials necessary to bring such product candidates to market and to establish manufacturing, marketing and distribution
39
capabilities, either internally or through collaborations with third parties. Our future capital requirements will depend on many factors, including, among others:
• the scope, rate of progress, results and costs of our preclinical studies, clinical trials and other research and development activities;
• the scope, rate of progress and costs of our manufacturing development and commercial manufacturing activities;
• the cost, timing and outcomes of regulatory proceedings (including FDA review of any BLA or NDA we file);
• payments required with respect to development milestones we achieve under our in-licensing agreements;
• the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims, including litigation costs and the outcome of such litigation;
• the costs associated with commercializing our product candidates, if they receive regulatory approval;
• the cost of manufacturing our product candidates and any products we commercialize;
• the cost and timing of developing our ability to establish sales and marketing capabilities;
• the potential requirement to repay our outstanding government provided loans;
• competing technological efforts and market developments;
• changes in our existing research relationships;
• our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;
• the timing and receipt of revenues from existing or future products, if any; and
• payments received under any future strategic collaborations.
We anticipate that we will continue to generate significant losses in the future as we incur expenses to complete our clinical trial programs for our product candidates, develop our pipeline and pursue regulatory approval of our product candidates. We believe that our existing cash and cash equivalents will allow us to fund our operating plan in the near and medium term. However, our operating plan may change as a result of factors currently unknown to us.
There can be no assurance that our revenue and expense forecasts will prove to be accurate, and any change in the foregoing assumptions could require us to obtain additional financing earlier than anticipated. There is a risk of delay or failure at any stage of developing a product candidate, and the time required and costs involved in successfully accomplishing our objectives cannot be accurately predicted. Actual drug research and development costs could substantially exceed budgeted amounts, which could force us to delay, reduce the scope of or eliminate one or more of our research or development programs.
We are party to license agreements with various parties pursuant to which we have obtained licenses to certain patents, patent applications and other intellectual property related to our product candidates and product development efforts. Pursuant to most of these license agreements, we are obligated to make aggregate payments ranging from approximately $350,000 to $4.3 million under our license agreements (and in some cases, for each product candidate in such license) upon achievement of development and regulatory approval milestones specified in the applicable license. The timing of our achievement of these events and corresponding milestone payments to our licensors is subject to factors relating to the clinical and regulatory development and commercialization of our product candidates, many of which are beyond our control. We may become obligated to make a milestone payment when we do not have the cash on hand to make such payment, which could require us to delay our clinical trials, curtail our operations, scale back our commercialization or marketing efforts or seek funds to meet these obligations on terms unfavorable to us.
We may never be able to generate a sufficient amount of product revenue to cover our expenses. Until we do, we expect to seek additional funding through public or private equity or debt financings, collaborative relationships, capital lease transactions or other available financing transactions. However, there can be no assurance that additional financing will be available on acceptable terms, if at all, and such financings could be dilutive to existing stockholders. Moreover, in the event that additional funds are obtained through arrangements with collaborators, such arrangements may require us to relinquish rights to certain of our technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves.
40
If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs. Our failure to obtain adequate financing when needed and on acceptable terms would have a material adverse effect on our business, financial condition and results of operations.
Even though we have received governmental support in the past, we may not continue to receive support at the same level or at all.
We have received significant financial assistance, primarily in the form of forgivable loans, from state and local governments. We have also received significant financial assistance, primarily in the form of grants and contracts, from federal agencies to support our infectious disease research. There can be no assurance that we will continue to receive the same level of assistance from these or other government agencies, if at all.
Through our subsidiary, BioProtection Systems Corporation, or BPS, we have received funding from multiple government agencies for our Ebola vaccine product candidate development efforts. There is no guarantee that we will receive sufficient, or any, future grant funding to meet our obligations related to our Ebola vaccine development or that we or Merck will succeed in developing an Ebola vaccine. The termination of a United States government grant, contract or relationship as a result of our failure to satisfy any of our obligations under the grants or contracts would have a negative impact on our operations and harm our reputation and ability to procure government contracts. Additionally, there can be no assurance that we will secure comparable contracts with, or grants from, the United States government in the future.
Changes in our effective income tax rate could adversely affect our results of operations in the future.
For the three and nine months ended September 30, 2018, we have recorded a $7.0 million tax benefit. Our effective income tax rate, as well as our relative domestic and international tax liabilities, will depend in part on the allocation of any future income among different jurisdictions. In addition, various factors may have favorable or unfavorable effects on our effective income tax rate in individual jurisdictions or in the aggregate. These factors include whether tax authorities agree with our interpretations of existing tax laws, any required accounting for stock options and other share-based compensation, changes in tax laws and rates (including the recently enacted U.S. federal income tax law changes), our future levels of research and development spending, changes in accounting standards, changes in the mix of any future earnings in the various tax jurisdictions in which we may operate, the outcome of any examinations by the U.S. Internal Revenue Service or other tax authorities, the accuracy of our estimates for unrecognized tax benefits and realization of deferred tax assets and changes in overall levels of pre-tax earnings. The effect on our income tax liabilities resulting from the above-mentioned factors or other factors could have a material adverse effect on our results of operations.
The recently enacted comprehensive tax reform bill could adversely affect our business and financial condition.
On December 22, 2017 the Tax Act was signed into law. The Tax Act significantly revised the Internal Revenue Code of 1986, as amended and included, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits.  Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act is uncertain and our business and financial condition could be adversely affected.  In addition, it is uncertain if and to what extent various states will conform to the newly enacted Tax Act.  The impact of this tax reform on holders of our common stock is also uncertain and could be adverse.  We urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.
Risks Relating to Competition
We compete in an industry characterized by extensive research and development efforts and rapid technological progress. New discoveries or commercial developments by our competitors could render our potential products obsolete or non-competitive.
New developments occur and are expected to continue to occur at a rapid pace, and there can be no assurance that discoveries or commercial developments by our competitors will not render some or all of our potential products obsolete or non-competitive, which would have a material adverse effect on our business, financial condition and results of operations.
41
We expect to compete with fully integrated and well-established pharmaceutical and biotechnology companies in the near and long term. Most of these companies have substantially greater financial, research and development, manufacturing and marketing experience and resources than we do and represent substantial long-term competition for us. Such companies may succeed in discovering and developing pharmaceutical products more rapidly than we do or pharmaceutical products that are safer, more effective or less costly than any that we may develop. Such companies also may be more successful than we are in production and marketing. Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical and established biotechnology companies. Academic institutions, governmental agencies and other public and private research organizations also conduct clinical trials, seek patent protection and establish collaborative arrangements for the development of oncology products.
We may face competition based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities, reimbursement coverage, price and patent position. There can be no assurance that our competitors will not develop safer and more effective products, commercialize products earlier than we do, or obtain patent protection or intellectual property rights that limit our ability to commercialize our products.
There can be no assurance that our issued patents or pending patent applications, if issued, will not be challenged, invalidated or circumvented or that the rights granted thereunder will provide us with proprietary protection or a competitive advantage.
The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Many of the products that we are attempting to develop and commercialize will be competing with existing therapies. In addition, a number of companies are pursuing the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face competition from pharmaceutical and biotechnology companies both in the United States and abroad. Our competitors may utilize discovery technologies and techniques or collaborate with third parties in order to develop products more rapidly or successfully than we or our collaborators are able to do. Many of our competitors, particularly large pharmaceutical companies, have substantially greater financial, technical and human resources than we do. In addition, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies and may establish exclusive collaborative or licensing relationships with our competitors.
We face intense competition in our development activities. We face competition from many companies in the United States and abroad, including a number of large pharmaceutical companies, firms specialized in the development and production of vaccines, checkpoint inhibitors, and other immunotherapies, and major universities and research institutions. Many companies have entered into the field of immuno-oncology and are developing or commercializing products in areas that we have targeted for product development. Some of these products use therapeutic approaches that may compete directly with our product candidates. Most of our competitors possess substantially greater financial, technical and human resources than we possess. In addition, many of our competitors have significantly greater experience than we have in conducting preclinical and nonclinical testing and human clinical trials of product candidates, scaling up manufacturing operations and obtaining regulatory approvals of drugs and manufacturing facilities. Accordingly, our competitors may succeed in obtaining regulatory approval for drugs more rapidly than we do. We expect to face growing competition for enrollment of patients in our clinical trials, which could delay or adversely affect our ability to complete such trials. We may also be adversely effected by the clinical trial results of our competitors. For example, if a competitor announces inconclusive or negative clinical trial results with respect to an IDO pathway inhibitor, expectations about IDO pathway inhibitors may be generally impacted and we may experience difficulty in enrolling patients in our indoximod trials. If we obtain regulatory approval and launch commercial sales of our product candidates, we also will compete with respect to manufacturing efficiency and sales and marketing capabilities, areas in which we currently have limited experience.
We also face competition from pharmaceutical and biotechnology companies, academic institutions, government agencies and private research organizations in recruiting and retaining highly qualified scientific personnel and consultants and in the development and acquisition of technologies. Moreover, technology controlled by third parties that may be advantageous to our business may be acquired or licensed by our competitors, thereby preventing us from obtaining technology on commercially reasonable terms, if at all. We will also compete for the services of third parties that may have already developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies to target the diseases on which we have focused both inside and outside of the United States.
Our competitive position will also depend upon our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes and secure sufficient capital resources for the often lengthy period between technological conception and commercial sales. We will require substantial capital resources to complete development of some or all of our products, obtain the necessary regulatory approvals and successfully manufacture and market our products. In order
42
to secure capital resources, we may elect to sell additional capital stock, which would dilute the holdings of existing stockholders. We may also attempt to obtain funds through research grants and agreements with commercial collaborators. However, these types of financings are uncertain because they are at the discretion of the organizations and companies that control the funds. Accordingly, we may not receive any additional funds from grants or collaborations.
Research and discoveries by others may result in breakthroughs that render indoximod, NLG802 and NLG919 product candidates, or our other potential products obsolete even before they begin to generate any revenue. If the FDA approves the commercial sale of any of our product candidates, we will also be competing with respect to marketing capabilities and manufacturing efficiency, areas in which we have limited or no experience. We expect that competition among products approved for sale will be based, among other things, on product efficacy, price, safety, reliability, availability, patent protection, and sales, marketing and distribution capabilities. Our profitability and financial position will suffer if our products receive regulatory approval but cannot compete effectively in the marketplace.
Our future products, if any, may not be accepted in the marketplace and therefore, we may not be able to generate significant revenue, or any revenue.
Even if our potential products are approved for sale, physicians and the medical community may not ultimately use them or may use them only in applications more restricted than we expect. Our future products, if successfully developed, will compete with a number of traditional immuno-oncology products manufactured and marketed by major pharmaceutical and other biotechnology companies. Our products will also compete with new products currently under development by such companies and others. Physicians will prescribe a product only if they determine, based on experience, clinical data, side effect profiles and other factors, that it is beneficial as compared to other products currently in use. Many other factors influence the adoption of new products, including marketing and distribution restrictions, course of treatment, adverse publicity, product pricing, the views of thought leaders in the medical community and coverage and adequate reimbursement by government and private third-party payers.
Risks Relating to Our Arrangements with Third Parties
We rely on third parties to conduct our preclinical studies and our clinical trials. If these third parties do not perform as contractually required or expected, we may not be able to obtain regulatory approval for our product candidates, or we may be delayed in doing so.
We do not have the ability to conduct preclinical studies or clinical trials independently for our product candidates. We must rely on third parties, such as contract research organizations, medical institutions, academic institutions, clinical investigators and contract laboratories, as well as our strategic collaborators and the third parties that they may use, to conduct our preclinical studies and clinical trials. Other than to the extent that Merck is responsible for clinical trials of our Ebola vaccine product candidate, we are responsible for confirming that our studies are conducted in accordance with applicable regulations and that each of our clinical trials is conducted in accordance with its general investigational plan and protocol. The FDA requires us to comply with GLP for conducting and recording the results of our preclinical studies and with GCP for conducting, monitoring, recording and reporting the results of clinical trials, to assure that data and reported results are accurate and that the clinical trial participants are adequately protected. Our reliance on third parties does not relieve us of these responsibilities. If the third parties conducting our clinical trials do not perform their contractual duties or obligations, do not meet expected deadlines, fail to comply with GCP, do not adhere to our clinical trial protocols or otherwise fail to generate reliable clinical data, we may need to enter into new arrangements with alternative third parties and our clinical trials may be more costly than expected or budgeted, be extended, delayed or terminated or may need to be repeated, and we may not be able to obtain regulatory approval for or to commercialize the product candidate being tested in such trials, or may be delayed in doing so.
Further, if our contract manufacturers are not in compliance with regulatory requirements at any stage, including post-marketing approval, we may be fined, forced to remove a product from the market and/or experience other adverse consequences, including delays, which could materially harm our business.
We are also dependent on Merck for the development of the product candidates that are the subject of the Merck Agreement. If the company does not succeed in advancing the product candidate to final approval, or decides to discontinue its collaboration with us, such failure or decision, could materially harm our business.
43
If we fail to enter into any needed collaboration agreements for our product candidates, or if we enter into collaborations that are ultimately unsuccessful, we may be unable to commercialize any potential product effectively or at all.
To successfully commercialize any potential product, we will need substantial financial resources as well as expertise and physical resources and systems. We may elect to develop some or all of these physical resources and systems and expertise ourselves or we may seek to collaborate with another company that can provide some or all of such physical resources and systems as well as financial resources and expertise, as we did in the case of the Genentech Agreement and the Merck Agreement. Such collaborations are complex, and any potential discussions may not result in a definitive agreement for many reasons. For example, whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of our clinical trials, the potential market for the subject product candidates, the costs and complexities of manufacturing and delivering the potential product to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of our technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. If we were to determine that a collaboration for a potential product is necessary or beneficial and were unable to enter into such a collaboration on acceptable terms, we might elect to delay or scale back the commercialization of the potential product in order to preserve our financial resources or to allow us adequate time to develop the required physical resources and systems and expertise ourselves.
If we enter into a collaboration agreement we consider acceptable, including the Merck Agreement to develop and commercialize our Ebola vaccine product candidate, the collaboration may not proceed as quickly, smoothly or successfully as we plan. The risks in a collaboration agreement include the following:
• the collaborator may not apply the expected financial resources, efforts or required expertise in developing the physical resources and systems necessary to successfully commercialize the subject potential product;
• the collaborator may not invest in the development of a sales and marketing force and the related infrastructure at levels that ensure that sales of the potential product reach their full potential;
• disputes may arise between us and a collaborator that delay the commercialization or adversely affect its sales or profitability of the potential product; or
• the collaborator may independently develop, or develop with third parties, products that could compete with the potential product.
Under the Merck Agreement and any other collaboration for our product candidates, we will be dependent on our collaborators’ performance of their responsibilities and their cooperation with us. Our collaborators may not perform their obligations under our agreements with them or otherwise cooperate with us. We cannot control whether our collaborators will devote the necessary resources to the activities contemplated by our collaborative agreements, nor can we control the timing of their performance. Our collaborators may choose to pursue existing or alternative technologies in preference to those being developed in collaboration with us. Disputes may arise between us and our collaborators that delay the development and commercialization of our product candidates, and such disputes may be difficult and costly to resolve or may not be resolved. In addition, a collaborator for the potential product may have the right to terminate the collaboration at its discretion, or to discontinue development of a particular product candidate. For example, in June 2017, Genentech gave notice that it is terminating the Genentech Agreement with respect to NLG919 and gave additional notice in May 2018 that the remainder of the Agreement would terminate no later than November 6, 2018. Further, Merck has the right to terminate the Merck Agreement for any reason after a specified advance notice period. Any termination may require us to seek a new collaborator, which we may not be able to do on a timely basis, if at all, or may require us to delay or scale back the development or commercialization efforts. The occurrence of any of these events could adversely affect the development or commercialization of the potential product and materially harm our business and stock price by delaying the sale of any product that may be approved by the FDA in the future, by slowing the growth of such sales, by reducing the profitability of the product and/or by adversely affecting the reputation of the product.
44
We may explore strategic collaborations that may never materialize or may fail.
We may, in the future, periodically explore a variety of possible strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in the process of seeking appropriate strategic collaborators, and such collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.
We are required under the Genentech Agreement and the Merck Agreement, and we may be required under other collaborations, to relinquish important rights to and control over the development of our product candidates to our collaborators or otherwise be subject to unfavorable terms.
Our collaborations, including any future strategic collaborations we enter into, could subject us to a number of risks, including:
• we may be required to undertake the expenditure of substantial operational, financial and management resources;
• other than under the Genentech Agreement and the Merck Agreement, we may be required to issue equity securities that would dilute our existing stockholders’ percentage ownership;
• we may be required to assume substantial actual or contingent liabilities;
• we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our product candidates;
• strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;
• strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs;
• strategic collaborators may not commit adequate resources to the marketing and distribution of our product candidates, limiting our potential revenues from these products;
• disputes may arise between us and our strategic collaborators that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management’s attention and consumes resources;
• strategic collaborators may experience financial difficulties;
• strategic collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;
• business combinations or significant changes in a strategic collaborator’s business strategy may also adversely affect a strategic collaborator’s willingness or ability to complete its obligations under any arrangement;
• strategic collaborators could decide to move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and
• strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates.
Risks Relating to Protecting Our Intellectual Property
If we are unable to protect our proprietary rights or to defend against infringement claims, we may not be able to compete effectively or operate profitably.

Our success will depend, in part, on our ability to obtain patents, operate without infringing the proprietary rights of others and maintain trade secrets, both in the United States and other countries. Patent matters in the biotechnology and pharmaceutical industries can be highly uncertain and involve complex legal and factual questions. Accordingly, the validity, breadth, and
45
enforceability of our patents and the existence of potentially blocking patent rights of others cannot be predicted, either in the United States or in other countries.

There can be no assurance that we will discover or develop patentable products or processes, or that patents will issue from any of the currently pending patent applications or that claims granted on issued patents will be sufficient to protect our technology or adequately cover the products we may actually sell. Potential competitors or other researchers in the field may have filed patent applications, been issued patents, published articles or otherwise created prior art that could restrict or block our efforts to obtain additional patents. There also can be no assurance that our issued patents or pending patent applications, if issued, will not be challenged, invalidated, rendered unenforceable or circumvented or that the rights granted thereunder will provide us with proprietary protection or competitive advantages. Our patent rights also depend on our compliance with technology and patent licenses upon which our patent rights are based and upon the validity of assignments of patent rights from consultants and other inventors that were, or are, not employed by us.

In addition, competitors may manufacture and sell our potential products in those foreign countries where we have not filed for patent protection or where patent protection may be unavailable, not obtainable or ultimately not enforceable. In addition, even where patent protection is obtained, third-party competitors may challenge our patent claims in the various patent offices, for example via opposition in the European Patent Office or reexamination or interference proceedings in the United States Patent and Trademark Office, or USPTO. The ability of such competitors to sell such products in the United States or in foreign countries where we have obtained patents is usually governed by the patent laws of the countries in which the product is sold.
Merck, which has sublicensed our Ebola vaccine product candidate, has received correspondence from Yale University asserting that it owns certain intellectual property rights with respect to the Ebola vaccine that they assert, among other things, may need to be licensed by Merck. We also received correspondence from Yale University relating to the research and construction of the Ebola vaccine product by our licensor PHAC. If Merck were required to pay royalties to Yale University, that could result in a reduction of Merck’s royalty obligations to us. If Merck otherwise suffered damages as a result of claims by Yale University, it is possible that Merck could seek indemnification from us.
We will incur significant ongoing expenses in maintaining our patent portfolio. Should we lack the funds to maintain our patent portfolio or to enforce our rights against infringers, we could be adversely impacted. Even if claims of infringement are without merit, any such action could divert the time and attention of management and impair our ability to access additional capital and/or cost us significant funds to defend.
We intend to rely on patent rights for our product candidates and any future product candidates. If we are unable to obtain or maintain exclusivity from the combination of these approaches, we may not be able to compete effectively in our markets.
We rely or will rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. Our success depends in large part on our and our licensors’ ability to obtain regulatory exclusivity and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technologies and product candidates.
We have sought to protect our proprietary position by filing patent applications related to our technologies and product candidates that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable, or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.
We, independently or together with our licensors, have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent, or whether
46
any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.
If we cannot obtain and maintain effective protection of exclusivity from our regulatory efforts and intellectual property rights, including patent protection or data exclusivity, for our product candidates, we may not be able to compete effectively, and our business and results of operations would be harmed.
We may not have sufficient patent term protections for our product candidates to effectively protect our business.
Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20 years after it is filed. Additional patent terms may be available through a patent term adjustment process, resulting from the USPTO delays during prosecution. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from generic medications.
Patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent or data exclusivity terms of our product candidates. We will likely rely on patent term extensions, and we cannot provide any assurances that any such patent term extensions will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our product candidates for an extended period after regulatory approval, if any, which would negatively impact our business, financial condition, results of operations, and prospects. If we do not have sufficient patent terms or regulatory exclusivity to protect our product candidates, our business and results of operations will be adversely affected.
Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.
On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The United States Patent and Trademark Office has developed regulations and procedures to govern administration of the Leahy-Smith Act, but many of the substantive changes to patent law associated with the Leahy-Smith Act, particularly the first-inventor-to-file provisions, only became effective 18 months after its enactment. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.
We may be subject to litigation with respect to the ownership and use of intellectual property that will be costly to defend or pursue and uncertain in its outcome.
Our success also will depend, in part, on our refraining from infringing patents or otherwise violating intellectual property owned or controlled by others. Pharmaceutical companies, biotechnology companies, universities, research institutions, and others may have filed patent applications or have received, or may obtain, issued patents in the United States or elsewhere relating to aspects of our technology. It is uncertain whether the issuance of any third-party patents will require us to alter our products or processes, obtain licenses, or cease certain activities. Some third-party applications or patents may conflict with our issued patents or pending applications. Any such conflict could result in a significant reduction of the scope or value of our issued or licensed patents.
In addition, if patents issued to other companies contain blocking, dominating or conflicting claims and such claims are ultimately determined to be valid, we may be required to obtain licenses to these patents or to develop or obtain alternative non-infringing technology and cease practicing those activities, including potentially manufacturing or selling any products deemed to infringe those patents. If any licenses are required, there can be no assurance that we will be able to obtain any such licenses on commercially favorable terms, if at all, and if these licenses are not obtained, we might be prevented from pursuing the development and commercialization of certain of our potential products. Our failure to obtain a license to any technology that we may require to commercialize our products on favorable terms may have a material adverse impact on our business, financial condition and results of operations.
47
Litigation, which could result in substantial costs to us (even if determined in our favor), may also be necessary to enforce any patents issued or licensed to us or to determine the scope and validity of the proprietary rights of others. There can be no assurance that our issued or licensed patents would be held valid by a court of competent jurisdiction or that any third party would be found to infringe our patents.
In addition, if our competitors filed patent applications in the United States that claim technology also claimed by us, and such applications were filed before the Leahy-Smith Act took effect, we may have to participate in interference proceedings to determine priority of invention. These proceedings, if initiated by the USPTO, could result in substantial cost to us, even if the eventual outcome is favorable to us. Such proceedings can be lengthy; are costly to defend and involve complex questions of law and fact, the outcomes of which are difficult to predict. An adverse outcome with respect to a third party claim or in an interference proceeding could subject us to significant liabilities, require us to license disputed rights from third parties, or require us to cease using such technology, any of which could have a material adverse effect on our business, financial condition and results of operations.
We also rely on trade secrets to protect technology, especially where patent protection is not believed to be appropriate or obtainable or where patents have not issued. We attempt to protect our proprietary technology and processes, in part, with confidentiality agreements and assignment of invention agreements with our employees and confidentiality agreements with our consultants and certain contractors. There can be no assurance that these agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independently discovered by competitors. We may fail in certain circumstances to obtain the necessary confidentiality agreements, or their scope or term may not be sufficiently broad to protect our interests.
If our trade secrets or other intellectual property becomes known to our competitors, it could result in a material adverse effect on our business, financial condition and results of operations. To the extent that we or our consultants or research collaborators use intellectual property owned by others in work for us, disputes may also arise as to the rights to related or resulting know-how and inventions.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop our own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States.
These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. 
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries, particularly some developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. 
Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.
48
Risks Relating to Our Exposure to Litigation
We are exposed to potential product liability or similar claims, and insurance against these claims may not be available to us at a reasonable rate in the future.
Our business exposes us to potential liability risks that are inherent in the testing, manufacturing, marketing and commercial sale of human therapeutic products. Clinical trials involve the testing of product candidates on human subjects or volunteers under a research plan and carry a risk of liability for personal injury or death to patients due to unforeseen adverse side effects, improper administration of the product candidate, or other factors. Many of these patients are already seriously ill and are therefore particularly vulnerable to further illness or death. In addition, healthy volunteers in our indoximod clinical trial or our Ebola vaccine product candidate clinical trial may suffer, or perceive themselves to suffer, personal injury or death related to the Ebola vaccine product candidates and may initiate legal action against us.
We currently carry clinical trial liability insurance in the amount of $5.0 million in the aggregate for claims related to our product candidates other than our Ebola vaccine product candidate. We currently carry clinical trial liability insurance in the amount of $10.0 million in the aggregate for claims related to our Ebola vaccine product candidate. We additionally currently carry clinical trial coverage in lower aggregate amounts in local markets where our clinical trials are conducted on a selective, trial by trial basis. There can be no assurance that we will be able to maintain such insurance or that the amount of such insurance will be adequate to cover claims. We could be materially and adversely affected if we were required to pay damages or incur defense costs in connection with a claim outside the scope of indemnity or insurance coverage, if the indemnity is not performed or enforced in accordance with its terms, or if our liability exceeds the amount of applicable insurance. In addition, there can be no assurance that insurance will continue to be available on terms acceptable to us, if at all, or that if obtained, the insurance coverage will be sufficient to cover any potential claims or liabilities. Similar risks would exist upon the commercialization or marketing of any future products by us or our collaborators.
On December 9, 2014, the HHS declared our Ebola vaccine product candidate covered under the Public Readiness and Emergency Preparedness Act. This declaration provides immunity under U.S. law against legal claims related to the manufacturing, testing, development, distribution and administration of our vaccine candidate. It does not generally provide immunity for a claim brought in a court outside the United States.
Regardless of their merit or eventual outcome, product liability claims may result in:
• decreased demand for our product;
• injury to our reputation and significant negative media attention;
• withdrawal of clinical trial volunteers;
• costs of litigation;
• distraction of management; and
• substantial monetary awards to plaintiffs.
We are involved in a securities class-action litigation and are at risk of additional similar litigation in the future that could divert management’s attention and adversely affect our business and could subject us to significant liabilities.
In the past, securities class action litigation has often been brought against a company following periods of volatility in the market price of securities. We are a party to the securities class action litigation described in Part II, Item 1 of this Quarterly Report on Form 10-Q under the heading “Legal Proceedings.” The defense of this litigation may increase our expenses and divert our management’s attention and resources and any unfavorable outcome could have a material adverse effect on our business and results of operations. Any adverse determination in this litigation, or any amounts paid to settle this litigation could require that we make significant payments. In addition, we may in the future be the target of other securities class actions or similar litigation.
49
Risks Related to Ownership of Our Common Stock
The market price of our common stock may be highly volatile, and could decline significantly.
The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including those described elsewhere in this “Risk Factors” section of this Quarterly Report on Form 10-Q and the following:
◦ new products, product candidates or new uses for existing products introduced or announced by our strategic collaborators, or our competitors, and the timing of these introductions or announcements;
◦ actual or anticipated results from and any delays in our clinical trials, as well as results of regulatory reviews relating to the approval of our product candidates;
◦ variations in the level of expenses related to any of our product candidates or clinical development programs, including those relating to the timing of invoices from, and other billing practices of, our clinical research organizations and clinical trial sites;
◦ expenses related to, or our ability or perceived ability to secure, an adequate supply of any future products approved for commercial sale;
◦ the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;
◦ disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;
• announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures and capital commitments;
• the commercial or clinical success or failure, or perceived success or failure, of our collaborators, including Merck;
• additions or departures of key scientific or management personnel;
• conditions or trends in the biotechnology and biopharmaceutical industries;
• media attention, or changes in media attention, given to cancer and cancer treatment, the recent Ebola epidemic and efforts to develop treatments and vaccines for Ebola, or any other condition or disease that our product candidates are being developed to treat;
• actual or anticipated changes in earnings estimates, development timelines or recommendations by securities analysts;
• actual and anticipated fluctuations in our quarterly operating results;
• the financial projections we may provide to the public, and any changes in these projections or our failure to meet these projections;
• deviations from securities analysts’ estimates or the impact of other analyst rating downgrades by any securities analysts who follow our common stock;
• other events or factors, including those resulting from political uncertainty, war, incidents of terrorism, natural disasters or responses to these events;
• changes in accounting principles;
• discussion of us or our stock price by the financial and scientific press and in online investor communities;
• general economic and market conditions and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; and
• sales of common stock by us or our stockholders in the future, as well as the overall trading volume of our common stock.
In addition, the stock market in general and the market for biotechnology and biopharmaceutical companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. These broad market and industry factors may seriously harm the market price of our common
50
stock, regardless of our operating performance. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. We are currently party to the securities class action litigation described in Part II, Item 1 of this Quarterly Report on Form 10-Q under the heading “Legal Proceedings.” This litigation and others like it that could be brought against us in the future could result in substantial costs and diversion of management’s attention and resources, which could materially and adversely affect our business and financial condition.
Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.
As of September 30, 2018, our executive officers, directors and principal stockholders, together with their respective affiliates, owned approximately 58.84% of our common stock, including shares subject to outstanding options that are exercisable within 60 days after September 30, 2018. These stockholders will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of our Board of Directors, future issuances of our common stock or other securities, declarations of dividends on our common stock and approval of other significant corporate transactions. This concentration of ownership could have the effect of delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material and adverse effect on the fair market value of our common stock. In addition, sales of shares beneficially owned by executive officers and directors and their affiliates could be viewed negatively by third parties and have a negative impact on our stock price. Moreover, we cannot assure you as to how these shares may be distributed and subsequently voted.
We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to meet compliance obligations.
As a public company, we incur significant legal, accounting and other expenses to comply with reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and The NASDAQ Global Market. Meeting the requirements of these rules and regulations entails significant legal and financial compliance costs, makes some activities more difficult, time-consuming or costly and may also place undue strain on our personnel, systems and resources. Our management and other personnel devote a substantial amount of time to these compliance requirements. In addition, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our Board of Directors, our board committees or as executive officers.
Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our ability to produce accurate financial statements and on our stock price.
Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to publish a report by our management on our internal control over financial reporting. To achieve compliance with Section 404, we have engaged in a process to document and evaluate our internal control over financial reporting, which has been both costly and challenging. To maintain compliance on an ongoing basis, we will need to dedicate internal resources, engage outside consultants and adopt a detailed work plan. Despite our effort, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.
We do not expect to pay any cash dividends for the foreseeable future. Investors may never obtain a return on their investment.
You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking only cash dividends should not purchase our common stock.
51
Provisions in our certificate of incorporation, our by-laws or Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.
Provisions of our certificate of incorporation, our by-laws or Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control of our company or changes in our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interest. These provisions include:
• the division of our Board of Directors into three classes with staggered, three-year terms;
• advance notice requirements for stockholder proposals and nominations;
• the inability of stockholders to call special meetings;
• limitations on the ability of stockholders to remove directors or amend our by-laws; and
• the ability of our Board of Directors to designate the terms of and issue new series of preferred stock without stockholder approval, which could include the right to approve an acquisition or other change in our control or could be used to institute a rights plan, also known as a poison pill, that would work to dilute the stock ownership of a potential hostile acquirer, likely preventing acquisitions that have not been approved by our Board of Directors.
In addition, Section 203 of the Delaware General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person that together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.
The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition.
The holdings of our stockholders may be diluted, and the prices of our securities may decrease, by the exercise of outstanding stock options or by future issuances of securities by us.
We may issue additional common stock, preferred stock, restricted stock units, or securities convertible into or exchangeable for our common stock. Furthermore, substantially all shares of common stock for which our outstanding stock options are exercisable are, once they have been purchased, eligible for immediate sale in the public market. The issuance of additional common stock, preferred stock, restricted stock units, or securities convertible into or exchangeable for our common stock or the exercise of stock options would dilute existing investors and could adversely affect the price of our securities. In addition, such securities may have rights senior to the rights of securities held by existing investors.
Our ability to use our net operating loss carryforwards and certain other tax attributes is limited by Sections 382 and 383 of the Internal Revenue Code.
Sections 382 and 383 of the Internal Revenue Code limit a corporation’s ability to utilize its net operating loss carryforwards and certain other tax attributes (including research credits) to offset any future taxable income or tax if the corporation experiences a cumulative ownership change of more than 50% over any rolling three-year period. State net operating loss carryforwards (and certain other tax attributes) may be similarly limited. A Section 382 ownership change can therefore result in significantly greater tax liabilities than a corporation would incur in the absence of such a change, and any increased liabilities could adversely affect the corporation’s business, results of operations, financial condition and cash flow.
Based on Section 382 ownership change analyses, we believe that, from our inception through December 31, 2017, we experienced Section 382 ownership changes in September 2001 and March 2003, and BPS experienced Section 382 ownership changes in January 2006 and January 2011. These ownership changes limited our ability to utilize federal net operating loss carryforwards and certain other tax attributes that accrued prior to the respective ownership changes of us and our subsidiaries and may continue to limit our ability to utilize such attributes in the future.
52
Additional ownership changes may occur in the future as a result of events over which we will have little or no control, including purchases and sales of our equity by our 5% stockholders, the emergence of new 5% stockholders, additional equity offerings or redemptions of our stock or certain changes in the ownership of any of our 5% stockholders.
Accounting pronouncements may impact our reported results of operations and financial position.
U.S. GAAP and related implementation guidelines and interpretations can be highly complex and involve subjective judgments. Changes in these rules or their interpretation, the adoption of new pronouncements or the application of existing pronouncements to changes in our business could significantly alter our reported financial statements and results of operations.
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline.
53
ITEM 1. LEGAL PROCEEDINGS
On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York, or the Court, captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545, or the Securities Action. Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick & Foti, LLC as lead counsel in the Securities Action. On October 31, 2016, the lead plaintiffs filed an amended complaint asserting claims under the federal securities laws against the Company, the Company’s Chief Executive Officer Charles J. Link, Jr., and the Company’s Chief Medical Officer and President Nicholas Vahanian, or collectively, the Defendants. The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company’s investors. In particular, the lead plaintiffs allege that the Defendants made material misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L. The lead plaintiffs dido not quantify any alleged damages in the amended complaint but, in addition to attorneys’ fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company’s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the amended complaint on July 14, 2017. The lead plaintiffs filed an opposition to the motion to dismiss on September 12, 2017. The Defendants filed a reply in support of the motion to dismiss on September 26, 2017. Oral argument was held on October 19, 2017, after which the Court reserved decision. On March 29, 2018, the Court dismissed the amended complaint for failure to state a claim, without prejudice, and gave the lead plaintiffs until May 4, 2018 to file any amended complaint attempting to remedy the defects in their claims. On May 4, 2018, the lead plaintiffs filed a second amended complaint asserting claims under the federal securities laws against the Defendants. Like the first amended complaint, the second amended complaint alleges that the Defendants made material false and/or misleading statements or omissions relating to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L that caused losses to the Company’s investors. The lead plaintiffs did not quantify any alleged damages in the second amended complaint but, in addition to attorneys’ fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company’s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the second amended complaint on July 31, 2018. The lead plaintiffs filed an opposition to the motion to dismiss the second amended complaint on September 14, 2018. The Defendants filed a reply in support of the motion to dismiss the second amended complaint on October 9, 2018. Oral argument was held on October 19, 2018, after which the Court reserved decision. The Company intends to continue defending the Securities Action vigorously.
On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company’s Chief Executive Officer Charles J. Link, Jr., the Company’s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth, or collectively, the Morrow Defendants, captioned Morrow v. Link., et al., Case 1:17-cv-03039, or the Morrow Action.  The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation of federal securities law.  The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.  The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company’s shareholders.  The language for such proposals is not specified in the complaint.  The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.  On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.  Also on May 19, 2017, plaintiffs’ counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.  The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.  By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise finally resolved.  Under the terms of the stay, the plaintiff in the Ely Action will be provided with any discovery that is provided in the Securities Action, and given an opportunity to participate in any mediation or settlement efforts in the Securities Action. The Company disputes the claims in the Ely Action and intends to defend against them vigorously.

54
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

None.

Use of Proceeds

Not applicable.


ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.


ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.  


ITEM 5. OTHER INFORMATION

None.


55
ITEM 6. EXHIBITS

The following exhibits are filed with this Form 10-Q or incorporated herein by reference to the document set forth next to the exhibit listed below. Where so indicated, exhibits that were previously filed are incorporated by reference.

Incorporated By Reference
Exhibit Number
Description
Form
Filing Date
Number
Filed Herewith
3.1
8-K
11/18/20113.1
3.2
8-K
5/14/20133.1
3.3
8-K
11/18/20113.2
4.1
S-1/A
10/26/20114.1
4.2
Reference is made to Exhibits 3.1, 3.2 and 3.3 hereof
10.1
* X 
10.2
† 
X
10.3
† 
X
10.4
† 
X
10.5
† 
X
10.6
S-1/A 11/8/201110.11
31.1
X
31.2
X
32.1
#
X
101.INS
‡
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
X
101.SCH
 ‡
XBRL Taxonomy Extension Schema Document
X
101.CAL
 ‡
XBRL Taxonomy Extension Calculation Linkbase Document
X
101.DEF
 ‡
XBRL Taxonomy Extension Definition Linkbase Document
X
101.LAB
 ‡
XBRL Taxonomy Extension Label Linkbase Document
X
101.PRE
 ‡
XBRL Taxonomy Extension Presentation Linkbase Document
X
____________________
†
Indicates management contract or compensatory plan.
*
Indicates confidential treatment has been requested with respect to specific portions of this exhibit. Omitted portions have been filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 19434, as amended.
#
"The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of NewLink Genetics Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing."
‡
Filed herewith electronically.

56
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

NEWLINK GENETICS CORPORATION
By:
/s/ Charles J. Link, Jr.
Charles J. Link, Jr.
Chief Executive Officer
(Principal Executive Officer)
Date: November 2, 2018 
By:
/s/ Carl W. Langren
Carl W. Langren
Chief Financial Officer and Secretary
(Principal Financial Officer)
Date: November 2, 2018 

57
 EX-10.1 2 nlnk-2018930x10qxex101.htm EXHIBIT 10.1 Document
[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Exhibit 10.1

AMENDMENT 3 TO
LICENSE AND COLLABORATION AGREEMENT

This third Amendment (this “Amendment 3”) is effective as of the last date of signature (the “Amendment Effective Date”), and is entered into by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”), and BIOPROTECTION SYSTEMS CORPORATION, a corporation organized and existing under the laws of Delaware (“NewLink”) and a wholly owned subsidiary of NEWLINK GENETICS CORPORATION, a corporation organized and existing under the laws of Delaware (“NL”).

RECITALS:

WHEREAS, Merck and NewLink are parties to that certain License and Collaboration Agreement dated November 21, 2014, and further amended on December 5, 2017 and May 10, 2018 (the “Agreement”); and

WHEREAS, Merck and NewLink desire to further amend the Agreement as set forth herein.

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the receipt and sufficiency of which are hereby acknowledged, Merck and NewLink hereby agree as follows:


1. The Parties agree to amend the listing of NewLink Third Party Agreements. In order to effect this amendment, Schedule 2.9.4 of the Agreement is deleted in its entirety and replaced with the revised Schedule 2.9.4 provided in this Amendment

2. The Parties acknowledge and agree the Transition Period of the Agreement has ended.

3. The Parties acknowledge and agree that Merck has requested that, for a period starting July 1, 2018 and ending May 10, 2019 (the “[*] Transition Period”), NewLink maintains that certain agreement between [*] effective as of October 20, 2014, and subsequently amended February 27, 2015 and January 13, 2016, which concerns [*] (the “[*]”). NewLink agrees it will use reasonable efforts to maintain the [*] for the duration of the Fisher Transition Period.

4. Beginning July 1, 2018, Merck shall reimburse NewLink for NewLink’s reasonable expenses incurred in the course of maintaining the [*], including:
a. amounts billed to NewLink under the [*] including the ongoing costs [*],
b. expenses related [*] if reasonably required by [*]
c. expenses related to any [*] if reasonably required by [*],
d. consultant fees,
e. plus the greater of:
i. [*] of the total of such expenses, or
ii. [*] per calendar quarter or any portion thereof.
NewLink shall bill Merck quarterly and Merck shall remit payment within 30 days of the date of each invoice. All amounts due under this Amendment are in addition to any other amounts Merck

[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
may owe NewLink, including, but not limited to, any amounts due to NewLink under the May 10, 2018 amendment referenced in the recitals to this Amendment above.

5. Throughout the [*] Transition Period, Merck shall provide periodic updates to NewLink regarding Merck’s efforts to find [*]. NewLink also agrees to provide reasonable cooperation to Merck [*]. In the event it becomes apparent that [*] during the [*] Transition Period, for purposes of clarity, then commercially reasonable efforts shall include [*].

6. The [*] Transition Period will end upon the earlier of:
a. written notice from Merck;
b. [*], or
c. May 10, 2019, unless extended as set forth in Amendment section 6 of this Amendment.
 
7. It is anticipated that Merck will make the necessary arrangements to [*] prior to termination of the [*] Transition Period. [*].
 
8. Provided that, as evidenced by the quarterly reports received by NewLink in accordance with Amendment section 3, Merck has made commercially reasonable efforts to [*], Merck may request in writing an extension of the [*] Transition Period. During any such extension after May 10, 2019, in addition to the reimbursement obligations set forth in Amendment section 2, Merck shall pay NewLink *] for each month of extension or any part thereof. Upon the conditions of this Section 6 being met, such extended period shall be part of the [*] Transition Period, and the remaining provisions of this Amendment shall apply.

9. Merck shall indemnify, defend and hold the NewLink Indemnitees harmless from and against any Liabilities arising, directly or indirectly out of or in connection with or relating to performance by any NewLink Indemnitee and/or any Third Party of the obligations set forth in this Amendment; except to the extent such Liabilities result from the gross negligence or willful misconduct of NewLink or other NewLink Indemnitees. THE SERVICES TO BE PERFORMED BY NEWLINK UNDER THIS AMENDMENT ARE FURNISHED AS IS, WHERE IS, WITH ALL FAULTS AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

10. Capitalized terms used and not defined herein shall have the meaning ascribed to such terms in the Agreement.

11. Except as specifically set forth in this Amendment, the Agreement will continue in full force and effect without change. If there is any conflict between the terms of this Amendment and the Agreement, this Amendment will govern.

12. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. In addition, this Amendment may be executed by facsimile or “PDF” and such facsimile or “PDF” signature shall be deemed to be an original.


[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
13. This Amendment shall be governed by and construed in accordance with the laws of the State of New York and the patent laws of the United States without reference to any rules of conflict of laws or renvoi.

[Signature Page Follows]

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.


Merck Sharp & Dohme Corp.   Bioprotection Systems Corporation

By:  /s/ Benjamin Thorner    By:  /s/ Carl Langren

Name:  Benjamin Thorner    Name: Carl Langren 

Title: SVP & Head of BD&L   Title: Chief Financial Officer

Dated: __9/25/2018   Dated: 10/9/2018


[*]  Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Schedule 2.9.4

NewLink Third Party Agreements to be Assigned to Merck

[*] [*] [*] 
[*] [*] [*] 
[*] [*] [*] 
[*] [*] [*] 
[*] [*] [*] 
[*] [*] [*] 
[*] [*] [*] 
[*] [*] [*] 
[*] [*] [*] 
[*] [*] [*] 
[*] [*] [*] 
[*] [*] [*] 
[*] [*] [*] 




 EX-10.2 3 nlnk-2018930x10qxex102.htm EXHIBIT 10.2 Document
Exhibit 10.2
July 26, 2018
John B. Henneman, III

Re: Separation and Release Agreement
Dear Jack:
This letter sets forth the terms of the separation agreement (the “Agreement”) that NewLink Genetics Corporation (the “Company”) is offering to aid in your employment transition.
1. Transition and Separation Date. 
 
(a) Transition Period. You hereby resign as Chief Financial Officer and Secretary of the Company, and from any other office or position you may hold with the Company or any affiliated entity, effective as of July 26, 2018. From such date through the “Separation Date” (as defined below) (the “Transition Period”), you will serve as the Company’s Chief Administrative Officer with responsibility over the law and human resources functions of the Company, and will provide transition assistance over the finance function as may be requested by the Company’s Chief Executive Officer or new Chief Financial Officer. The “Separation Date” shall be the earlier of November 9, 2018 or the date your employment with the Company ends pursuant to Section 9 of your Employment Agreement with the Company dated December 31, 2015 (the “Employment Agreement”). On the first regular payroll date after the Separation Date, the Company will pay you all accrued base salary and all remaining accrued but unused vacation earned for your services through the Separation Date, less applicable payroll deductions and withholdings. You are entitled to these payments regardless of whether or not you sign this Agreement.
(b) Employment Agreement. During the Transition Period, and except as modified by this Agreement, the terms of the Employment Agreement (including Section 4 (Base Salary) and Section 7 (Other Benefits) thereof) shall continue in effect; provided, however, that (i) Section 2 of the Employment Agreement shall not restrict you from service on boards of directors or engaging in activities outside the Company so long as such activities do not interfere with your responsibilities during the Transition Period (subject to your Employee Proprietary Information, Inventions, Non-Competition, and Non-Solicitation Agreement with the Company (the “Proprietary Information Agreement” attached hereto as Exhibit A)), and (ii) Section 9(g) and Section 10 of the Employment Agreement shall not apply.
2. Expense Reimbursements. You agree that, within forty-five (45) days of the Separation Date, you will submit to the Company your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement. The Company will reimburse you for these expenses pursuant to its regular business practice.

3. Severance Benefits. In consideration for the general release of claims and the ADEA Waiver you are providing in Section 12 (Release of Claims; ADEA Waiver) of this Agreement, and for all other promises you are making and obligations you are undertaking by entering into this Agreement, allowing it to become fully effective and non-revocable, and for complying with its terms, the Company shall provide you with the severance payments and benefits (collectively, the “Severance Benefits”) described below. Except as expressly provided otherwise, all cash benefits shall be paid subject to applicable payroll deductions and withholdings.
(a) Cash Severance. 


Exhibit 10.2
(i) Initial Severance Payment. On the first regularly scheduled payroll pay date after the Effective Date (as defined in Section 12(e) (ADEA Waiver) of this Agreement), the Company will pay you a lump sum severance payment of $42,360.00 (the “Initial Severance Payment”), reflecting the difference between your annual salary before your voluntary July 2017 pay reduction, and your current annual salary.
(ii) 2018 Bonus. The Company also will pay you a bonus for your 2018 services (the “Bonus Payment”) calculated as follows: (i) $152,496 (representing eleven-twelfths of your Target Bonus as set forth in your Employment Agreement based on your current salary level), multiplied by the percentage completion of the Company’s 2018 corporate goals (“2018 Goals”) (and assuming, for these purposes, 100% completion of your individual goals). You understand and agree that the Board of Directors of the Company (the “Board”) may revise the 2018 Goals at any time to reflect developments during the course of 2018, and that the Board’s decision regarding any revisions to its 2018 Goals, and/or the percentage completion of those Goals, shall be final and binding, provided that any such changes result in a percentage of completion no lower than that determined for incumbent executives. The Bonus Payment will be paid to you at the same time 2018 bonuses are paid to other executives, but not later than March 15, 2019.

(iii) Continuation Payments. Consistent with the severance provisions set forth in Sections 9(g) and 11 of the Employment Agreement, the Company will pay you cash severance in the form of continuing payment of your current base salary for a period of twelve (12) months, paid on the Company’s customary payroll schedule, beginning on the first payroll schedule after the Separation Date (the “Salary Continuation Payments”); provided, however, that, as required by Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”), the Salary Continuation Payments shall not commence until the first regularly scheduled payroll date that is six (6) months after the Separation Date (the “Deferred Initial Payment Date”), on which date the Company will pay to you (or your beneficiaries) a lump sum amount equal to the sum of the Salary Continuation Payments otherwise scheduled to be made prior to the Deferred Initial Payment Date. The remaining Salary Continuation Payments shall be paid on the Company’s regular payroll payment dates thereafter until paid in full. No interest will be paid to you on any amounts for which payment is delayed pursuant to the foregoing provision. Notwithstanding the foregoing, in the event that Separation Date occurs prior to November 9, 2018 for any reason other than your resignation, the period of Salary Continuation Payments shall be extended by the number of days between the Separation Date and November 9, 2018.

(b) Healthcare Continuation Coverage Payments.

(i) COBRA Premiums. As an additional severance benefit, if you timely elect continued COBRA coverage under the Company’s group health plan (including any dental and/or vision coverage), the Company will reimburse you for the COBRA premiums you pay to continue such coverage (including coverage for any eligible dependents, if applicable) (the “COBRA Premiums”) through the period (the “COBRA Premium Period”) starting on the Separation Date and ending on the earliest to occur of: (i) expiration of the period of Salary Continuation Payments (as such period may be extended pursuant to Section 3(a)(iii) above); (ii) the date you become eligible for group health insurance coverage through a new employer; or (iii) the date you cease to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event you become covered under another employer’s group health plan or otherwise cease to be eligible for COBRA during the COBRA Premium Period, you shall immediately provide written notification of such event to the Company’s Human Resources Manager. You

Exhibit 10.2
must submit to the Company documentary proof of the fact and amount of any COBRA Premiums paid within sixty (60) days of making such payment, in order to be reimbursed hereunder. Reimbursements will be paid within thirty (30) days of submission.
(ii) Alternative Cash Payments in Lieu of COBRA Premiums. Notwithstanding the foregoing, if the Company determines, in its reasonable discretion, that it cannot reimburse the COBRA Premiums without a substantial risk of violating applicable law (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), the Company instead shall pay you, on the first day of each calendar month following such determination, a fully taxable cash payment which, after taxes, is equal to the COBRA Premium amount the Company would have otherwise reimbursed you for that month (assuming a 37% tax rate) (such amount, the “Alternative Cash Payment”), for the remainder of the COBRA Premium Period. You may, but are not obligated to, use such Alternative Cash Payments toward the cost of COBRA premiums.

(c) Equity. You have been granted options to purchase shares of the Company’s common stock (the “Options”) and certain restricted stock units (the “RSUs,” and together with the Options, the “Awards”) pursuant to the Company’s 2009 Equity Incentive Plan (the “Plan”). Under the terms of the applicable governing agreements and Plan documents, vesting of any unvested Awards would cease on the Separation Date. As an additional severance benefit, the Company will: (i) accelerate the vesting of the outstanding and unvested Awards set forth on Exhibit B (the “Subject Awards”) so that you are credited with an additional twelve (12) months of vesting as of the Separation Date (or for the period of Salary Continuation Payments if longer due to extension of the period of Salary Continuation Payments pursuant to Section 3(a)(iii) above) (the “Accelerated Vesting”); and (ii) extend the exercise period under the governing agreements and Plan documents so that you have until November 8, 2020 to exercise any vested Subject Awards (including any Awards accelerated hereunder) (the “Extended Exercise Period”). The vesting of your other Awards will cease as of the Separation Date and the exercise period of such Awards will remain unchanged. To the extent that any performance criteria under any Award have not been satisfied as of the Separation Date, such Awards shall terminate as of the Separation Date. Except as expressly provided in this Section, the Options and RSUs will continue to be governed by the terms of the governing agreements and Plan documents. You acknowledge and agree that the Extended Exercise Period may convert any portion of the Options that were incentive stock options into non-qualified stock options, thereby changing their tax treatment; and you should seek advice from your own tax advisors about this extension.

(d) 409A Compliance. It is intended that the Severance Benefits provided to you hereunder comply with, or be exempt from, Section 409A, and that any ambiguities herein will be interpreted to so comply and/or be exempt from Section 409A. It is intended that all of the benefits and payments under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulations Sections 1.409A‑1(b)(4), 1.409A‑1(b)(5) and 1.409A‑1(b)(9), and this Agreement will be interpreted accordingly. To the extent not so exempt, this Agreement (and any definitions hereunder) will be interpreted in a manner that complies with the Section 409A requirements. For purposes of Section 409A, your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. If the period of time you could sign this Agreement crosses over two calendar years, the Agreement shall be deemed to have become effective on the last possible date it could become effective.


Exhibit 10.2
4. Other Compensation or Benefits. You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive after the Separation Date any additional compensation, severance or benefits, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account). By way of example, you acknowledge that you have not earned and are not owed any bonus, incentive compensation, commissions or equity (other than as provided or referenced herein) from the Company.

5. Proprietary Information, Non-Solicitation and Non-Competition Obligations. You acknowledge and agree to abide by your continuing obligations under the Proprietary Information Agreement after the Separation Date to the extent provided therein, including but not limited to your obligations not to use or disclose any confidential or proprietary information of the Company, to comply with your post-employment non-competition and non-solicitation restrictions and to return company property; provided that you shall be permitted to purchase and retain your Company-provided cellphone, computer and any related equipment for their respective book value.

6. Confidentiality. The provisions of this Agreement will be held in strictest confidence by you and will not be publicized or disclosed in any manner whatsoever; provided, however, that: (a) you may disclose this Agreement in confidence to your immediate family; (b) you may disclose this Agreement in confidence to your attorney, accountant, auditor, tax preparer, and financial advisor; and (c) you may disclose this Agreement insofar as such disclosure may be required by law. Nothing herein shall alter any corporate or other reporting right or obligations applicable to the Company.

7. Non-Disparagement. Both you and the Company (through its officers and directors only, and only for so long as they serve in such capacities) agree not to disparage the other party, and the other party’s officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided that both you and the Company may respond accurately and fully to any question, inquiry or request for information from the Company’s Chief Executive Officer or any member of the Board or when required by legal process.

8. Public Statements. Both the Company and you shall respond to third party inquiries, and the Company shall issue a press release, effectively stating that you have resigned from your position as Chief Financial Officer on the date set forth above. The content of such press release will be as mutually agreed upon by you and the Company.

9. References. In response to any request for references from a prospective employer, the Company will verify only your last job title and dates of employment.

10. Cooperation.

(a) Transition Briefings. Through October 31, 2019, you agree to cooperate fully with the Company in all matters relating to the transition of your work and responsibilities on behalf of the Company, including, but not limited to, transitioning any work relationships and providing oral and written briefings (as requested) with respect to any past or present work activities and institutional knowledge, to such other persons as may be designated by the Company. You agree to make yourself available to respond to such inquiries with reasonable promptness, either telephonically or by email (as requested), unless the Company requests that you come to the Company for such discussion or to review certain documents or materials related to the inquiry. The Company will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding forgone wages, salary,

Exhibit 10.2
or other compensation), and will make reasonable efforts to accommodate your schedule.

(b) No Voluntary Adverse Assistance. You agree that you will not voluntarily provide assistance, information or advice, directly or indirectly (including through agents or attorneys), to any third party (including both persons and entities) in connection with any claim or cause of action of any kind brought against, or being prepared against, the Company by any third party, nor shall you induce or encourage any person or entity to bring such claims; provided, however, that nothing herein shall limit or restrict your right to engage in any of the protected activities described in Section 13 (Protected Rights) below.

(c) Other Voluntary Cooperation. You agree to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during your employment with the Company. Such cooperation includes, without limitation, making yourself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony. The Company will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding forgone wages, salary, or other compensation), and will make reasonable efforts to accommodate your scheduling needs. In addition, you agree to execute all documents (if any) necessary to carry out the terms of this Agreement.
11. No Admissions. Nothing contained in this Agreement shall be construed as an admission by you or the Company of any liability, obligation, wrongdoing or violation of law.

12. Releases of Claims. On the Separation Date, and subject to the parties’ re-execution of the Agreement as of such date, the following releases (the “Releases”) shall become effective.

(a) Henneman Release of Claims. In exchange for the Severance Benefits, including the Initial Severance Payment, the Salary Continuation Payments, the Bonus, the reimbursement of your COBRA Premiums (or Alternative Cash Payments), the Accelerated Vesting, the Extended Exercise Period, and all other consideration provided to you by the Company under this Agreement that you would not otherwise be entitled to receive (the “Release Consideration”), you agree to the terms below.
(i) General Release. You hereby generally and completely release the Company and its parent or subsidiary entities, successors, predecessors and affiliates, and its and their directors, officers, employees, consultants, shareholders, agents, attorneys, insurers, affiliates and assigns (collectively, the “Released Parties”) of and from any and all claims, liabilities and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the “Released Claims”).

(ii) Scope of Release. The Released Claims include, but are not limited to: (1) all claims arising from or in any way related to your employment with the Company, or the termination of that employment; (2) all claims related to your compensation or benefits from the Company (except as expressly provided in this Agreement), including but not limited to salary, bonuses, commissions, vacation pay, PTO, expense reimbursement, severance pay, fringe benefits, profit sharing, stock, stock options, or any other ownership or equity interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing, including but not limited to any claims arising under or based on your initial employment offer letter or subsequent Employment Agreement (including claims for severance benefits thereunder); (4) all tort claims, including but not

Exhibit 10.2
limited to claims for battery, negligence, fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims in all jurisdictions, including but not limited to claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964, the federal Americans with Disabilities Act of 1990, the federal Family and Medical Leave Act, the Equal Pay Act of 1963, the Fair Labor Standards Act, the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act (together, the “ADEA”), the Employee Retirement Income Security Act of 1974, the Worker Adjustment and Retraining Notification Act (and all similar state and local laws), the Iowa Civil Rights Act of 1965, the Iowa Wage Payment Collection Law, the Texas Commission on Human Rights Act, the Texas Payday Law, the Texas Labor Code, and any statute or regulation administered by the Texas Workforce Commission.

(iii) Excluded Claims. Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”): (1) rights to apply for unemployment insurance benefits; (2) rights to workers’ compensation disability benefits, claims and payments, if applicable; (3) rights with respect to outstanding equity awards granted to you by the Company; (4) any rights or claims for indemnification pursuant to any written indemnification agreement with the Company to which you are a party, or under Company bylaws or articles, or under applicable law; (5) any rights to coverage under any directors and officers liability insurance policy maintained by the Company; (6) any rights which are not waivable as a matter of law; and (7) any claims for breach of this Agreement. You represent and warrant that, other than the Excluded Claims, you are not aware of any claims you have or may have against any of the Released Parties that are not included in the Released Claims.

(b) ADEA Waiver. You further specifically agree that, as part of the Released Claims, you are releasing any claims that you could assert under the ADEA (the “ADEA Waiver”). You acknowledge that: you are knowingly and voluntarily waiving and releasing any rights you have under the ADEA; that the Release Consideration is being given in partial consideration for the ADEA Waiver; and that the Release Consideration is in addition to anything of value to which you were already entitled. You further acknowledge that you have been advised, as required by the ADEA, that: (1) this ADEA Waiver does not apply to any rights or claims that arise after the date you sign this Agreement; (2) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so); (3) you have forty-five (45) days to consider this Agreement (although you may choose voluntarily to sign it earlier); (4) you have seven (7) days following the date you sign this Agreement to revoke the Agreement (in a written revocation provided to and received by the Company’s CEO within the 7-day revocation period); and (5) the Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after you sign this Agreement, provided that you have not timely revoked it (the “Effective Date”). You understand and agree that, if you revoke the ADEA Waiver, you will not be entitled to the Release Consideration.
(c) Company Release of Claims. In exchange for you entering into this Agreement, including providing the releases of claims and the ADEA Waiver set forth above, the Company hereby generally and completely releases you of and from any and all claims, liabilities and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring prior to or on the date the Company signs this Agreement; provided, however, that nothing herein shall release or waive: (1) any rights the Company has under this Agreement or the Proprietary Information Agreement (attached as Exhibit A); (2) any claims arising out of your obligations to protect and not to disclose or make unauthorized use of any of the Company’s confidential and proprietary information, including but not limited to claims under the Uniform Trade Secret Act or the Proprietary Information Agreement; or (3) any claims (whether direct or for indemnification or contribution) arising from any

Exhibit 10.2
willful material misconduct by you which constitutes theft, fraud, embezzlement, conversion of a business opportunity, or unlawful harassment. The Company hereby represents that it is not aware of any actual or potential claim against you that would be excluded from the foregoing release pursuant to either clauses (2) or (3) above.
13. Protected Rights. Nothing in this Agreement shall prevent you from challenging the validity of the release of claims provided herein in a legal or administrative proceeding. You further understand that nothing in this Agreement (including, without limitation, Section 6 (Confidentiality), Section 7 (Non-Disparagement) and Section 12 (Releases of Claims) above): limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”); prevents any party from providing information or disclosing the fact or terms of this Agreement as part of any government investigation: or prohibits any party from reporting possible violations of law or regulation to any Government Agencies or self-regulating entity under applicable law (including, but not limited to, the U.S. Securities and Exchange Commission’s Whistleblower Rule, of Section 21F of the U.S. Securities Exchange Act of 1934, as amended). While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to the maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any of the Released Claims and any rights you have waived by signing this Agreement.
 
14. Representations. You hereby represent that, except for amounts to be paid to you under this Agreement, you have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which you are eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which you have not already filed a claim.

15.  General. This Agreement, including Exhibit A, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to this subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other agreements, promises, warranties or representations concerning its subject matter (including but not limited to your Employment Agreement with the Company). This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties. This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of Iowa without respect to conflicts of law principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement, or rights hereunder, must be in writing to be effective and shall not be deemed to be a waiver of any successive or other breach or rights hereunder. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile, .PDF and electronic signatures shall be equivalent to original signatures.

To accept the terms set forth above (except for Section 12 hereof), please sign and date this

Exhibit 10.2
Agreement and return the fully‑executed Agreement to the Company by July 26, 2018. In addition, the Severance Benefits and the Releases are subject to your re-execution of this Agreement on the Separation Date. The Releases in Sections 12(c) shall become effective upon re-execution of this Agreement by that Company as of the Separation Date.
We wish you the best in your future endeavors.
Sincerely,
NewLink Genetics Corporation
By: _/s/ Charles J. Link, Jr. M.D.
Charles J. Link, Jr., M.D.
Chairman, Chief Executive Officer, and Chief Scientific Officer
Understood, Accepted and Agreed:
_/s/ John B. Henneman, III
John B. Henneman, III
___7/26/2018
Date
Re-Executed as of Separation Date:

NewLink Genetics Corporation
By: ____________________________________________________
Authorized Signatory
_______________________________________________________
Date
_______________________________________________________
John B. Henneman, III
_______________________________________________________
Date

Exhibit A -Proprietary Information Agreement
Exhibit B -Options and RSUs Subject to Twelve-Month Acceleration and Extended Exercise Period


Exhibit 10.2
Exhibit A
Proprietary Information Agreement


Exhibit 10.2
 
Exhibit B
Options Subject to Twelve-Month Acceleration and Extended Exercise Period


Grant Date Grant Number Options Option Price 
10/1/2014 100836 17,428 22.95 
10/1/2014 100836N 191,822 22.95 
1/2/2015 100941 136 43.65 
1/2/2015 100941N 6,364 43.65 
1/4/2016 101037 3,674 34.73 
1/4/2016 101037N 42,677 34.73 
8/9/2016 101242N 150,000 10.78 
1/3/2017 101382 7,731 10.55 
1/3/2017 101382N 61,019 10.55 
1/3/2017 800008 17,188 10.55 
1/3/2017 800011 17,187 10.55 
1/3/2017 800009 17,188 10.55 
1/3/2017 800010 17,187 10.55 
3/9/2018 800014-1 14,625 7.85 
3/9/2018 800014-1N 46,375 7.85 
3/9/2018 800014-2 10,163 7.85 
3/9/2018 800014-5 15,250 7.85 
3/9/2018 800014-6 15,250 7.85 
3/9/2018 800014-4 10,174 7.85 
3/9/2018 800014-3 10,163 7.85 


RSUs Subject to Twelve-Month Acceleration and Extended Exercise Period


Award Date Award Number RSUs 
10/1/2014 300042 10,198 
1/2/2015 300045 500 
1/4/2016 300070 8,101 



 EX-10.3 4 nlnk-2018930x10qxex103.htm EXHIBIT 10.3 Document
Exhibit 10.3
July 26, 2018
Brian Wiley

Re: Separation and Release Agreement
Dear Brian:
This letter sets forth the terms of the separation agreement (the “Agreement”) that NewLink Genetics Corporation (the “Company”) is offering to aid in your employment transition.
1. Separation Date. You hereby resign as Chief Commercial Officer of the Company, and from any other office or position you may hold with the Company or any affiliated entity, effective as of July 27, 2018. Within six (6) days after the Separation Date, the Company will pay you all accrued base salary and all remaining accrued but unused vacation earned for your services through the Separation Date, less applicable payroll deductions and withholdings. You are entitled to these payments regardless of whether or not you sign this Agreement.

2. Expense Reimbursements. You agree that, within thirty (30) days of the Separation Date, you will submit to the Company your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement. The Company will reimburse you for these expenses pursuant to its regular business practice.

3. Severance Benefits. In consideration for the general release of claims and the ADEA Waiver you are providing in Section 13 (Release of Claims; ADEA Waiver) of this Agreement, and for all other promises you are making and obligations you are undertaking by entering into this Agreement, allowing it to become fully effective and non-revocable, and for complying with its terms, the Company shall provide you with the severance payments and benefits (collectively, the “Severance Benefits”) described below. Except as expressly provided otherwise, all cash benefits shall be paid subject to applicable payroll deductions and withholdings.

(a) Cash Severance. 

(i)  Initial Severance Payment. On the first regularly scheduled payroll pay date after the Effective Date (as defined in Section 13(e) (ADEA Waiver) of this Agreement), the Company will pay you a lump sum severance payment of $18,535 (the “Initial Severance Payment”), reflecting the difference between your annual salary before your voluntary July 2017 pay reduction, and your current annual salary, for a period of six months.

(ii)  2018 Bonus. The Company also will pay you a bonus for your 2018 services (the “Bonus Payment”) calculated as follows: (i) $68,116 (representing seven-twelfths of your Target Bonus as set forth in your Employment Agreement based on your current salary level), multiplied by the percentage completion of the Company’s 2018 corporate (“2018 Goals”). The 2018 Goals were established by the Board in March 2018. You understand that the Board’s decision regarding the attainment of those Goals, shall be final and binding. The Bonus Payment will be paid to you no later than the time 2018 bonuses are paid to other executives, and in any event not later than March 15, 2019.

(iii)  Continuation Payments. Consistent with the severance provisions set

Exhibit 10.3
forth in Sections 9(g) and 11 of your Employment Agreement with the Company dated January 4 2016 (the “Employment Agreement”), The Company will pay you cash severance equal to $166,815, representing the base salary provided in your Employment Agreement, after giving effect to the reduction by the Amendment dated July 26, 2017, for a period of six (6) months (the “Salary Continuation Payment”). As required by Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”), the Salary Continuation Payment shall be paid upon the first regularly scheduled payroll date that is six (6) months after the Separation Date, on which date the Company will pay to you (or your beneficiaries) a lump sum amount equal to the sum of the Salary Continuation Payment. No interest will be paid to you on any amounts for which payment is delayed pursuant to the foregoing provision.

(b)  Healthcare Continuation Coverage Payments.

(i)  COBRA Election. To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company’s current group health insurance policies, you may be eligible to continue your group health insurance benefits at your own expense after the Separation Date.

(ii)  COBRA Premiums. As an additional severance benefit, if you timely elect continued coverage under COBRA, the Company will reimburse you for the COBRA premiums you pay to continue your basic medical coverage (including coverage for any eligible dependents, if applicable, but excluding dental and vision insurance coverage) (the “COBRA Premiums”) through the period (the “COBRA Premium Period”) starting on the Separation Date and ending on the earliest to occur of: (i) six (6) months after the Separation Date; (ii) the date you become eligible for group health insurance coverage through a new employer; or (iii) the date you cease to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event you become covered under another employer’s group health plan or otherwise cease to be eligible for COBRA during the COBRA Premium Period, you shall immediately provide written notification of such event to the Company’s Human Resources Manager. You must submit to the Company documentary proof of the fact and amount of any COBRA Premiums paid within sixty (60) days of making such payment, in order to be reimbursed hereunder. Reimbursements will be paid within thirty (30) days of submission.

(iii)  Alternative Cash Payments in Lieu of COBRA Premiums. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot reimburse the COBRA Premiums without a substantial risk of violating applicable law (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), the Company instead shall pay you, on the first day of each calendar month following such determination, a fully taxable cash payment which, after taxes, is equal to the COBRA Premium amount the Company would have otherwise reimbursed you for that month (assuming a 35% tax rate) (such amount, the “Alternative Cash Payment”), for the remainder of the COBRA Premium Period. You may, but are not obligated to, use such Alternative Cash Payments toward the cost of COBRA premiums.

(c) Equity. You have been granted options to purchase shares of the Company’s common stock (the “Options”) and certain restricted stock units (the “RSUs,” and together with the Options, the “Awards”) pursuant to the Company’s 2009 Equity Incentive Plan (the “Plan”). Under the terms of the applicable governing agreements and Plan documents, vesting of any unvested Awards would cease on the Separation Date. As an additional severance benefit, the Company will (i) accelerate the

Exhibit 10.3
vesting of the outstanding and unvested Awards set forth on Exhibit B (the “Subject Awards”) so that you are credited with an additional twelve (12) months of vesting as of the Separation Date (the “Accelerated Vesting”); and (ii) extend the exercise period under the governing agreements and Plan documents so that you have one (1) year from the Separation Date to exercise any vested Subject Awards (including any Awards accelerated hereunder) (the “Extended Exercise Period”). To the extent that any performance criteria under any Award have not been satisfied as of the Separation Date, such Awards shall terminate as of the Separation Date. Except as expressly provided in this Section, the Options and RSUs will continue to be governed by the terms of the governing agreements and Plan documents. You acknowledge and agree that the Extended Exercise Period may convert any portion of the Options that were incentive stock options into non-qualified stock options, thereby changing their tax treatment; and you should seek advice from your own tax advisors about this extension.

(d)  409A Compliance. It is intended that the Severance Benefits provided to you hereunder comply with, or be exempt from, Section 409, and that any ambiguities herein will be interpreted to so comply and/or be exempt from Section 409A. It is intended that all of the benefits and payments under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulations Sections 1.409A‑1(b)(4), 1.409A‑1(b)(5) and 1.409A‑1(b)(9), and this Agreement will be interpreted accordingly. To the extent not so exempt, this Agreement (and any definitions hereunder) will be interpreted in a manner that complies with the Section 409A requirements. For purposes of Section 409A, your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. If the period of time you could sign this Agreement crosses over two calendar years, the Agreement shall be deemed to have become effective on the last possible date it could become effective.

4. Other Compensation or Benefits. You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive after the Separation Date any additional compensation, severance or benefits, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account). By way of example, you acknowledge that you have not earned and are not owed any bonus, incentive compensation, commissions or equity (other than as provided or referenced herein) from the Company.

5. Return of Company Property. No later than the close of business on the Separation Date, you shall return to the Company all Company documents (and all copies thereof) and other Company property or information in your possession or control (collectively, “Company Property”), including, but not limited to: Company hardcopy and softcopy files, databases, notes, emails, correspondence, financial and operational information, current or potential customer lists and contact information, product and services information, research and development information, drawings, records, plans, forecasts, reports, payroll information, spreadsheets, studies, analyses, compilations of data, proposals, agreements, sales and marketing information, personnel information, specifications, code, software, electronically or computer-recorded information, tangible property and equipment (including, but not limited to, computing and communications devices, facsimile machines, mobile telephones, servers), credit cards, entry cards, identification badges and keys; and any materials of any kind which contain or embody any proprietary or confidential information of the Company and all reproductions thereof in whole or in part and in any medium. You shall make a diligent search to locate any such Company Property by the close of business on the Separation Date. In addition, if you have used any personally owned computing or communication device, server, or e-mail system to receive, store, review, prepare or transmit any confidential or

Exhibit 10.3
proprietary data, materials or information of the Company, then within five (5) business days after the Separation Date, you shall permanently delete and expunge such confidential or proprietary information from those systems without retaining any reproductions (in whole or in part); and you agree to make any such device or system available for inspection and analysis by the Company, upon its reasonable request, in order to permit the Company to determine whether you are in compliance with this provision. Your timely compliance with the provisions of this Section is a precondition to your receipt of the Severance Benefits and other benefits provided hereunder.

6. Proprietary Information, Non-Solicitation and Non-Competition Obligations. You acknowledge and agree to abide by your continuing obligations under your Employee Proprietary Information, Inventions, Non-Competition, and Non-Solicitation Agreement with the Company (the “Proprietary Information Agreement” attached hereto as Exhibit A), effective as of the beginning of your employment with the Company and continuing after the Separation Date, including but not limited to your obligations not to use or disclose any confidential or proprietary information of the Company and to comply with your post-employment non-competition and non-solicitation restrictions.

7. Confidentiality. The provisions of this Agreement will be held in strictest confidence by you and will not be publicized or disclosed in any manner whatsoever; provided, however, that: (a) you may disclose this Agreement in confidence to your immediate family; (b) you may disclose this Agreement in confidence to your attorney, accountant, auditor, tax preparer, and financial advisor; and (c) you may disclose this Agreement insofar as such disclosure may be required by law. Nothing herein shall alter any corporate or other reporting right or obligations applicable to the Company.

8. Non-Disparagement. Both you and the Company (through its officers and directors only, and only for so long as they serve in such capacities) agree not to disparage the other party, and the other party’s officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided that both you and the Company may respond accurately and fully to any question, inquiry or request for information when required by legal process.

9. Public Statements. Both the Company and you shall respond to third party inquiries, and the Company shall issue a press release, effectively stating that you have resigned from your position as Chief Commercial Officer, and from your employment with the Company, effective as of the Separation Date. The content of such press release will be mutually agreed.

10. References. In response to any request for references from a prospective employer, the Company will verify only your last job title and dates of employment.

11. Cooperation.

(a) Transition Briefings. Prior to and after the Separation Date, you agree to cooperate fully with the Company in all matters relating to the transition of your work and responsibilities on behalf of the Company, including, but not limited to, transitioning any work relationships and providing oral and written briefings (as requested) with respect to any past or present work activities and institutional knowledge, to such other persons as may be designated by the Company. You agree to make yourself available to respond to such inquiries with reasonable promptness, either telephonically or by email (as requested), unless the Company requests that you come to the Company for such discussion or to review certain documents or materials related to the inquiry.


Exhibit 10.3
(b) No Voluntary Adverse Assistance. You agree that you will not voluntarily provide assistance, information or advice, directly or indirectly (including through agents or attorneys), to any third party (including both persons and entities) in connection with any claim or cause of action of any kind brought against, or being prepared against, the Company by any third party, nor shall you induce or encourage any person or entity to bring such claims; provided, however, that nothing herein shall limit or restrict your right to engage in any of the protected activities described in Section 14 (Protected Rights) below.

(c) Other Voluntary Cooperation. You agree to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during your employment with the Company. Such cooperation includes, without limitation, making yourself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony. The Company will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding forgone wages, salary, or other compensation), and will make reasonable efforts to accommodate your scheduling needs. In addition, you agree to execute all documents (if any) necessary to carry out the terms of this Agreement.
12. No Admissions. Nothing contained in this Agreement shall be construed as an admission by you or the Company of any liability, obligation, wrongdoing or violation of law.

13. Release of Claims.  In exchange for the Severance Benefits, including the Salary Continuation Payments, the reimbursement of your COBRA Premiums (or Alternative Cash Payments), the Accelerated Vesting, and all other consideration provided to you by the Company under this Agreement that you would not otherwise be entitled to receive (the “Release Consideration”), you agree to the terms below.

(a) General Release. You hereby generally and completely release the Company and its parent or subsidiary entities, successors, predecessors and affiliates, and its and their directors, officers, employees, consultants, shareholders, agents, attorneys, insurers, affiliates and assigns (collectively, the “Released Parties”) of and from any and all claims, liabilities and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the “Released Claims”).

(b) Scope of Release. The Released Claims include, but are not limited to: (1) all claims arising from or in any way related to your employment with the Company, or the termination of that employment; (2) all claims related to your compensation or benefits from the Company (except as expressly provided in this Agreement), including but not limited to salary, bonuses, commissions, vacation pay, PTO, expense reimbursement, severance pay, fringe benefits, profit sharing, stock, stock options, or any other ownership or equity interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing, including but not limited to any claims arising under or based on your initial employment offer letter or subsequent Employment Agreement (including claims for severance benefits thereunder); (4) all tort claims, including but not limited to claims for battery, negligence, fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims in all jurisdictions, including but not limited to claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964, the federal Americans with Disabilities Act of 1990, the federal

Exhibit 10.3
Family and Medical Leave Act (, the Equal Pay Act of 1963, the Fair Labor Standards Act, the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act (together, the “ADEA”), the Employee Retirement Income Security Act of 1974, the Worker Adjustment and Retraining Notification Act (and all similar state and local laws), the Iowa Civil Rights Act of 1965, the Iowa Wage Payment Collection Law, the Texas Commission on Human Rights Act, the Texas Payday Law, the Texas Labor Code, and any statute or regulation administered by the Texas Workforce Commission.

(c) Excluded Claims. Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”): (1) rights to apply for unemployment insurance benefits; (2) rights to workers’ compensation disability benefits, claims and payments, if applicable; (3) any rights or claims for indemnification pursuant to any written indemnification agreement with the Company to which you are a party, or under Company bylaws or articles, or under applicable law; (4) any rights which are not waivable as a matter of law; or (5) any claims for breach of this Agreement. You represent and warrant that, other than the Excluded Claims, you are not aware of any claims you have or may have against any of the Released Parties that are not included in the Released Claims.

(d) ADEA Waiver. You further specifically agree that, as part of the Released Claims, you are releasing any claims that you could assert under the ADEA (the “ADEA Waiver”). You acknowledge that: you are knowingly and voluntarily waiving and releasing any rights you have under the ADEA; that the Release Consideration is being given in partial consideration for the ADEA Waiver; and that the Release Consideration is in addition to anything of value to which you were already entitled. You further acknowledge that you have been advised, as required by the ADEA, that: (1) this ADEA Waiver does not apply to any rights or claims that arise after the date you sign this Agreement; (2) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so); (3) you have forty-five (45) days to consider this Agreement (although you may choose voluntarily to sign it earlier); (4) you have seven (7) days following the date you sign this Agreement to revoke the Agreement (in a written revocation provided to and received by the Company’s CEO within the 7-day revocation period); and (5) the Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after you sign this Agreement, provided that you have not timely revoked it (the “Effective Date”). You understand and agree that, if you revoke the ADEA Waiver, you will not be entitled to the Release Consideration.

14. Protected Rights. Nothing in this Agreement shall prevent you from challenging the validity of the release of claims provided herein in a legal or administrative proceeding. You further understand that nothing in this Agreement (including, without limitation, Section 7 (Confidentiality), Section 8 (Non-Disparagement) and Section 13 (Releases of Claims) above): limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”); prevents any party from providing information or disclosing the fact or terms of this Agreement as part of any government investigation: or prohibits any party from reporting possible violations of law or regulation to any Government Agencies or self-regulating entity under applicable law (including, but not limited to, the U.S. Securities and Exchange Commission’s Whistleblower Rule, of Section 21F of the U.S. Securities Exchange Act of 1934, as amended). While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to the maximum extent permitted by law, you are otherwise waiving any

Exhibit 10.3
and all rights you may have to individual relief based on any of the Released Claims and any rights you have waived by signing this Agreement.

15. Representations. You hereby represent that, except for amounts to be paid to you under this Agreement, you have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which you are eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which you have not already filed a claim.

16. General. This Agreement, including Exhibit A, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to this subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other agreements, promises, warranties or representations concerning its subject matter (including but not limited to your Employment Agreement with the Company). This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties. This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of Iowa without respect to conflicts of law principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement, or rights hereunder, must be in writing to be effective and shall not be deemed to be a waiver of any successive or other breach or rights hereunder. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile, .PDF and electronic signatures shall be equivalent to original signatures.


Exhibit 10.3
To accept the terms set forth above, please sign and date this Agreement and return the fully‑executed Agreement to the Company within 21 days after the Separation Date.
We wish you the best in your future endeavors.
Sincerely,
NewLink Genetics Corporation
By: _/s/ Charles J. Link, Jr. M.D.
Charles J. Link, Jr., M.D.
Chairman, Chief Executive Officer, and Chief Scientific Officer

Exhibit A -Proprietary Information Agreement
Understood and Agreed:
_/s/ Brian Wiley
Brian Wiley

__7/26/2018
Date



Exhibit 10.3
Exhibit A
Proprietary Information Agreement


Exhibit 10.3
Exhibit B
Options Subject to Twelve-Month Acceleration and Extended Exercise Period


Grant Date Grant Number Options Option Price 
1/14/2013 100687 29693 11.79 
1/14/2013 100687N 174307 11.79 
8/9/2016 101243 0 10.78 
8/9/2016 101243N 30000 10.78 
1/3/2017 101383 9787 10.55 
1/3/2017 101383N 65213 10.55 
3/9/2018 800016-1 14076 7.85 
3/9/2018 800016-1N 40924 7.85 
3/9/2018 800016-2 9163 7.85 
3/9/2018 800016-4 9174 7.85 
3/9/2018 800016-3 9163 7.85 
3/9/2018 800016-5 13750 7.85 
3/9/2018 800016-6 13750 7.85 


RSUs Subject to Twelve-Month Acceleration and Extended Exercise Period


Award Date Award Number RSUs 
1/2/2015 300052 1,850 
1/4/2016 300076 3,191 




 EX-10.4 5 nlnk-2018930x10qxex104.htm EXHIBIT 10.4 Document
Exhibit 10.4
image1.jpg
EMPLOYMENT AGREEMENT
This Employment Agreement (the “Agreement”) is made as of this 26th day of July, 2018, by and between NewLink Genetics Corporation (the “Company”), and Carl Langren (“Executive”) (collectively, the “Parties”, each a “Party”).
Whereas, the Company wishes to employ and/or continue to employ Executive and to assure itself of Executive’s services on the terms set forth herein;
Whereas, Executive wishes to be employed by the Company on the terms set forth herein; and
Whereas, the Parties intend for this Agreement to set forth all of the terms and conditions of Executive’s employment with the Company, and to supersede and replace all prior agreements, arrangements, representations or understandings between the Parties regarding Executive’s employment with the Company.
AGREEMENT
Now, Therefore, in consideration of the mutual promises and covenants contained herein, the Parties agree as follows:
1. Employment. The Company will employ Executive and Executive shall serve the Company in the capacity of Chief Financial Officer (“CFO”).

2. Duties. Executive shall render exclusive, full-time services to the Company. Executive shall report to the Chief Executive Officer (“CEO”) in Executive’s role. Executive shall perform services under this Agreement primarily at the Company’s office in Austin, Texas, and from time to time at such other locations as may be necessary or as otherwise reasonably requested by the Company. Subject to the terms of this Agreement, Executive’s responsibilities, working conditions and duties may be changed, expanded or eliminated at the sole discretion of the CEO. Executive shall devote Executive’s best efforts and full business time, skill and attention to performance of Executive’s duties on behalf of the Company; provided, however, that Executive may engage in civic and not-for-profit activities (e.g. charitable and industry association activities) as long as such activities do not materially interfere with Executive’s obligations hereunder. During Executive’s employment with the Company, Executive agrees not to engage in any business or for-profit activities outside the Company, including serving on any advisory boards or boards of directors of for-profit entities, except with the prior written approval of the CEO, which approval may be rescinded at any time in the CEO’s sole discretion, provided that in the event of such rescission Executive shall be permitted reasonable time for orderly withdrawal from any board with respect to which such consent has been rescinded.  By signing this Agreement, Executive represents that, to the best of Executive’s knowledge, Executive is not subject to any other contract or duty that would interfere in any way with Executive’s employment with the Company or performance of employment duties hereunder.

3. Policies and Procedures. Executive shall be subject to and will comply with the policies and procedures of the Company, as they may be modified, expanded or eliminated from time to time at the Company’s sole discretion, except to the extent any such policy or procedure specifically conflicts with the express terms of this Agreement (in which case, this Agreement shall control).


Exhibit 10.4
4. Base Salary. For services rendered hereunder, Executive shall receive a base salary at the rate of $358,500 per year (“Base Salary”), paid periodically in accordance with ordinary Company payroll practices, subject to applicable payroll withholdings and deductions. Executive’s Base Salary shall also be subject to annual reviews and periodic adjustment; provided that Executive’s Base Salary may not be decreased without Executive’s express written consent except in connection with an across-the-board reduction proportionally affecting all senior executives of the Company.

5. Bonus. Executive will be eligible to receive an annual performance bonus (“Bonus”), with a target level at 40% of Executive’s Base Salary (the “Bonus Target”), with the annual amount of such Bonus to be determined in the sole discretion of the Company’s Board of Directors (the “Board”) or by its Compensation Committee (under authority delegated by the Board), based upon a review of both Executive's individual performance and the Company’s performance (both of which may include, but are not limited to, achievement of certain milestones or performance objectives, if any, established by the Board or the Compensation Committee (the “Bonus Plan”)). The Board or the Compensation Committee, in their sole discretion, shall determine the extent to which Executive has achieved any performance targets or other terms and conditions applicable to the Bonus; the amount of the Bonus (if any); and whether and to what extent a Bonus may be paid with respect to any year during which Executive's employment terminates, subject to the terms and conditions of this Agreement.  Bonuses are not earned until they are approved in writing by the Board or Compensation Committee. Any Bonuses earned shall be paid subject to applicable employment taxes, withholding and deductions. Except as otherwise expressly provided in this Agreement or in the Bonus Plan, Executive must remain continuously employed with the Company through the date a Bonus is approved in order to be eligible to receive such Bonus.

6. Stock Options. In consideration for entering into this Agreement, Executive shall be granted an option to purchase 100,000 shares of Company common stock (the “Option”) subject to the vesting schedule and all other terms, conditions and limitations applicable to such Option as set forth in the Company’s 2009 Equity Incentive Plan as it may be amended from time to time (the “Equity Plan”) and in Stock Award Agreements (as defined in the Equity Plan) approved by the Board and entered into by Executive. Such grants to be awarded close of market the first of the month following date of promotion. Executive may receive additional equity grants from time to time, in the sole discretion of the Board or a designated committee thereof.

7. Other Benefits. While employed by the Company pursuant to this Agreement, Executive shall be entitled to the following benefits:

a. Executive Benefits. The Executive shall be entitled to all benefits to which other executive officers of the Company are entitled, on the same terms and conditions in effect from time to time, including, without limitation, participation in pension and profit sharing plans, the Company’s 401(k) plan, group insurance policies and plans (including medical, health, vision, and disability insurance policies and plans, and the like) which may be maintained by the Company for the benefit of its executives. The Company reserves the right to alter, discontinue and/or amend its benefit plans and programs from time to time in its sole discretion.

b. Expense Reimbursement. The Executive shall receive, upon presentation of proper receipts and vouchers, reimbursement for direct and reasonable out-of-pocket expenses incurred in connection with the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policies and procedures in effect from time to time.

c. Vacation. Executive will accrue twenty-eight (28) days of paid vacation each full year, accrued in equal monthly increments, subject to Executive’s continuing service. Unused vacation will carry over from year to year; provided, however, that Executive shall not be entitled to carry over more than a total of fifty-six (56) days of accrued vacation. Once that maximum vacation balance has been reached, Executive will cease to accrue any additional vacation time until Executive uses some vacation time and brings Executive’s vacation balance below the applicable cap. Executive’s vacation rights shall otherwise be governed by the Company’s vacation policy and applicable law, as in effect from time to time.





Exhibit 10.4
8. Confidential Information, Rights and Duties.

a. Proprietary Information. Executive agrees to execute and abide by the Company’s Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement (the “Proprietary Information Agreement”), attached hereto as Exhibit A.

b. Exclusive Property. Executive agrees that all Company-related business procured by the Executive, and all Company-related business opportunities and plans made known to Executive while employed by the Company, are and shall remain the permanent and exclusive property of the Company.

9. Termination of Employment.

a. At-Will Status. The Company and Executive understand and agree that this employment relationship is at-will. Accordingly, there are no promises or representations concerning the duration of Executive’s employment relationship, and it may be terminated by either Executive or the Company at any time, with or without Cause or Good Reason (as defined herein), and with or without advance notice. Executive’s at-will status cannot be altered except in an express written agreement signed by Executive and the Company with the specific approval of the Company’s Board.

b. Termination Due to Death or Disability. Subject to applicable state or federal law, Executive’s employment with the Company will automatically terminate upon Executive’s death or Disability. For purposes of this Agreement, “Disability” means a physical or mental condition or disability which prevents Executive from performing Executive’s job responsibilities for more than six (6) months in any twelve (12) month period, or for more than four (4) consecutive months.

c. Resignation by Executive. Executive may resign from the Company with or without Good Reason. The Company requests that Executive provide at least three (3) weeks’ advance written notice of a termination without Good Reason to allow for an orderly transition. The Company may accelerate the date Executive’s resignation is to become effective, in its sole discretion. In the event the company accelerates the resignation effective date, the Executive will be paid Base Salary severance through the originally tendered resignation date, provided that in no such event will Executive be entitled to receive more than three (3) months of Base Salary severance beyond the accelerated resignation date.

d. Definition of Cause. For purposes of this Agreement, “Cause” for the Company to terminate Executive shall mean: (i) Executive’s incompetence or failure or refusal to perform satisfactorily any duties reasonably required of Executive by the Company (other than by reason of Disability), which failure continues for fifteen (15) days after Executive receives specific written notice to cure; (ii) Executive’s conviction or plea of guilty or nolo contendere to any felony or to any other crime involving dishonesty or moral turpitude; (iii) any act or omission which constitutes a material breach of this Agreement, the Proprietary Information Agreement, the Company’s policies, or Executive’s fiduciary duty to the Company; (iv) any act or omission in connection with Executive’s employment with the Company, which involves material personal dishonesty by Executive or demonstrates a willful or continuing disregard for the best interests of the Company; or (v) Executive’s engaging in dishonorable or disruptive behavior, practices or acts which cause, or could be reasonably expected to cause, material harm or bring disrepute to the Company.


Exhibit 10.4
e. Definition of Good Reason. For purposes of this Agreement, “Good Reason” means the occurrence of any of the following without Executive’s prior written consent: (i) a reduction in Executive’s Base Salary or benefits that materially diminishes the aggregate value of Executive’s compensation and benefits, unless a reduction is made in connection with an across-the-board reduction of all executives’ base salaries and/or employee benefits by a percentage less than 20% and at least equal to the percentage by which Executive’s Base Salary or employee benefits are reduced; (ii) in the event of such an across-the-board reduction and a subsequent across-the-board restoration of all or any portion of the reduced Base Salary or benefits, then a failure to restore Executive’s Base Salary or benefits in at least a proportional manner; (iii) any reduction of Bonus Target level; (iv) a material reduction in Executive’s duties, authority or responsibilities taken as a whole; or (v) a relocation of Executive’s principal place of employment that would result in an increase in Executive’s one-way commute by more than 30 miles. Notwithstanding the foregoing, “Good Reason” for Executive to resign shall not exist unless: (x) Executive provides the Company with specific written notice of the existence of the condition giving rise to Good Reason within ninety (90) days after its initial occurrence; (y) the Company fails to remedy such condition within thirty (30) days after its receipt of such written notice; and (z) Executive resigns within sixty (60) days after the cure period has lapsed.

f. Final Pay upon Termination for Any Reason. Except as otherwise provided by this Agreement and/or required by law, upon termination of Executive’s employment for any reason, the Company’s obligation to make payments hereunder shall cease, except that the Company shall pay all amounts due and payable for Executive’s services through Executive’s last day of employment (the “Separation Date”), including all accrued unpaid Base Salary and Bonus compensation earned through Separation Date, any benefits accrued prior to the Separation Date, all accrued but unused vacation as of the Separation Date, and any reimbursable business expenses incurred but not reimbursed as of the Separation Date.

g. Severance Benefits upon a Covered Termination (No Change in Control).

i. Severance Benefits. If Executive’s employment is terminated by the Company without Cause or as a result of Executive’s resignation for Good Reason or Executive’s death or Disability (each a “Covered Termination”), Executive (or Executive’s estate, as applicable) shall be eligible to receive the following severance benefits: (1) payment of an amount equal to twelve (12) months of Executive’s Base Salary in effect immediately prior to the Separation Date, less applicable payroll tax withholdings and deductions (the “Severance”) and (2) twelve (12) months of accelerated vesting of Executive’s Option and all other equity awards granted under the Equity Plan (the “Equity Awards”) (so that Executive becomes vested in the portion of the Equity Awards that would have become vested if Executive remained employed for 365 days after the Separation Date). In addition, the period following termination of employment during which the Equity Awards may be exercised shall be extended to twelve (12) months. Except for the foregoing accelerated vesting and extended exercise period benefit, all existing terms and conditions applicable to the Equity Awards shall remain in full force and effect. In addition, provided Executive timely elects to continue Executive’s group health insurance coverage after the Separation Date pursuant to the federal COBRA law or, if applicable, state insurance laws (collectively, “COBRA”), and the terms of the governing health insurance policies, the Company will reimburse the monthly COBRA health insurance premiums (the “COBRA Payments”) Executive pays to continue Executive’s health insurance coverage (including dependent coverage) for twelve (12) months after the Separation Date or until such earlier date as Executive either becomes eligible for group health insurance coverage through a new employer or ceases to be eligible for COBRA coverage (the “COBRA Payment Period”). Executive must submit to the Company appropriate documentation of the foregoing health insurance payments, within sixty (60) days of making such payments, in order to be reimbursed. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA Payments without a substantial risk of violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), at the end of each remaining month of the COBRA Payment Period, the Company shall pay Executive directly a taxable monthly amount which, after taxes, equals the COBRA Payment amount the Company would have otherwise paid to Executive (assuming a 35% tax rate). Executive agrees to promptly notify the Company in writing if Executive becomes eligible for group health insurance coverage through a new employer before the end of the specified reimbursement period. For sake of reference, all severance benefits provided in entire subsection 9(g)(i) shall be referred to collectively as the “Severance Benefits.”


Exhibit 10.4
ii. Preconditions. As a precondition to receiving any Severance Benefits, Executive must (1) remain in compliance with all continuing obligations Executive owes to the Company, including those set forth under Executive’s Proprietary Information Agreement, and (2) within twenty-one (21) days after the Separation Date, Executive must sign and return to the Company, a separation agreement and release of claims in substantially the form attached hereto as Exhibit B (the “Release”) and allow the Release to become fully-effective and non-revocable by its terms. The Severance will be paid in the form of continuing installments on the ordinary payroll schedule, and the Final Bonus will be paid in a lump sum following the Separation Date within ten (10) business days of the effective date of such Release.


10. Change In Control Benefits.

a. Change in Control Termination. If Executive’s employment with the Company is terminated by the Company without Cause (but not due to Executive’s death or Disability) or Executive resigns for Good Reason, and such termination or resignation occurs within one (1) month before, or within thirteen (13) months after a Change in Control (defined below) (each a “CIC Termination”), Executive shall be eligible to receive the following enhanced severance package (in lieu of the Severance Benefits described above): (i) payment of eighteen (18) months of Executive’s Base Salary as in effect immediately prior to the Separation Date, less applicable withholdings and deductions; (ii) payment of a bonus in the amount equal to the most recently paid Bonus as described in Section 5 above multiplied by (1.5), less applicable withholdings and deductions (the payments under clauses (i) and (ii) referred to as the “CIC Cash Severance”); and (iii) accelerated vesting of Executive’s Equity Awards so that Executive becomes one hundred percent (100%) vested in all such Equity Awards. In addition, the period following the Separation Date during which Executive’s Equity Awards may be exercised shall be extended to twelve (12) months. Except for the noted accelerated vesting and extended exercise period benefits, all existing terms and conditions applicable to the Equity Awards shall remain in full force and effect. In addition, provided Executive timely elects to continue Executive’s group health insurance coverage after the Separation Date pursuant to COBRA, and the terms of the governing health insurance policies, the Company will reimburse all monthly COBRA health insurance premiums the Executive pays to continue Executive’s health insurance coverage (including dependent coverage) for eighteen (18) months after the Separation Date or until such earlier date as Executive either becomes eligible for group health insurance coverage through a new employer or Executive ceases to be eligible for COBRA coverage. The Change in Control severance benefits shall be paid subject to the same preconditions and on the same terms and conditions applicable to the Severance Benefits; provided, however, that the CIC Cash Severance shall be paid in the form of a lump sum within ten (10) business days of the Effective Date of the Release required under Section 9(g)(ii) (Preconditions).

b. Definition of Change in Control. For purposes of this Agreement, “Change in Control” has the definition set forth in the Equity Plan.

11. Code Section 409A Compliance. Notwithstanding anything set forth in this Agreement to the contrary, any payments and benefits provided pursuant to this Agreement which constitute “deferred compensation” within the meaning of the Treasury Regulations issued pursuant to Section 409A shall not commence until Executive has incurred a “separation from service” (as such term is defined in the Treasury Regulation Section 1.409A-1(h) (“Separation From Service”), unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur the additional 20% tax under Section 409A.

For the avoidance of doubt, it is intended that the payments and benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9) and this Agreement will be construed to the greatest extent possible as consistent with those provisions. To the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A and incorporates by reference all required definitions and payment terms. For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A 2(b)(2)(iii)), Executive’s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if the Company (or, if applicable, the successor entity thereto) determines that any payments upon Executive’s Separation From Service set forth herein and/or under any other agreement with the Company constitute “deferred compensation” under Section 409A and Executive is, on Executive’s Separation From Service, a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of

Exhibit 10.4
the Code, then, solely, to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the payments upon Executive’s Separation From Service shall be delayed until the earlier to occur of: (a) the date that is six months and one day after Executive’s Separation From Service or (b) the date of Executive’s death (such applicable date, the “Specified Employee Initial Payment Date”). On the Specified Employee Initial Payment Date, the Company (or the successor entity thereto, as applicable) shall (A) pay to Executive a lump sum amount equal to the sum of the payments upon Executive’s Separation From Service that Executive would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of the severance benefits had not been so delayed pursuant to this section and (B) commence paying the balance of the severance benefits in accordance with the applicable payment schedules set forth in this Agreement.
None of the severance benefits under this Agreement will commence or otherwise be delivered prior to the effective date of the Release. Except to the minimum extent that payments must be delayed because Executive is a “specified employee” (as described above) or until the effectiveness of the Release, all amounts will be paid as soon as practicable in accordance with the Company’s normal payroll practices and no interest will be due on any amounts so deferred.
12. Better After Tax Provision. If any payment or benefit that Executive will or may receive from the Company or otherwise (a “280G Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then any such 280G Payment will be equal to the Reduced Amount. The “Reduced Amount” will be either (x) the largest portion of the 280G Payment that would result in no portion of the 280G Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the 280G Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the 280G Payment may be subject to the Excise Tax. If a reduction in a 280G Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”).

Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the 280G Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification will preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (B) as a second priority, 280G Payments that are contingent on future events (e.g., being terminated without Cause), will be reduced (or eliminated) before 280G Payments that are not contingent on future events; and (C) as a third priority, 280G Payments that are “deferred compensation” within the meaning of Section 409A of the Code will be reduced (or eliminated) before 280G Payments that are not “deferred compensation” within the meaning of Section 409A of the Code.
If Section 280G of the Code is not applicable by law to Executive, the Company will determine whether any similar law in Executive’s jurisdiction applies and should be taken into account.
The independent professional firm engaged by the Company for general tax audit purposes as of the day prior to the effective date of the Change in Control will make all determinations required to be made under this Section. If the firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized independent professional firm to make the determinations required hereunder. The Company will bear all expenses with respect to the determinations by such firm required to be made hereunder. The Company will use commercially reasonable efforts to cause the firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting

Exhibit 10.4
documentation, to the Company and Executive within thirty (30) calendar days after the date on which Executive’s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive.
If Executive receives a 280G Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section and the Internal Revenue Service determines thereafter that some portion of the 280G Payment is subject to the Excise Tax, Executive will promptly return to the Company a sufficient amount of the 280G Payment (after reduction pursuant to clause (x) of the first paragraph of this Section) so that no portion of the remaining 280G Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of the first paragraph of this Section, Executive will have no obligation to return any portion of the 280G Payment pursuant to the preceding sentence.
13. Miscellaneous.

a. Taxes. Executive shall be responsible for the payment of any taxes due on any and all compensation, stock option, or benefit provided by the Company pursuant to this Agreement which are not withheld by the Company. Executive agrees to indemnify and hold harmless the Company from any and all claims or penalties asserted against the Company arising from Executive’s failure to pay taxes due on any compensation, stock option, or benefit provided by the Company pursuant to this Agreement. Executive expressly acknowledges that the Company has not made any representation about the tax consequences of any consideration provided by the Company to Executive pursuant to this Agreement.

b. Modification/Waiver. This Agreement may not be amended, modified, superseded, canceled, renewed or expanded, or any terms or covenants hereof waived, except by a writing executed by each of the Parties or, in the case of a waiver, by the Party waiving compliance. Failure of any Party at any time to require performance of any provision hereof shall in no manner affect his, her or its right at a later time to enforce such provision. No waiver by a Party of a breach of this Agreement shall be deemed to be or construed as a waiver of any other breach of any term or condition contained in the Agreement.

c. Successors and Assigns. This Agreement may be assigned by the Company to an affiliated entity or to any successor or assignee of the Company with or without Executive’s consent. This Agreement shall not be assignable by Executive.

d. Notices. All notices to be given hereunder shall be in writing and shall be deemed to have been duly given on: the date personally or hand delivered; one (1) day after being sent by internationally-recognized overnight delivery courier; and three (3) days after being sent by certified mail, return receipt requested. Notices mailed to Executive shall be sent to Executive’s last home address as reflected in the Company’s personnel records. Executive promptly shall notify Company of any change in Executive’s address. Notices to be issued to the Company shall be directed to the CEO and shall be mailed to the Company’s headquarters.


Exhibit 10.4
e. Dispute Resolution. To aid in the rapid and economical resolution of any disputes that may arise in the course of Executive’s employment relationship, the Parties agree that any and all disputes, claims, or demands arising from or relating to the terms of this Agreement (including but not limited to the Proprietary Information Agreement incorporated by reference herein), Executive’s employment relationship with the Company, or the termination of that relationship (including statutory claims), shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration in Dallas, Texas conducted before a single neutral arbitrator by JAMS, Inc. (“JAMS”) or its successor, under the then applicable JAMS Arbitration Rules and Procedures for Employment Disputes (available at http://www.jamsadr.com/rules-employment-arbitration/) and subject to JAMS’ Policy on Employment Arbitration Minimum Standards of Procedural Fairness. The Parties acknowledge that by agreeing to this arbitration procedure, they waive the right to resolve any such dispute, claim or demand through a trial by jury or judge or by administrative proceeding. Executive will have the right to be represented by legal counsel at any arbitration proceeding, at Executive’s expense. The arbitrator shall: (a) have authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based; and (c) have authority to, in the arbitrator’s discretion, award recovery of attorneys’ fees and costs to the prevailing party. The Company shall pay all JAMS’ arbitration fees. Nothing in this Agreement is intended to prevent either Party from obtaining injunctive relief in a court of applicable jurisdiction to prevent irreparable harm pending the conclusion of any arbitration; or from enforcing any arbitration award in a court of applicable jurisdiction.

f. Entire Agreement. This Agreement, together with the Exhibits, sets forth the complete and exclusive agreement and understanding of the Parties with regard to the subject matter hereof, and supersedes any and all prior or contemporaneous agreements, promises, representations, or communications, written or oral, pertaining to the subject matter hereof. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement, and the invalid or unenforceable provision shall be modified to render it valid and enforceable consistent with the intent of the parties insofar as possible under applicable law. For purposes of construing this Agreement, any ambiguities shall not be construed against any party as the drafter. This Agreement may be executed in counterparts, which shall be deemed to be part of one original, and facsimile signatures shall be equivalent to original signatures. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Iowa, without regard to conflict of laws principles.

In Witness Whereof, the Parties have each duly executed this Agreement as of the date written above to indicate their understanding and acceptance of all of the above-stated terms and conditions.
NewLink Genetics Corporation

By: /s/ Charles J. Link, Jr. M.D. 
Its: CEO 


Executive

/s/ Carl Langren
Carl Langren



Exhibit 10.4

Exhibit A
EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT
This Employee Proprietary Information, Inventions, Non-competition, and Non-solicitation Agreement (this “Agreement”) is made in consideration for my employment or continued employment by NewLink Genetics Corporation or any of its subsidiaries (the “Company”), and the compensation now and hereafter paid to me. I hereby agree as follows:
1. Nondisclosure.

1.1 Recognition of Company’s Rights; Nondisclosure. At all times during my employment and thereafter, I will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information (defined below), except as such disclosure, use or publication may be required in connection with my work for the Company, or unless an officer of the Company expressly authorizes such in writing. I will obtain Company’s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that relates to my work at Company and/or incorporates any Proprietary Information. I hereby assign to the Company any rights I may have or acquire in such Proprietary Information and recognize that all Proprietary Information shall be the sole property of the Company and its assigns.
1.2 Proprietary Information. The term “Proprietary Information” shall mean any and all confidential and/or proprietary knowledge, data or information of the Company. By way of illustration but not limitation, “Proprietary Information” includes (a) tangible and intangible information relating to antibodies and other biological materials, cell lines, samples of assay components, media and/or cell lines and procedures and formulations for producing any such assay components, media and/or cell lines, formulations, products, processes, know-how, designs, formulas, methods, developmental or experimental work, clinical data, improvements, discoveries, plans for research, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers, and information regarding the skills and compensation of other employees of the Company; (b) trade secrets, inventions, mask works, ideas, processes, formulas, source and object codes, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques (hereinafter collectively referred to as “Inventions”); (c) information regarding plans for research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; and (d) information regarding the skills and compensation of other employees of the Company. Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is generally known in the trade or industry, which is not gained as result of a breach of this Agreement, and my own, skill, knowledge, know-how and experience to whatever extent and in whichever way I wish.
1.3 Third Party Information. I understand, in addition, that the Company has received and in the future will receive from third parties confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for the Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an officer of the Company in writing.
1.4 No Improper Use of Information of Prior Employers and Others. During my employment by the Company I will not improperly use or disclose any confidential information or trade secrets, if any, of any third party, including but not limited to any former employer or any other person or entity to whom I have an obligation of confidentiality, and I will not bring onto the premises of the Company any unpublished documents or any property belonging to any third party, including but not limited to any former employer or any other person or entity to whom I have an obligation of confidentiality unless consented to in writing by that third party. I will use in the

Exhibit 10.4
performance of my duties only information which is generally known and used by persons with training and experience comparable to my own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided, obtained, or developed by or for the Company.
2. Assignment of Inventions.

2.1 Proprietary Rights. The term “Proprietary Rights” shall mean all trade secret, patent, copyright, mask work and other intellectual property rights throughout the world.
2.2 Prior Inventions. Inventions, if any, patented or unpatented, which I made prior to the commencement of my employment with the Company are excluded from the scope of this Agreement. To preclude any possible uncertainty, I have set forth on Exhibit A (Previous Inventions) attached hereto a complete list of all Inventions that I have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of my employment with the Company, that I consider to be my property or the property of third parties and that I wish to have excluded from the scope of this Agreement (collectively referred to as “Prior Inventions”). If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Prior Inventions in Exhibit A but am only to disclose a cursory name for each such invention, a listing of the party (ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason. A space is provided on Exhibit A for such purpose. If no such disclosure is attached, I represent that there are no Prior Inventions. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or machine, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license (with rights to sublicense through multiple tiers of sublicensees) to make, have made, modify, use and sell such Prior Invention. Notwithstanding the foregoing, I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions without the Company’s prior written consent.
2.3 Assignment of Inventions. Subject to Sections 2.4, and 2.6, I hereby assign and agree to assign in the future (when any such Inventions or Proprietary Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to the Company all my right, title and interest in and to any and all Inventions (and all Proprietary Rights with respect thereto) whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or learned by me, either alone or jointly with others, during the period of my employment with the Company. Inventions assigned to the Company, or to a third party as directed by the Company pursuant to this Section 2, are hereinafter referred to as “Company Inventions.”
2.4 Nonassignable Inventions. I recognize that, in the event of a specifically applicable state law, regulation, rule, or public policy (“Specific Inventions Law”), this Agreement will not be deemed to require assignment of any invention which qualifies fully for protection under a Specific Inventions Law by virtue of the fact that any such invention was, for example, developed entirely on my own time without using the Company’s equipment, supplies, facilities, or trade secrets and neither related to the Company’s actual or demonstrably anticipated business, research or development, nor resulted from work performed by me for the Company. In the absence of a Specific Inventions Law, the preceding sentence will not apply.
2.5 Obligation to Keep Company Informed. During the period of my employment with the Company, I will promptly disclose to the Company fully and in writing all Inventions authored, conceived or reduced to practice by me, either alone or jointly with others; and all patent applications filed by me or on my behalf. At the time of each such disclosure, I will advise the Company in writing of any Inventions that I believe fully qualify for protection under the provisions of a Specific Inventions Law; and I will at that time provide to the Company in writing all evidence necessary to substantiate that belief. The Company will keep in confidence and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to the Company pursuant to this Agreement relating to Inventions that qualify fully for protection under a Specific Inventions Law. I will preserve the confidentiality of any Invention that does not fully qualify for protection under a Specific Inventions Law.

Exhibit 10.4
2.6 Government or Third Party. I also agree to assign all my right, title and interest in and to any particular Company Invention to a third party, including without limitation the United States, as directed by the Company.
2.7 Works for Hire. I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment at the Company and which are protectable by copyright are “works made for hire,” pursuant to United States Copyright Act (17 U.S.C., Section 101).
2.8 Enforcement of Proprietary Rights. 
i. Obligation to Assist. I will assist the Company in every proper way to obtain, and from time to time enforce, United States and foreign Proprietary Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Proprietary Rights to the Company or its designee. My obligation to assist the Company with respect to Proprietary Rights relating to such Company Inventions in any and all countries shall continue beyond the termination of my employment, but the Company shall compensate me at a reasonable rate after my termination for time actually spent by me at the Company’s request on such assistance.

ii. Appointment of Attorney in Fact. In the event the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in the preceding paragraph, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Proprietary Rights assigned hereunder to the Company.

3. No Conflicts, Non-Solicitation, and Non-Interference. I acknowledge that during my employment I will have access to and knowledge of Proprietary Information. To protect the Company’s Proprietary Information, I agree that during the period of my employment by the Company I will not, without the Company’s express written consent, engage in any other employment or business activity directly related to the business in which the Company is now involved or becomes involved, nor will I engage in any other activities which conflict with my obligations to the Company or the interests of the Company. For the period of my employment by the Company and continuing until one year after my last day of employment with the Company, I will not: (a) directly or indirectly induce any employee of the Company to terminate or reduce his or her relationship with the Company; (b) solicit the business of any Client or Customer of the Company (other than on behalf of the Company) for any competitive purpose; or (c) induce any supplier, vendor, consultant or independent contractor of the Company to terminate or reduce his, her or its relationship with the Company. I agree that for purposes of this Agreement, a “Client or Customer” is any person or entity with whom or which, at any time during the two year period prior to my last day of employment with the Company, (i) I had direct dealings; (ii) an individual whom I supervised had direct dealings; or (iii) about whom or which I obtained confidential information. If any restriction set forth in this Section is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.

4. Covenant Not to Compete. I acknowledge that during my employment I will have access to and knowledge of Proprietary Information. To protect the Company’s Proprietary Information, I agree that during my employment with the Company, whether full-time or part-time, and for a period of one year after my last day of employment with the Company, I will not directly or indirectly engage in (whether as an employee, consultant, proprietor, partner, director or otherwise), or have any ownership interest in, or participate in the financing, operation, management or control of, any person, entity, corporation or business that engages in a “Restricted Business” in a “Restricted Territory” (as defined below). It is agreed that ownership of (i) no more than one percent

Exhibit 10.4
(1%) of the outstanding voting stock of a publicly traded corporation, or (ii) any stock I presently own shall not constitute a violation of this provision.

4.1 Reasonable. I agree and acknowledge that the time limitation on the restrictions in this paragraph, combined with the geographic scope, is reasonable. I also acknowledge and agree that this paragraph is reasonably necessary for the protection of the Company’s Proprietary Information as defined in paragraph 1.2 herein, that through my employment I shall receive adequate consideration for any loss of opportunity associated with the provisions herein, and that these provisions provide a reasonable way of protecting the Company’s business value, some of which will be imparted to me in the ordinary course of my employment with the Company. If any restriction set forth in this paragraph 4 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.
4.2 As used herein, the terms:
(i) “Restricted Business” shall mean a business that is engaged in or is preparing to engage in any of the areas that the Company is actively pursuing, including but not limited to research, development and/or commercialization of (1) one or more products for the treatment of cancer or infectious disease based upon the Company’s HyperAcute technology platform; (2) one or more products for the treatment of cancer based upon IDO, TDO or PTEN inhibitors; (3) vaccines against the Ebola virus; or (4) any other area of research, development, or commercialization drug or biologic candidate potentially likely which is intended to address the same enzymatic target (such as, for example, IDO) as any drug or biologic candidate that (i) is the subject area of research, development, or commercialization in which the Company or any subsidiary is engaged pursuant to a program which is being materially funded by the Company, a strategic partner of the Company, and/or a grant to the Company and (ii) as to which I participated in or was familiar with the details of such the research, development or commercialization during their time of my employment with Company or regarding which I possess Confidential Information. For purposes of the preceding sentence, the determination of the scope of the Company’s business activities shall be made as of the date of termination of my employment.

(ii) “Restricted Territory” shall mean any state, county, or locality in the United States in which the Company conducts business and any other country, city, state, jurisdiction, or territory in which the Company does business or plans to do business.

5. Records. I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and any other form that may be required by the Company) of all Proprietary Information developed by me and all Company Inventions made by me during the period of my employment at the Company, which records shall be available to and remain the sole property of the Company at all times.

6. No Conflicting Obligation. I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by the Company, nor any other lawful obligation I have to any third party. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict herewith.

7. Return of Company Materials. When I leave the employ of the Company, or earlier if requested by the Company, I will deliver to the Company any and all drawings, notes, memoranda, specifications, devices, formulas, documents, materials, and tangible or intangible property of the Company together with all copies thereof, and any other material containing or embodying any Company Inventions, Third Party Information or Proprietary Information of the Company without retaining any reproductions or embodiments thereof in whole or in part and in any medium. By way of example, such items include but are not limited to: Company files, records, plans, forecasts, reports, studies, analyses, proposals, agreements, financial information, information regarding potential business development partners, research and development information, sales and marketing information, operational

Exhibit 10.4
and personnel information, code, software, databases, computer-recorded information, and tangible property and equipment (including, but not limited to, computers, data storage devices, facsimile machines, mobile telephones, servers, credit cards, entry cards, identification badges and keys). In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed. I further agree that any property situated on the Company’s premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice.

8. Legal and Equitable Remedies. Because my services are personal and unique and because I may have access to and become acquainted with the Proprietary Information of the Company, the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement.

9. Notices. Any notices required or permitted hereunder shall be given to the appropriate party at the address specified below or at such other address as the party shall specify in writing. Such notice shall be deemed given upon personal delivery or express delivery service (e.g., FedEx) to the appropriate address; upon delivery via facsimile; or if sent by certified or registered mail, three days after the date of mailing.

10. Notification of New Employer. In the event that I leave the employ of the Company, I hereby consent to the notification of my new employer of my rights and obligations under this Agreement.

11. General Provisions.

11.1 Governing Law; Consent to Personal Jurisdiction and Exclusive Forum. This Agreement will be governed by and construed according to the laws of the State of Iowa as such laws are applied to agreements entered into and to be performed entirely within Iowa between Iowa residents. I hereby expressly understand and consent that my employment is a transaction of business in the State of Iowa and constitutes the minimum contacts necessary to make me subject to the personal jurisdiction of the federal courts located in the State of Iowa, and the state courts located in the County of Story, Iowa, for any lawsuit filed against me by Company arising from or related to this Agreement. I agree and acknowledge that any controversy arising out of or relating to this Agreement or the breach thereof, or any claim or action to enforce this Agreement or portion thereof, or any controversy or claim requiring interpretation of this Agreement must be brought in a forum located within the State of Iowa. No such action may be brought in any forum outside the State of Iowa. Any action brought in contravention of this paragraph by one party is subject to dismissal at any time and at any stage of the proceedings by the other, and no action taken by the other in defending, counter claiming or appealing shall be construed as a waiver of this right to immediate dismissal. A party bringing an action in contravention of this paragraph shall be liable to the other party for the costs, expenses and attorney’s fees incurred in successfully dismissing the action or successfully transferring the action to the federal courts located in the State of Iowa, or the state courts located in the County of Story, Iowa.
11.2 Severability. In case any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement; this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein; and such provision shall be deemed modified and enforceable, insofar as possible consistent with its original intent. By way of example, if, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.

Exhibit 10.4
11.3 Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives and will be for the benefit of the Company, its successors, and its assigns. My obligations under this Agreement are not assignable to any party.
11.4 Survival. The provisions of this Agreement shall survive the termination of my employment and the assignment of this Agreement by the Company to any successor in interest or other assignee.
11.5 Employment. I agree and understand that my employment is at-will which means I or the Company each have the right to terminate my employment, with or without advanced notice and with or without cause. I further agree and understand that nothing in this Agreement shall confer any right with respect to continuation of employment by the Company, nor shall it interfere in any way with my right or the Company’s right to terminate my employment at any time, with or without cause.
11.6 Waiver. To be valid, any waiver by me or the Company of any breach of this Agreement or right hereunder shall be specifically stated in writing, and shall not be a waiver of any preceding or succeeding breach unless so specifically stated. No waiver of any right under this Agreement and applicable law shall be construed as a waiver of any other right. Neither party shall be required to give notice to enforce strict adherence to all terms of this Agreement.
11.7 Entire Agreement. The obligations pursuant to this Agreement shall apply to any time during which I was previously, or am in the future, employed or engaged as a consultant by the Company, if no other agreement governs the subject matter thereof. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior communications and representations with respect to such subject matter. No modification of or amendment to this Agreement will be effective unless in writing and signed by the party to be charged. Any subsequent changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.


Exhibit 10.4
EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT
ACKNOWLEDGEMENT FORM

I acknowledge that I have been given a copy of the Employee Proprietary Information and Inventions Agreement, that I have read it, and that I understand its terms and procedures. Furthermore, I agree to abide by it and understand that if NewLink determines my conduct warrants it, I may be subject to discipline for breaches hereof, up to and including the immediate termination of my employment.



Carl Langren      
Employee’s Name (Please Print)



/s/ Carl Langren      
Employee’s Signature



7/26/2018      
Date




Exhibit 10.4

Exhibit B
RELEASE
[To be signed on or within twenty-one (21) days after the Separation Date]
My employment with NewLink Genetics Corporation (the “Company”) ended in all capacities on ___________ (the “Separation Date”). I hereby confirm that I have been paid all compensation owed to me by the Company for all hours worked; I have received all the leave and leave benefits and protections for which I was eligible, pursuant to the Company’s policies, applicable law, or otherwise; and I have not suffered any on-the-job injury or illness for which I have not already filed a workers’ compensation claim.

If I choose to enter into this Release and allow it to become effective by its terms, the Company will provide me with certain severance benefits pursuant to the terms of the Employment Agreement between me and the Company dated _______, 2015 (the “Agreement”). I understand that I am not entitled to such severance benefits unless I return this fully-executed Release to the Company within twenty-one (21) days after the Separation Date, and allow this Release to become fully effective and non-revocable by its terms. (Capitalized terms used but not defined in this Release shall have the meaning ascribed to them in the Agreement.)

In exchange for the severance benefits to which I would not otherwise be entitled, I hereby generally and completely release the Company and its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the “Released Parties”) from any and all claims, liabilities and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring prior to or at the time that I sign this Release, including but not limited to claims arising from or in any way related to my employment with the Company or the termination of that employment (collectively, the “Released Claims”). By way of example, the Released claims include, but are not limited to: (1) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (2) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (3) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (4) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), and Iowa and Texas state laws.
Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”): (a) any claims for breach of the Agreement arising after the date on which I sign this Release; (2) claims for reimbursement of properly incurred business expenses prior to and through the Separation Date which are submitted to the Company for reimbursement within thirty (30) days after the Separation Date; (3) all rights I have in respect of the Equity Awards; (4) all claims for or rights to indemnification pursuant to the articles of incorporation and bylaws of the Company, any indemnification agreement to which I am a party, or under applicable law; and (5) all claims which cannot be waived as a matter of law. I understand that nothing in this Release prevents me from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or any other government agency, except that I acknowledge and agree that I am hereby waiving my right to any monetary benefits in connection with any such claim, charge or proceeding. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims that I have or might have against any of the parties released above that are not included in the Released Claims.


Exhibit 10.4
[IF EXECUTIVE IS 40 YEARS OF AGE OR OLDER] I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA, and that the consideration given for this Release is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised, as required by the ADEA, that: (a) my waiver and release does not apply to any rights or claims that may arise after the date I sign this Release; (b) I have been advised that I have the right to consult with an attorney prior to executing this Release (although I may choose voluntarily not to do so); (c) I have been given twenty-one (21) days to consider this Release (although I may choose voluntarily to sign it earlier); (d) I have seven (7) days following my execution of this Release to revoke my acceptance of it (with such revocation to be delivered in writing to the Company within the 7-day revocation period); and (e) this Release will not be effective until the date upon which the revocation period has expired, which will be the eighth day after I sign it, provided I do not earlier revoke it (“Effective Date”).
I further agree: (a) not to disparage the Company or any of the other Released Parties, in any manner likely to be harmful to its or their business, business reputation or personal reputation (although I may respond accurately and fully to any question, inquiry or request for information as required by legal process); (b) not to voluntarily (except in response to legal compulsion) assist any third party in bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceedings against the Company, its affiliates, officers, directors, employees or agents; and (c) to reasonably cooperate with the Company by voluntarily (without legal compulsion) providing accurate and complete information, in connection with the Company’s actual or contemplated defense, prosecution or investigation of any claims or demands by or against third parties, or other matters, arising from events, acts, or omissions that occurred during my employment with the Company. I hereby certify that I have returned, without retaining any reproductions (in whole or in part), all information, materials and other property of the Company, including but not limited to any such information, materials or property contained on any personally-owned electronic or other storage device (such as computer, cellular phone, PDA, tablet or the like).
This Release, together with the Agreement (including all Exhibits and documents incorporated therein by reference), constitutes the complete, final and exclusive embodiment of the entire agreement between me and the Company with regard to this subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained in the Release or the Agreement, and it entirely supersedes any other such promises, warranties or representations, whether oral or written.

Reviewed, Understood and Agreed:

By:       Date:



 EX-10.5 6 nlnk-2018930x10qxex105.htm EXHIBIT 10.5 Document
Exhibit 10.5
image1.jpg
EMPLOYMENT AGREEMENT
This Employment Agreement (the “Agreement”) is made as of this 26th day of July, 2018, by and between NewLink Genetics Corporation (the “Company”), and Lori Lawley (“Executive”) (collectively, the “Parties”, each a “Party”).
Whereas, the Company wishes to employ and/or continue to employ Executive and to assure itself of Executive’s services on the terms set forth herein;
Whereas, Executive wishes to be employed by the Company on the terms set forth herein; and
Whereas, the Parties intend for this Agreement to set forth all of the terms and conditions of Executive’s employment with the Company, and to supersede and replace all prior agreements, arrangements, representations or understandings between the Parties regarding Executive’s employment with the Company.
AGREEMENT
Now, Therefore, in consideration of the mutual promises and covenants contained herein, the Parties agree as follows:
1. Employment. The Company will employ Executive and Executive shall serve the Company in the capacity of Vice President - Finance and Corporate Controller ("VP Finance”).

2. Duties. Executive shall render exclusive, full-time services to the Company. Executive shall report to the Chief Financial Officer (“CFO”) in Executive’s role. Executive shall perform services under this Agreement primarily at the Company’s office in Austin, Texas, and from time to time at such other locations as may be necessary or as otherwise reasonably requested by the Company. Subject to the terms of this Agreement, Executive’s responsibilities, working conditions and duties may be changed, expanded or eliminated at the sole discretion of the CFO. Executive shall devote Executive’s best efforts and full business time, skill and attention to performance of Executive’s duties on behalf of the Company; provided, however, that Executive may engage in civic and not-for-profit activities (e.g. charitable and industry association activities) as long as such activities do not materially interfere with Executive’s obligations hereunder. During Executive’s employment with the Company, Executive agrees not to engage in any business or for-profit activities outside the Company, including serving on any advisory boards or boards of directors of for-profit entities, except with the prior written approval of the CFO, which approval may be rescinded at any time in the CFO’s sole discretion, provided that in the event of such rescission Executive shall be permitted reasonable time for orderly withdrawal from any board with respect to which such consent has been rescinded.  By signing this Agreement, Executive represents that, to the best of Executive’s knowledge, Executive is not subject to any other contract or duty that would interfere in any way with Executive’s employment with the Company or performance of employment duties hereunder.

3. Policies and Procedures. Executive shall be subject to and will comply with the policies and procedures of the Company, as they may be modified, expanded or eliminated from time to time at the Company’s sole discretion, except to the extent any such policy or procedure specifically conflicts with the express terms of this Agreement (in which case, this Agreement shall control).


Exhibit 10.5
4. Base Salary. For services rendered hereunder, Executive shall receive a base salary at the rate of $200,000 per year (“Base Salary”), paid periodically in accordance with ordinary Company payroll practices, subject to applicable payroll withholdings and deductions. Executive’s Base Salary shall also be subject to annual reviews and periodic adjustment; provided that Executive’s Base Salary may not be decreased without Executive’s express written consent except in connection with an across-the-board reduction proportionally affecting all senior executives of the Company.

5. Bonus. Executive will be eligible to receive an annual performance bonus (“Bonus”), with a target level at 25% of Executive’s Base Salary (the “Bonus Target”), with the annual amount of such Bonus to be determined in the sole discretion of the Company’s Board of Directors (the “Board”) or by its Compensation Committee (under authority delegated by the Board), based upon a review of both Executive's individual performance and the Company’s performance (both of which may include, but are not limited to, achievement of certain milestones or performance objectives, if any, established by the Board or the Compensation Committee (the “Bonus Plan”). The Board or the Compensation Committee, in their sole discretion, shall determine the extent to which Executive has achieved any performance targets or other terms and conditions applicable to the Bonus; the amount of the Bonus (if any); and whether and to what extent a Bonus may be paid with respect to any year during which Executive's employment terminates, subject to the terms and conditions of this Agreement.  Bonuses are not earned until they are approved in writing by the Board or Compensation Committee. Any Bonuses earned shall be paid subject to applicable employment taxes, withholding and deductions. Except as otherwise expressly provided in this Agreement or in the Bonus Plan, Executive must remain continuously employed with the Company through the date a Bonus is approved in order to be eligible to receive such Bonus.

6. Stock Options. In consideration for entering into this Agreement, Executive shall be granted an option to purchase 25,000 shares of Company common stock (the “Option”), subject to the vesting schedule and all other terms, conditions and limitations applicable to such Option as set forth in the Company’s 2009 Equity Incentive Plan as it may be amended from time to time (the “Equity Plan”) and in Stock Award Agreements (as defined in the Equity Plan) approved by the Board and entered into by Executive. Such grants to be awarded close of market the first of the month following date of promotion. Executive may receive additional equity grants from time to time, in the sole discretion of the Board or a designated committee thereof.

7. Other Benefits. While employed by the Company pursuant to this Agreement, Executive shall be entitled to the following benefits:

a. Executive Benefits. The Executive shall be entitled to all benefits to which other executive officers of the Company are entitled, on the same terms and conditions in effect from time to time, including, without limitation, participation in pension and profit sharing plans, the Company’s 401(k) plan, group insurance policies and plans (including medical, health, vision, and disability insurance policies and plans, and the like) which may be maintained by the Company for the benefit of its executives. The Company reserves the right to alter, discontinue and/or amend its benefit plans and programs from time to time in its sole discretion.

b. Expense Reimbursement. The Executive shall receive, upon presentation of proper receipts and vouchers, reimbursement for direct and reasonable out-of-pocket expenses incurred in connection with the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policies and procedures in effect from time to time.

c. Vacation. Executive will accrue twenty-eight (28) days of paid vacation each full year, accrued in equal monthly increments, subject to Executive’s continuing service. Unused vacation will carry over from year to year; provided, however, that Executive shall not be entitled to carry over more than a total of twenty-eight (28) days of accrued vacation. Once that maximum vacation balance has been reached, Executive will cease to accrue any additional vacation time until Executive uses some vacation time and brings Executive’s vacation balance below the cap. Executive’s vacation rights shall otherwise be governed by the Company’s vacation policy and applicable law, as in effect from time to time.





Exhibit 10.5
8. Confidential Information, Rights and Duties.

a. Proprietary Information. Executive agrees to execute and abide by the Company’s Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement (the “Proprietary Information Agreement”), attached hereto as Exhibit A.

b. Exclusive Property. Executive agrees that all Company-related business procured by the Executive, and all Company-related business opportunities and plans made known to Executive while employed by the Company, are and shall remain the permanent and exclusive property of the Company.

9. Termination of Employment.

a. At-Will Status. The Company and Executive understand and agree that this employment relationship is at-will. Accordingly, there are no promises or representations concerning the duration of Executive’s employment relationship, and it may be terminated by either Executive or the Company at any time, with or without Cause or Good Reason (as defined herein), and with or without advance notice. Executive’s at-will status cannot be altered except in an express written agreement signed by Executive and the Company with the specific approval of the Company’s Board.

b. Termination Due to Death or Disability. Subject to applicable state or federal law, Executive’s employment with the Company will automatically terminate upon Executive’s death or Disability. For purposes of this Agreement, “Disability” means a physical or mental condition or disability which prevents Executive from performing Executive’s job responsibilities for more than six (6) months in any twelve (12) month period, or for more than four (4) consecutive months.

c. Resignation by Executive. Executive may resign from the Company with or without Good Reason. The Company requests that Executive provide at least three (3) weeks’ advance written notice of a termination without Good Reason to allow for an orderly transition. The Company may accelerate the date Executive’s resignation is to become effective, in its sole discretion. In the event the company accelerates the resignation effective date, the Executive will be paid Base Salary severance through the originally tendered resignation date, provided that in no such event will Executive be entitled to receive more than three (3) months of Base Salary severance beyond the accelerated resignation date.

d. Definition of Cause. For purposes of this Agreement, “Cause” for the Company to terminate Executive shall mean: (i) Executive’s incompetence or failure or refusal to perform satisfactorily any duties reasonably required of Executive by the Company (other than by reason of Disability), which failure continues for fifteen (15) days after Executive receives specific written notice to cure; (ii) Executive’s conviction or plea of guilty or nolo contendere to any felony or to any other crime involving dishonesty or moral turpitude; (iii) any act or omission which constitutes a material breach of this Agreement, the Proprietary Information Agreement, the Company’s policies, or Executive’s fiduciary duty to the Company; (iv) any act or omission in connection with Executive’s employment with the Company, which involves material personal dishonesty by Executive or demonstrates a willful or continuing disregard for the best interests of the Company; or (v) Executive’s engaging in dishonorable or disruptive behavior, practices or acts which cause, or could be reasonably expected to cause, material harm or bring disrepute to the Company.


Exhibit 10.5
e. Definition of Good Reason. For purposes of this Agreement, “Good Reason” means the occurrence of any of the following without Executive’s prior written consent: (i) a reduction in Executive’s Base Salary or benefits that materially diminishes the aggregate value of Executive’s compensation and benefits, unless a reduction is made in connection with an across-the-board reduction of all executives’ base salaries and/or employee benefits by a percentage less than 20% and at least equal to the percentage by which Executive’s Base Salary or employee benefits are reduced; (ii) in the event of such an across-the-board reduction and a subsequent across-the-board restoration of all or any portion of the reduced Base Salary or benefits, then a failure to restore Executive’s Base Salary or benefits in at least a proportional manner; (iii) a material reduction in Executive’s duties, authority or responsibilities taken as a whole; or (iv) a relocation of Executive’s principal place of employment that would result in an increase in Executive’s one-way commute by more than 30 miles. Notwithstanding the foregoing, “Good Reason” for Executive to resign shall not exist unless: (x) Executive provides the Company with specific written notice of the existence of the condition giving rise to Good Reason within ninety (90) days after its initial occurrence; (y) the Company fails to remedy such condition within thirty (30) days after its receipt of such written notice; and (z) Executive resigns within sixty (60) days after the cure period has lapsed.

f. Final Pay upon Termination for Any Reason. Except as otherwise provided by this Agreement and/or required by law, upon termination of Executive’s employment for any reason, the Company’s obligation to make payments hereunder shall cease, except that the Company shall pay all amounts due and payable for Executive’s services through Executive’s last day of employment (the “Separation Date”), including all accrued unpaid Base Salary and Bonus compensation earned through Separation Date, any benefits accrued prior to the Separation Date, all accrued but unused vacation as of the Separation Date, and any reimbursable business expenses incurred but not reimbursed as of the Separation Date.

g. Severance Benefits upon a Covered Termination (No Change in Control).

i. Severance Benefits. If Executive’s employment is terminated by the Company without Cause or as a result of Executive’s resignation for Good Reason or Executive’s death or Disability (each a “Covered Termination”), Executive (or Executive’s estate, as applicable) shall be eligible to receive the following severance benefits: (1) payment of an amount equal to six (6) months of Executive’s Base Salary in effect immediately prior to the Separation Date, less applicable payroll tax withholdings and deductions (the “Severance”) and (2) twelve (12) months of accelerated vesting of Executive’s Option and all other equity awards granted under the Equity Plan (the “Equity Awards”) (so that Executive becomes vested in the portion of the Equity Awards that would have become vested if Executive remained employed for 365 days after the Separation Date). Except for the foregoing accelerated vesting benefit, all existing terms and conditions applicable to the Equity Awards shall remain in full force and effect. In addition, provided Executive timely elects to continue Executive’s group health insurance coverage after the Separation Date pursuant to the federal COBRA law or, if applicable, state insurance laws (collectively, “COBRA”), and the terms of the governing health insurance policies, the Company will reimburse the monthly COBRA health insurance premiums (the “COBRA Payments”) Executive pays to continue Executive’s health insurance coverage (including dependent coverage) for six (6) months after the Separation Date or until such earlier date as Executive either becomes eligible for group health insurance coverage through a new employer or ceases to be eligible for COBRA coverage (the “COBRA Payment Period”). Executive must submit to the Company appropriate documentation of the foregoing health insurance payments, within sixty (60) days of making such payments, in order to be reimbursed. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA Payments without a substantial risk of violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), at the end of each remaining month of the COBRA Payment Period, the Company shall pay Executive directly a taxable monthly amount which, after taxes, equals the COBRA Payment amount the Company would have otherwise paid to Executive (assuming a 35% tax rate). Executive agrees to promptly notify the Company in writing if Executive becomes eligible for group health insurance coverage through a new employer before the end of the specified reimbursement period. For sake of reference, all severance benefits provided in entire subsection 9(g)(i) shall be referred to collectively as the “Severance Benefits.”

ii. Preconditions. As a precondition to receiving any Severance Benefits, Executive must (1) remain in compliance with all continuing obligations Executive owes to the Company, including those set forth under Executive’s Proprietary Information Agreement, and (2) within twenty-one (21) days after the Separation Date, Executive must sign and return to the Company, a separation agreement and release of claims in substantially the form attached hereto as Exhibit B (the “Release”) and allow the Release to become fully-effective and non-revocable by its terms. The Severance will be paid in the form of continuing installments on the ordinary payroll schedule, and the Final Bonus will be paid in a lump sum following the Separation Date within ten (10) business days of the effective date of such Release.


Exhibit 10.5

10. Change In Control Benefits.

a. Change in Control Termination. If Executive’s employment with the Company is terminated by the Company without Cause (but not due to Executive’s death or Disability) or Executive resigns for Good Reason, and such termination or resignation occurs within one (1) month before, or within thirteen (13) months after a Change in Control (defined below) (each a “CIC Termination”), Executive shall be eligible to receive the following enhanced severance package (in lieu of the Severance Benefits described above): (i) payment of twelve (12) months of Executive’s Base Salary as in effect immediately prior to the Separation Date, less applicable withholdings and deductions; (ii) payment of a bonus in the amount equal to the most recently paid Bonus as described in Section 5 above, less applicable withholdings and deductions (the payments under clauses (i) and (ii) referred to as the “CIC Cash Severance”); and (iii) accelerated vesting of Executive’s Equity Awards so that Executive becomes one hundred percent (100%) vested in all such Equity Awards. Except for the noted accelerated vesting benefits, all existing terms and conditions applicable to the Equity Awards shall remain in full force and effect. In addition, provided Executive timely elects to continue Executive’s group health insurance coverage after the Separation Date pursuant to COBRA, and the terms of the governing health insurance policies, the Company will reimburse all monthly COBRA health insurance premiums the Executive pays to continue Executive’s health insurance coverage (including dependent coverage) for twelve (12) months after the Separation Date or until such earlier date as Executive either becomes eligible for group health insurance coverage through a new employer or Executive ceases to be eligible for COBRA coverage. The Change in Control severance benefits shall be paid subject to the same preconditions and on the same terms and conditions applicable to the Severance Benefits; provided, however, that the CIC Cash Severance shall be paid in the form of a lump sum within ten (10) business days of the Effective Date of the Release required under Section 9(g)(ii) (Preconditions).

b. Definition of Change in Control. For purposes of this Agreement, “Change in Control” has the definition set forth in the Equity Plan.

11. Code Section 409A Compliance. Notwithstanding anything set forth in this Agreement to the contrary, any payments and benefits provided pursuant to this Agreement which constitute “deferred compensation” within the meaning of the Treasury Regulations issued pursuant to Section 409A shall not commence until Executive has incurred a “separation from service” (as such term is defined in the Treasury Regulation Section 1.409A-1(h) (“Separation From Service”), unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur the additional 20% tax under Section 409A.

For the avoidance of doubt, it is intended that the payments and benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9) and this Agreement will be construed to the greatest extent possible as consistent with those provisions. To the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A and incorporates by reference all required definitions and payment terms. For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A 2(b)(2)(iii)), Executive’s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if the Company (or, if applicable, the successor entity thereto) determines that any payments upon Executive’s Separation From Service set forth herein and/or under any other agreement with the Company constitute “deferred compensation” under Section 409A and Executive is, on Executive’s Separation From Service, a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely, to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the payments upon Executive’s Separation From Service shall be delayed until the earlier to occur of: (a) the date that is six months and one day after Executive’s Separation From Service or (b) the date of Executive’s death (such applicable date, the “Specified Employee Initial Payment Date”). On the

Exhibit 10.5
Specified Employee Initial Payment Date, the Company (or the successor entity thereto, as applicable) shall (A) pay to Executive a lump sum amount equal to the sum of the payments upon Executive’s Separation From Service that Executive would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of the severance benefits had not been so delayed pursuant to this section and (B) commence paying the balance of the severance benefits in accordance with the applicable payment schedules set forth in this Agreement.
None of the severance benefits under this Agreement will commence or otherwise be delivered prior to the effective date of the Release. Except to the minimum extent that payments must be delayed because Executive is a “specified employee” (as described above) or until the effectiveness of the Release, all amounts will be paid as soon as practicable in accordance with the Company’s normal payroll practices and no interest will be due on any amounts so deferred.
12. Better After Tax Provision. If any payment or benefit that Executive will or may receive from the Company or otherwise (a “280G Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then any such 280G Payment will be equal to the Reduced Amount. The “Reduced Amount” will be either (x) the largest portion of the 280G Payment that would result in no portion of the 280G Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the 280G Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the 280G Payment may be subject to the Excise Tax. If a reduction in a 280G Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”).

Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the 280G Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification will preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (B) as a second priority, 280G Payments that are contingent on future events (e.g., being terminated without Cause), will be reduced (or eliminated) before 280G Payments that are not contingent on future events; and (C) as a third priority, 280G Payments that are “deferred compensation” within the meaning of Section 409A of the Code will be reduced (or eliminated) before 280G Payments that are not “deferred compensation” within the meaning of Section 409A of the Code.
If Section 280G of the Code is not applicable by law to Executive, the Company will determine whether any similar law in Executive’s jurisdiction applies and should be taken into account.
The independent professional firm engaged by the Company for general tax audit purposes as of the day prior to the effective date of the Change in Control will make all determinations required to be made under this Section. If the firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized independent professional firm to make the determinations required hereunder. The Company will bear all expenses with respect to the determinations by such firm required to be made hereunder. The Company will use commercially reasonable efforts to cause the firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Company and Executive within thirty (30) calendar days after the date on which Executive’s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive.

Exhibit 10.5
If Executive receives a 280G Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section and the Internal Revenue Service determines thereafter that some portion of the 280G Payment is subject to the Excise Tax, Executive will promptly return to the Company a sufficient amount of the 280G Payment (after reduction pursuant to clause (x) of the first paragraph of this Section) so that no portion of the remaining 280G Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of the first paragraph of this Section, Executive will have no obligation to return any portion of the 280G Payment pursuant to the preceding sentence.
13. Miscellaneous.

a. Taxes. Executive shall be responsible for the payment of any taxes due on any and all compensation, stock option, or benefit provided by the Company pursuant to this Agreement which are not withheld by the Company. Executive agrees to indemnify and hold harmless the Company from any and all claims or penalties asserted against the Company arising from Executive’s failure to pay taxes due on any compensation, stock option, or benefit provided by the Company pursuant to this Agreement. Executive expressly acknowledges that the Company has not made any representation about the tax consequences of any consideration provided by the Company to Executive pursuant to this Agreement.

b. Modification/Waiver. This Agreement may not be amended, modified, superseded, canceled, renewed or expanded, or any terms or covenants hereof waived, except by a writing executed by each of the Parties or, in the case of a waiver, by the Party waiving compliance. Failure of any Party at any time to require performance of any provision hereof shall in no manner affect his, her or its right at a later time to enforce such provision. No waiver by a Party of a breach of this Agreement shall be deemed to be or construed as a waiver of any other breach of any term or condition contained in the Agreement.

c. Successors and Assigns. This Agreement may be assigned by the Company to an affiliated entity or to any successor or assignee of the Company with or without Executive’s consent. This Agreement shall not be assignable by Executive.

d. Notices. All notices to be given hereunder shall be in writing and shall be deemed to have been duly given on: the date personally or hand delivered; one (1) day after being sent by internationally-recognized overnight delivery courier; and three (3) days after being sent by certified mail, return receipt requested. Notices mailed to Executive shall be sent to Executive’s last home address as reflected in the Company’s personnel records. Executive promptly shall notify Company of any change in Executive’s address. Notices to be issued to the Company shall be directed to the CEO and shall be mailed to the Company’s headquarters.


Exhibit 10.5
e. Dispute Resolution. To aid in the rapid and economical resolution of any disputes that may arise in the course of Executive’s employment relationship, the Parties agree that any and all disputes, claims, or demands arising from or relating to the terms of this Agreement (including but not limited to the Proprietary Information Agreement incorporated by reference herein), Executive’s employment relationship with the Company, or the termination of that relationship (including statutory claims), shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration in Dallas, Texas conducted before a single neutral arbitrator by JAMS, Inc. (“JAMS”) or its successor, under the then applicable JAMS Arbitration Rules and Procedures for Employment Disputes (available at http://www.jamsadr.com/rules-employment-arbitration/) and subject to JAMS’ Policy on Employment Arbitration Minimum Standards of Procedural Fairness. The Parties acknowledge that by agreeing to this arbitration procedure, they waive the right to resolve any such dispute, claim or demand through a trial by jury or judge or by administrative proceeding. Executive will have the right to be represented by legal counsel at any arbitration proceeding, at Executive’s expense. The arbitrator shall: (a) have authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based; and (c) have authority to, in the arbitrator’s discretion, award recovery of attorneys’ fees and costs to the prevailing party. The Company shall pay all JAMS’ arbitration fees. Nothing in this Agreement is intended to prevent either Party from obtaining injunctive relief in a court of applicable jurisdiction to prevent irreparable harm pending the conclusion of any arbitration; or from enforcing any arbitration award in a court of applicable jurisdiction.

f. Entire Agreement. This Agreement, together with the Exhibits, sets forth the complete and exclusive agreement and understanding of the Parties with regard to the subject matter hereof, and supersedes any and all prior or contemporaneous agreements, promises, representations, or communications, written or oral, pertaining to the subject matter hereof. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement, and the invalid or unenforceable provision shall be modified to render it valid and enforceable consistent with the intent of the parties insofar as possible under applicable law. For purposes of construing this Agreement, any ambiguities shall not be construed against any party as the drafter. This Agreement may be executed in counterparts, which shall be deemed to be part of one original, and facsimile signatures shall be equivalent to original signatures. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Iowa, without regard to conflict of laws principles.

In Witness Whereof, the Parties have each duly executed this Agreement as of the date written above to indicate their understanding and acceptance of all of the above-stated terms and conditions.
NewLink Genetics Corporation

By: /s/ Charles J. Link, Jr. M.D. 
Its: CEO 


Executive

/s/ Lori Lawley
Lori Lawley



Exhibit 10.5

Exhibit A
EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT
This Employee Proprietary Information, Inventions, Non-competition, and Non-solicitation Agreement (this “Agreement”) is made in consideration for my employment or continued employment by NewLink Genetics Corporation or any of its subsidiaries (the “Company”), and the compensation now and hereafter paid to me. I hereby agree as follows:
1. Nondisclosure.

1.1 Recognition of Company’s Rights; Nondisclosure. At all times during my employment and thereafter, I will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information (defined below), except as such disclosure, use or publication may be required in connection with my work for the Company, or unless an officer of the Company expressly authorizes such in writing. I will obtain Company’s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that relates to my work at Company and/or incorporates any Proprietary Information. I hereby assign to the Company any rights I may have or acquire in such Proprietary Information and recognize that all Proprietary Information shall be the sole property of the Company and its assigns.
1.2 Proprietary Information. The term “Proprietary Information” shall mean any and all confidential and/or proprietary knowledge, data or information of the Company. By way of illustration but not limitation, “Proprietary Information” includes (a) tangible and intangible information relating to antibodies and other biological materials, cell lines, samples of assay components, media and/or cell lines and procedures and formulations for producing any such assay components, media and/or cell lines, formulations, products, processes, know-how, designs, formulas, methods, developmental or experimental work, clinical data, improvements, discoveries, plans for research, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers, and information regarding the skills and compensation of other employees of the Company; (b) trade secrets, inventions, mask works, ideas, processes, formulas, source and object codes, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques (hereinafter collectively referred to as “Inventions”); (c) information regarding plans for research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; and (d) information regarding the skills and compensation of other employees of the Company. Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is generally known in the trade or industry, which is not gained as result of a breach of this Agreement, and my own, skill, knowledge, know-how and experience to whatever extent and in whichever way I wish.
1.3 Third Party Information. I understand, in addition, that the Company has received and in the future will receive from third parties confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for the Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an officer of the Company in writing.
1.4 No Improper Use of Information of Prior Employers and Others. During my employment by the Company I will not improperly use or disclose any confidential information or trade secrets, if any, of any third party, including but not limited to any former employer or any other person or entity to whom I have an obligation of confidentiality, and I will not bring onto the premises of the Company any unpublished documents or any property belonging to any third party, including but not limited to any former employer or any other person or entity to whom I have an obligation of confidentiality unless consented to in writing by that third party. I will use in the

Exhibit 10.5
performance of my duties only information which is generally known and used by persons with training and experience comparable to my own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided, obtained, or developed by or for the Company.
2. Assignment of Inventions.

2.1 Proprietary Rights. The term “Proprietary Rights” shall mean all trade secret, patent, copyright, mask work and other intellectual property rights throughout the world.
2.2 Prior Inventions. Inventions, if any, patented or unpatented, which I made prior to the commencement of my employment with the Company are excluded from the scope of this Agreement. To preclude any possible uncertainty, I have set forth on Exhibit A (Previous Inventions) attached hereto a complete list of all Inventions that I have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of my employment with the Company, that I consider to be my property or the property of third parties and that I wish to have excluded from the scope of this Agreement (collectively referred to as “Prior Inventions”). If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Prior Inventions in Exhibit A but am only to disclose a cursory name for each such invention, a listing of the party (ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason. A space is provided on Exhibit A for such purpose. If no such disclosure is attached, I represent that there are no Prior Inventions. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or machine, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license (with rights to sublicense through multiple tiers of sublicensees) to make, have made, modify, use and sell such Prior Invention. Notwithstanding the foregoing, I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions without the Company’s prior written consent.
2.3 Assignment of Inventions. Subject to Sections 2.4, and 2.6, I hereby assign and agree to assign in the future (when any such Inventions or Proprietary Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to the Company all my right, title and interest in and to any and all Inventions (and all Proprietary Rights with respect thereto) whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or learned by me, either alone or jointly with others, during the period of my employment with the Company. Inventions assigned to the Company, or to a third party as directed by the Company pursuant to this Section 2, are hereinafter referred to as “Company Inventions.”
2.4 Nonassignable Inventions. I recognize that, in the event of a specifically applicable state law, regulation, rule, or public policy (“Specific Inventions Law”), this Agreement will not be deemed to require assignment of any invention which qualifies fully for protection under a Specific Inventions Law by virtue of the fact that any such invention was, for example, developed entirely on my own time without using the Company’s equipment, supplies, facilities, or trade secrets and neither related to the Company’s actual or demonstrably anticipated business, research or development, nor resulted from work performed by me for the Company. In the absence of a Specific Inventions Law, the preceding sentence will not apply.
2.5 Obligation to Keep Company Informed. During the period of my employment with the Company, I will promptly disclose to the Company fully and in writing all Inventions authored, conceived or reduced to practice by me, either alone or jointly with others; and all patent applications filed by me or on my behalf. At the time of each such disclosure, I will advise the Company in writing of any Inventions that I believe fully qualify for protection under the provisions of a Specific Inventions Law; and I will at that time provide to the Company in writing all evidence necessary to substantiate that belief. The Company will keep in confidence and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to the Company pursuant to this Agreement relating to Inventions that qualify fully for protection under a Specific Inventions Law. I will preserve the confidentiality of any Invention that does not fully qualify for protection under a Specific Inventions Law.

Exhibit 10.5
2.6 Government or Third Party. I also agree to assign all my right, title and interest in and to any particular Company Invention to a third party, including without limitation the United States, as directed by the Company.
2.7 Works for Hire. I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment at the Company and which are protectable by copyright are “works made for hire,” pursuant to United States Copyright Act (17 U.S.C., Section 101).
2.8 Enforcement of Proprietary Rights. 
i. Obligation to Assist. I will assist the Company in every proper way to obtain, and from time to time enforce, United States and foreign Proprietary Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Proprietary Rights to the Company or its designee. My obligation to assist the Company with respect to Proprietary Rights relating to such Company Inventions in any and all countries shall continue beyond the termination of my employment, but the Company shall compensate me at a reasonable rate after my termination for time actually spent by me at the Company’s request on such assistance.

ii. Appointment of Attorney in Fact. In the event the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in the preceding paragraph, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Proprietary Rights assigned hereunder to the Company.

3. No Conflicts, Non-Solicitation, and Non-Interference. I acknowledge that during my employment I will have access to and knowledge of Proprietary Information. To protect the Company’s Proprietary Information, I agree that during the period of my employment by the Company I will not, without the Company’s express written consent, engage in any other employment or business activity directly related to the business in which the Company is now involved or becomes involved, nor will I engage in any other activities which conflict with my obligations to the Company or the interests of the Company. For the period of my employment by the Company and continuing until one year after my last day of employment with the Company, I will not: (a) directly or indirectly induce any employee of the Company to terminate or reduce his or her relationship with the Company; (b) solicit the business of any Client or Customer of the Company (other than on behalf of the Company) for any competitive purpose; or (c) induce any supplier, vendor, consultant or independent contractor of the Company to terminate or reduce his, her or its relationship with the Company. I agree that for purposes of this Agreement, a “Client or Customer” is any person or entity with whom or which, at any time during the two year period prior to my last day of employment with the Company, (i) I had direct dealings; (ii) an individual whom I supervised had direct dealings; or (iii) about whom or which I obtained confidential information. If any restriction set forth in this Section is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.

4. Covenant Not to Compete. I acknowledge that during my employment I will have access to and knowledge of Proprietary Information. To protect the Company’s Proprietary Information, I agree that during my employment with the Company, whether full-time or part-time, and for a period of one year after my last day of employment with the Company, I will not directly or indirectly engage in (whether as an employee, consultant, proprietor, partner, director or otherwise), or have any ownership interest in, or participate in the financing, operation, management or control of, any person, entity, corporation or business that engages in a “Restricted Business” in a “Restricted Territory” (as defined below). It is agreed that ownership of (i) no more than one percent

Exhibit 10.5
(1%) of the outstanding voting stock of a publicly traded corporation, or (ii) any stock I presently own shall not constitute a violation of this provision.

4.1 Reasonable. I agree and acknowledge that the time limitation on the restrictions in this paragraph, combined with the geographic scope, is reasonable. I also acknowledge and agree that this paragraph is reasonably necessary for the protection of the Company’s Proprietary Information as defined in paragraph 1.2 herein, that through my employment I shall receive adequate consideration for any loss of opportunity associated with the provisions herein, and that these provisions provide a reasonable way of protecting the Company’s business value, some of which will be imparted to me in the ordinary course of my employment with the Company. If any restriction set forth in this paragraph 4 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.
4.2 As used herein, the terms:
(i) “Restricted Business” shall mean a business that is engaged in or is preparing to engage in any of the areas that the Company is actively pursuing, including but not limited to research, development and/or commercialization of (1) one or more products for the treatment of cancer or infectious disease based upon the Company’s HyperAcute technology platform; (2) one or more products for the treatment of cancer based upon IDO, TDO or PTEN inhibitors; (3) vaccines against the Ebola virus; or (4) any other area of research, development, or commercialization drug or biologic candidate potentially likely which is intended to address the same enzymatic target (such as, for example, IDO) as any drug or biologic candidate that (i) is the subject area of research, development, or commercialization in which the Company or any subsidiary is engaged pursuant to a program which is being materially funded by the Company, a strategic partner of the Company, and/or a grant to the Company and (ii) as to which I participated in or was familiar with the details of such the research, development or commercialization during their time of my employment with Company or regarding which I possess Confidential Information. For purposes of the preceding sentence, the determination of the scope of the Company’s business activities shall be made as of the date of termination of my employment.

(ii) “Restricted Territory” shall mean any state, county, or locality in the United States in which the Company conducts business and any other country, city, state, jurisdiction, or territory in which the Company does business or plans to do business.

5. Records. I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and any other form that may be required by the Company) of all Proprietary Information developed by me and all Company Inventions made by me during the period of my employment at the Company, which records shall be available to and remain the sole property of the Company at all times.

6. No Conflicting Obligation. I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by the Company, nor any other lawful obligation I have to any third party. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict herewith.

7. Return of Company Materials. When I leave the employ of the Company, or earlier if requested by the Company, I will deliver to the Company any and all drawings, notes, memoranda, specifications, devices, formulas, documents, materials, and tangible or intangible property of the Company together with all copies thereof, and any other material containing or embodying any Company Inventions, Third Party Information or Proprietary Information of the Company without retaining any reproductions or embodiments thereof in whole or in part and in any medium. By way of example, such items include but are not limited to: Company files, records, plans, forecasts, reports, studies, analyses, proposals, agreements, financial information, information regarding potential business development partners, research and development information, sales and marketing information, operational

Exhibit 10.5
and personnel information, code, software, databases, computer-recorded information, and tangible property and equipment (including, but not limited to, computers, data storage devices, facsimile machines, mobile telephones, servers, credit cards, entry cards, identification badges and keys). In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed. I further agree that any property situated on the Company’s premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice.

8. Legal and Equitable Remedies. Because my services are personal and unique and because I may have access to and become acquainted with the Proprietary Information of the Company, the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement.

9. Notices. Any notices required or permitted hereunder shall be given to the appropriate party at the address specified below or at such other address as the party shall specify in writing. Such notice shall be deemed given upon personal delivery or express delivery service (e.g., FedEx) to the appropriate address; upon delivery via facsimile; or if sent by certified or registered mail, three days after the date of mailing.

10. Notification of New Employer. In the event that I leave the employ of the Company, I hereby consent to the notification of my new employer of my rights and obligations under this Agreement.

11. General Provisions.

11.1 Governing Law; Consent to Personal Jurisdiction and Exclusive Forum. This Agreement will be governed by and construed according to the laws of the State of Iowa as such laws are applied to agreements entered into and to be performed entirely within Iowa between Iowa residents. I hereby expressly understand and consent that my employment is a transaction of business in the State of Iowa and constitutes the minimum contacts necessary to make me subject to the personal jurisdiction of the federal courts located in the State of Iowa, and the state courts located in the County of Story, Iowa, for any lawsuit filed against me by Company arising from or related to this Agreement. I agree and acknowledge that any controversy arising out of or relating to this Agreement or the breach thereof, or any claim or action to enforce this Agreement or portion thereof, or any controversy or claim requiring interpretation of this Agreement must be brought in a forum located within the State of Iowa. No such action may be brought in any forum outside the State of Iowa. Any action brought in contravention of this paragraph by one party is subject to dismissal at any time and at any stage of the proceedings by the other, and no action taken by the other in defending, counter claiming or appealing shall be construed as a waiver of this right to immediate dismissal. A party bringing an action in contravention of this paragraph shall be liable to the other party for the costs, expenses and attorney’s fees incurred in successfully dismissing the action or successfully transferring the action to the federal courts located in the State of Iowa, or the state courts located in the County of Story, Iowa.
11.2 Severability. In case any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement; this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein; and such provision shall be deemed modified and enforceable, insofar as possible consistent with its original intent. By way of example, if, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.

Exhibit 10.5
11.3 Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives and will be for the benefit of the Company, its successors, and its assigns. My obligations under this Agreement are not assignable to any party.
11.4 Survival. The provisions of this Agreement shall survive the termination of my employment and the assignment of this Agreement by the Company to any successor in interest or other assignee.
11.5 Employment. I agree and understand that my employment is at-will which means I or the Company each have the right to terminate my employment, with or without advanced notice and with or without cause. I further agree and understand that nothing in this Agreement shall confer any right with respect to continuation of employment by the Company, nor shall it interfere in any way with my right or the Company’s right to terminate my employment at any time, with or without cause.
11.6 Waiver. To be valid, any waiver by me or the Company of any breach of this Agreement or right hereunder shall be specifically stated in writing, and shall not be a waiver of any preceding or succeeding breach unless so specifically stated. No waiver of any right under this Agreement and applicable law shall be construed as a waiver of any other right. Neither party shall be required to give notice to enforce strict adherence to all terms of this Agreement.
11.7 Entire Agreement. The obligations pursuant to this Agreement shall apply to any time during which I was previously, or am in the future, employed or engaged as a consultant by the Company, if no other agreement governs the subject matter thereof. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior communications and representations with respect to such subject matter. No modification of or amendment to this Agreement will be effective unless in writing and signed by the party to be charged. Any subsequent changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.


Exhibit 10.5
EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT
ACKNOWLEDGEMENT FORM

I acknowledge that I have been given a copy of the Employee Proprietary Information and Inventions Agreement, that I have read it, and that I understand its terms and procedures. Furthermore, I agree to abide by it and understand that if NewLink determines my conduct warrants it, I may be subject to discipline for breaches hereof, up to and including the immediate termination of my employment.



Lori Lawley      
Employee’s Name (Please Print)



/s/ Lori Lawley      
Employee’s Signature



July 26, 2018      
Date




Exhibit 10.5

Exhibit B
RELEASE
[To be signed on or within twenty-one (21) days after the Separation Date]
My employment with NewLink Genetics Corporation (the “Company”) ended in all capacities on ___________ (the “Separation Date”). I hereby confirm that I have been paid all compensation owed to me by the Company for all hours worked; I have received all the leave and leave benefits and protections for which I was eligible, pursuant to the Company’s policies, applicable law, or otherwise; and I have not suffered any on-the-job injury or illness for which I have not already filed a workers’ compensation claim.

If I choose to enter into this Release and allow it to become effective by its terms, the Company will provide me with certain severance benefits pursuant to the terms of the Employment Agreement between me and the Company dated _______, 2015 (the “Agreement”). I understand that I am not entitled to such severance benefits unless I return this fully-executed Release to the Company within twenty-one (21) days after the Separation Date, and allow this Release to become fully effective and non-revocable by its terms. (Capitalized terms used but not defined in this Release shall have the meaning ascribed to them in the Agreement.)

In exchange for the severance benefits to which I would not otherwise be entitled, I hereby generally and completely release the Company and its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the “Released Parties”) from any and all claims, liabilities and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring prior to or at the time that I sign this Release, including but not limited to claims arising from or in any way related to my employment with the Company or the termination of that employment (collectively, the “Released Claims”). By way of example, the Released claims include, but are not limited to: (1) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (2) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (3) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (4) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), and Iowa and Texas state laws.
Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”): (a) any claims for breach of the Agreement arising after the date on which I sign this Release; (2) claims for reimbursement of properly incurred business expenses prior to and through the Separation Date which are submitted to the Company for reimbursement within thirty (30) days after the Separation Date; (3) all rights I have in respect of the Equity Awards; (4) all claims for or rights to indemnification pursuant to the articles of incorporation and bylaws of the Company, any indemnification agreement to which I am a party, or under applicable law; and (5) all claims which cannot be waived as a matter of law. I understand that nothing in this Release prevents me from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or any other government agency, except that I acknowledge and agree that I am hereby waiving my right to any monetary benefits in connection with any such claim, charge or proceeding. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims that I have or might have against any of the parties released above that are not included in the Released Claims.


Exhibit 10.5
[IF EXECUTIVE IS 40 YEARS OF AGE OR OLDER] I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA, and that the consideration given for this Release is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised, as required by the ADEA, that: (a) my waiver and release does not apply to any rights or claims that may arise after the date I sign this Release; (b) I have been advised that I have the right to consult with an attorney prior to executing this Release (although I may choose voluntarily not to do so); (c) I have been given twenty-one (21) days to consider this Release (although I may choose voluntarily to sign it earlier); (d) I have seven (7) days following my execution of this Release to revoke my acceptance of it (with such revocation to be delivered in writing to the Company within the 7-day revocation period); and (e) this Release will not be effective until the date upon which the revocation period has expired, which will be the eighth day after I sign it, provided I do not earlier revoke it (“Effective Date”).
I further agree: (a) not to disparage the Company or any of the other Released Parties, in any manner likely to be harmful to its or their business, business reputation or personal reputation (although I may respond accurately and fully to any question, inquiry or request for information as required by legal process); (b) not to voluntarily (except in response to legal compulsion) assist any third party in bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceedings against the Company, its affiliates, officers, directors, employees or agents; and (c) to reasonably cooperate with the Company by voluntarily (without legal compulsion) providing accurate and complete information, in connection with the Company’s actual or contemplated defense, prosecution or investigation of any claims or demands by or against third parties, or other matters, arising from events, acts, or omissions that occurred during my employment with the Company. I hereby certify that I have returned, without retaining any reproductions (in whole or in part), all information, materials and other property of the Company, including but not limited to any such information, materials or property contained on any personally-owned electronic or other storage device (such as computer, cellular phone, PDA, tablet or the like).
This Release, together with the Agreement (including all Exhibits and documents incorporated therein by reference), constitutes the complete, final and exclusive embodiment of the entire agreement between me and the Company with regard to this subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained in the Release or the Agreement, and it entirely supersedes any other such promises, warranties or representations, whether oral or written.

Reviewed, Understood and Agreed:

By:       Date:


 EX-31.1 7 nlnk-2018930x10qxex311.htm CEO CERTIFICATION Document

EXHIBIT 31.1

CERTIFICATION

I, Charles J. Link, Jr., certify that:

1. I have reviewed this quarterly report on Form 10-Q of NewLink Genetics Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles
c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
1. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 2, 2018

By:
/s/ Charles J. Link, Jr.
Charles J. Link, Jr.
Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 8 nlnk-2018930x10qxex312.htm CFO CERTIFICATION Document

EXHIBIT 31.2

CERTIFICATION

I, Carl W. Langren, certify that:

1. I have reviewed this quarterly report on Form 10-Q of NewLink Genetics Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
1. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 2, 2018
By:
/s/ Carl W. Langren 
Carl W. Langren 
Chief Financial Officer and Secretary
(Principal Financial Officer)


 EX-32.1 9 nlnk-2018930x10qxex321.htm SECTION 1350 CERTIFICATION Document

EXHIBIT 32.1

CERTIFICATION

Pursuant to the requirements set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Charles J. Link, Jr., Chief Executive Officer of NewLink Genetics Corporation (the “Company”), and Carl W. Langren, Chief Financial Officer and Secretary of the Company, each hereby certifies that, to the best of his knowledge:

1. The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2018, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 2, 2018

By:
/s/ Charles J. Link, Jr.
Charles J. Link, Jr.
Chief Executive Officer
(Principal Executive Officer)

By:
/s/ Carl W. Langren 
Carl W. Langren 
Chief Financial Officer and Secretary
(Principal Financial Officer)


A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its Staff upon request. This certification “accompanies” the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

 EX-101.SCH 10 nlnk-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statement of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2104103 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2205201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2107104 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Revenues (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Revenues (Effects of New Accounting Pronouncements) (Details) link:presentationLink link:calculationLink link:definitionLink 2111105 - Disclosure - License and Research Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - License and Research Collaboration Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2113106 - Disclosure - Common Stock Equity Incentive Plan link:presentationLink link:calculationLink link:definitionLink 2314302 - Disclosure - Common Stock Equity Incentive Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Common Stock Equity Incentive Plan (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - Common Stock Equity Incentive Plan (Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2120107 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2122108 - Disclosure - Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 2323303 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2424412 - Disclosure - Net Loss per Common Share (Net Loss Per Share Computation) (Details) link:presentationLink link:calculationLink link:definitionLink 2425413 - Disclosure - Net Loss per Common Share (Antidilutive Securities) (Details) link:presentationLink link:calculationLink link:definitionLink 2126109 - Disclosure - Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 2327304 - Disclosure - Restructuring Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2428414 - Disclosure - Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2129110 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 nlnk-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 nlnk-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 nlnk-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Common Stock Common Stock [Member] Range [Domain] Range Range [Domain] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Balance at beginning of period Balance at end of period Restructuring Reserve Options exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Significant Accounting Policies Significant Accounting Policies [Text Block] Accounts payable Accounts Payable, Current Income Statement Location [Domain] Income Statement Location [Domain] Antidilutive Securities Antidilutive Securities [Axis] Accounting Policies [Abstract] Payments under capital lease obligations and principal payments on notes payable Repayments of Debt and Capital Lease Obligations Cash Flows From Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Performance Stock Performance Shares [Member] Fair Value Disclosure of notes payable and capital lease obligations Long-term Debt and Capital Lease Obligations, Including Current Maturities Treasury stock, shares Treasury Stock, Shares Restructuring Type Restructuring Type [Axis] Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Restricted Stock Restricted Stock [Member] Computer Equipment Computer Equipment [Member] Equity Award Equity Award [Domain] Purchase of equipment Payments to Acquire Property, Plant, and Equipment Operating expenses: Operating Expenses [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Weighted average grant-date fair value per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value FInancing proceeds Sale of Stock, Consideration Received on Transaction Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Additional Paid-in Capital Additional Paid-in Capital [Member] Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Income tax receivable Income Taxes Receivable, Current Common stock, outstanding shares Balance at beginning of period (shares) Balance at end of period (shares) Common Stock, Shares, Outstanding Common Stock Equity Incentive Plan Disclosure of Compensation Related Costs, Share-based Payments [Text Block] General and Administrative Expense General and Administrative Expense [Member] Repurchase of common stock Payments for Repurchase of Common Stock Weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Upfront cash payments Revenue Recognition, Milestone Method, Revenue Recognized Income Statement Location [Axis] Income Statement Location [Axis] Risk free interest rate, maximum (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Forfeited / cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Property and equipment, net Property, Plant and Equipment, Net Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Blank check preferred stock, outstanding shares Preferred Stock, Shares Outstanding Vested, weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value License and Collaborative Arrangement Collaborative Arrangement [Member] Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Restructuring Charges Restructuring and Related Activities Disclosure [Text Block] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Evergreen increase (percent) SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum Stock Option Employee Stock Option [Member] Restructuring and Related Activities [Abstract] Schedule of New Accounting Pronouncements Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Restructuring and Related Costs Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Expected Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Alliance manager LicenseRevenueManagerLabor Loss from operations Operating Income (Loss) Options forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Statement [Table] Statement [Table] Schedule of Financing Rounds Financings [Table] Financings [Table] Commitments and Contingencies Disclosure [Abstract] Weighted average vesting period for non-vested option awards, in years Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Basic and diluted loss per share (in dollars per share) Earnings Per Share, Basic and Diluted Current portion of notes payable and obligations under capital leases Long-term Debt and Capital Lease Obligations, Current Number of shares remained available for issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Follow-on Offering FollowOnOfferingMember Type of Restructuring Type of Restructuring [Domain] Unvested at beginning of period (in shares) Unvested at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Accumulated deficit Retained Earnings (Accumulated Deficit) Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Revenues Grant revenue Revenue from Contract with Customer, Including Assessed Tax Volatility rate, maximum (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Income taxes receivable Increase (Decrease) in Income Taxes Payable Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Cash Flows From Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement of Stockholders' Equity [Abstract] Research and development Research and Development Expense Miscellaneous (expense) income Other Nonoperating Income (Expense) Total liabilities Liabilities Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Supplemental disclosure of cash flows information: Supplemental Cash Flow Information [Abstract] Sales of shares under stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Document Period End Date Document Period End Date Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current Assets [Member] Maximum available under ATM offering MaximumAvailableUnderATMOffering 2010 Non-Employee Directors' Stock Option Plan A2010NonEmployeeDirectorsStockOptionPlanMember Cash Flows From Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Interest income Investment Income, Interest ATM Offering ATMOfferingMember Current portion of deferred rent Deferred Rent Credit, Current Long-term liabilities: Liabilities, Noncurrent [Abstract] Share-based compensation expense Allocated Share-based Compensation Expense Public Offering PublicOfferingMember Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Common stock, $0.01 par value: Authorized shares — 75,000,000 at September 30, 2018 and December 31, 2017; issued 37,305,626 and 37,168,122 at September 30, 2018 and December 31, 2017, respectively, and outstanding 37,216,892 and 37,109,556 at September 30, 2018 and December 31, 2017, respectively Common Stock, Value, Outstanding Assets Assets: Assets [Abstract] Research and Development Expense Research and Development Expense [Member] Expected dividend rate (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Organization, Consolidation and Presentation of Financial Statements [Abstract] Range [Axis] Range Range [Axis] Blank check preferred stock, authorized shares Preferred Stock, Shares Authorized Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and Cash Equivalents, at Carrying Value Employee Severance Cost Employee Severance [Member] Current portion of unearned revenue Deferred Revenue, Current Percentage reduction in force Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Financings Financings [Line Items] [Line Items] for Financings [Table] Document Fiscal Year Focus Document Fiscal Year Focus Revenue from Contract with Customer [Abstract] Share-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Treasury stock, at cost: 88,734 and 58,566 shares at September 30, 2018 and December 31, 2017, respectively Treasury Stock, Value Total assets Total assets Assets IPO IPO [Member] Total long-term liabilities Liabilities, Noncurrent Exercisable, weighted average remaining contractual term, in years Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Fair value of awards vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Plan Name Plan Name [Domain] 2009 Equity Incentive Plan A2009EquityIncentivePlanMember Government contract receivable Government Contract Receivable Document Fiscal Period Focus Document Fiscal Period Focus Expired, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price License and collaboration revenue License and Service [Member] Document Type Document Type Income tax receivable Income Taxes Receivable, Noncurrent Blank check preferred stock, issued shares Preferred Stock, Shares Issued Deferred rent Deferred Rent Credit, Noncurrent Entity Emerging Growth Company Entity Emerging Growth Company Accumulated Deficit Retained Earnings [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Income Statement [Abstract] Number of shares of common stock sold Stock Issued During Period, Shares, New Issues Cash refunds received for taxes, net Income Taxes Paid, Net Other income and expense: Nonoperating Income (Expense) [Abstract] Grant revenue Grant [Member] Schedule of Restructuring Charges Schedule of Restructuring and Related Costs [Table] Stock Option Activity Schedule of Stock Options Roll Forward [Table Text Block] Lab Equipment Equipment [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Income tax benefit Income Tax Expense (Benefit) Total current assets Assets, Current Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Balance Sheet Location [Axis] Balance Sheet Location [Axis] Statement of Financial Position [Abstract] Total compensation cost related to non-vested option awards Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Total current liabilities Liabilities, Current Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Other receivables Increase (Decrease) in Other Receivables Income tax benefit from Tax Act TaxCutsandJobsActof2017IncomeTaxExpenseBenefit General and administrative General and Administrative Expense Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Basic and Diluted Net Loss per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Number of shares issued Sale of Stock, Number of Shares Issued in Transaction Risk-free interest rate, minimum (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Authorized Increases of Common Stock under the 2009 Plan Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Total liabilities and stockholders' equity Total liabilities and stockholders' equity Liabilities and Equity Expensed Restructuring Charges Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Merck MerckSharpeandDohmeCorpMember Property and equipment Property, Plant and Equipment, Policy [Policy Text Block] Additional paid-in capital Additional Paid in Capital Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Description of Business Nature of Operations [Text Block] Cash paid for interest Interest Paid, Including Capitalized Interest, Operating and Investing Activities Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Statement, Equity Components Equity Components [Axis] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Forfeited/cancelled, weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Assumptions Used in Black-Scholes Pricing Model for New Grants Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Award Type Award Type [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Issuance of common stock, net of offering costs Proceeds from Issuance of Common Stock Total non-current assets Assets, Noncurrent Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Options exercisable at end of period (in shares) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Common stock, issued shares Common Stock, Shares, Issued Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Total operating expenses Operating Expenses Blank check preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Granted, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average grant-date fair value per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Outstanding, weighted average exercise price at beginning of period (in dollars per share) Outstanding, weighted average exercise price at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Net loss before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Outstanding, weighted average remaining contractual term, in years Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based compensation Share-based Compensation Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Accrued expenses for subcontractor fees GovernmentContractAccruedSubcontractorFees Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Adjustments Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Basis of Presentation Basis of Accounting [Text Block] Net loss Net loss Loss attributable to common stockholders Net Income (Loss) Attributable to Parent Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Unearned revenue Increase (Decrease) in Deferred Revenue Entity Small Business Entity Small Business Increase in number of shares authorized Authorized Shares Added Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Commitments and Contingencies Disclosure Commitments and Contingencies Disclosure [Text Block] Cash Payments Payments for Restructuring Useful life Property, Plant and Equipment, Useful Life Entity Filer Category Entity Filer Category Stockholders' equity: Equity [Abstract] Genentech GenentechInc.Member Principles of Consolidation Consolidation, Policy [Policy Text Block] Commissions paid Payments for Commissions Cumulative effect of accounting change Cumulative Effect on Retained Earnings, Net of Tax Repurchase of common stock (shares) Shares Paid for Tax Withholding for Share Based Compensation Proceeds on sale of equipment Proceeds from Sale of Property, Plant, and Equipment Forfeitured, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Accrued expenses Accrued Liabilities, Current Contract Manufacturing Organization Equipment ContractManufacturingOrganizationEquipmentMember Income Tax Disclosure [Abstract] Counterparty Name [Axis] Counterparty Name [Axis] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Product and Service [Axis] Product and Service [Axis] Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Statement [Line Items] Statement [Line Items] Balance without Adoption of Topic 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Entity Registrant Name Entity Registrant Name Other receivables Other Receivables, Net, Current Other income, net Nonoperating Income (Expense) Liabilities and Stockholders' Equity Liabilities [Abstract] Treasury Stock Treasury Stock [Member] Current liabilities: Liabilities, Current [Abstract] Sales of shares under stock purchase plan (shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Amendment Flag Amendment Flag Exercise of stock options and restricted stock vested (shares) Options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Weighted average grant date fair value at beginning of period (in dollars per share) Weighted average grant date fair value at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Sale of Stock [Axis] Sale of Stock [Axis] Income Taxes Income Tax Disclosure [Text Block] Entity Central Index Key Entity Central Index Key Other costs Payments of Stock Issuance Costs Statement of Cash Flows [Abstract] Interest expense Interest Expense Balance Sheet Location [Domain] Balance Sheet Location [Domain] Basic and diluted average shares outstanding (in shares) Basic and diluted weighted-average shares (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Unbilled contracts receivable Government Contract Receivable, Unbilled Amounts (Gain) Loss on sale of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Number of options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Common stock, authorized shares Common Stock, Shares Authorized Earnings Per Share [Abstract] Deferred rent Increase (Decrease) in Deferred Charges Number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Exercised, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Product and Service [Domain] Product and Service [Domain] Minimum Minimum [Member] Type of Adoption [Domain] Type of Adoption [Domain] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Current assets: Assets, Current [Abstract] Uncertain tax positions Liability for Uncertainty in Income Taxes, Current Restructuring Charges Restructuring Cost and Reserve [Line Items] Repurchase of common stock Adjustments Related to Tax Withholding for Share-based Compensation Stockholders' Equity: Stockholders' Equity, Number of Shares, Par Value and Other Disclosures [Abstract] Royalty obligation payable to Iowa Economic Development Authority DeferredGovernmentGrantsObligationsNoncurrent Volatility rate, minimum (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 2010 Employee Stock Purchase Plan A2010EmployeeStockPurchasePlanMember Exercise of stock options and restricted stock vested Stock Issued During Period, Value, Stock Options Exercised Fees and commissions Payments for Brokerage Fees Total operating revenues Revenues Total stockholders' equity Balance at beginning of period Balance at end of period Stockholders' Equity Attributable to Parent Net Loss per Common Share Earnings Per Share [Text Block] Blank check preferred stock, $0.01 par value: Authorized shares — 5,000,000 at September 30, 2018 and December 31, 2017; issued and outstanding shares — 0 at September 30, 2018 and December 31, 2017 Preferred Stock, Value, Outstanding Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities License and Research Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Notes payable and obligations under capital leases Long-term Debt and Capital Lease Obligations Plan Name Plan Name [Axis] Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Revenues Revenue from Contract with Customer [Text Block] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Equity Component Equity Component [Domain] Maximum Maximum [Member] Exercisable, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price EX-101.PRE 14 nlnk-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 image1.jpg begin 644 image1.jpg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nlnk-20180930_g1.jpg begin 644 nlnk-20180930_g1.jpg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end XML 17 nlnk-20180930_htm.xml IDEA: XBRL DOCUMENT 0001126234 2018-01-01 2018-09-30 0001126234 us-gaap:GrantMember 2018-01-01 2018-09-30 0001126234 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001126234 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001126234 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001126234 2018-07-01 2018-07-31 0001126234 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001126234 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001126234 2017-07-01 2017-07-31 0001126234 2017-01-01 2017-12-31 0001126234 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-09-30 0001126234 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001126234 us-gaap:GrantMember 2017-01-01 2017-09-30 0001126234 us-gaap:EmployeeSeveranceMember 2017-12-31 0001126234 us-gaap:EmployeeSeveranceMember 2018-01-01 2018-09-30 0001126234 us-gaap:EmployeeSeveranceMember 2018-09-30 0001126234 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001126234 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001126234 us-gaap:LicenseAndServiceMember 2018-07-01 2018-09-30 0001126234 us-gaap:LicenseAndServiceMember 2017-07-01 2017-09-30 0001126234 us-gaap:LicenseAndServiceMember 2018-01-01 2018-09-30 0001126234 us-gaap:LicenseAndServiceMember 2017-01-01 2017-09-30 0001126234 2018-07-01 2018-09-30 0001126234 2017-07-01 2017-09-30 0001126234 2017-01-01 2017-09-30 0001126234 us-gaap:CommonStockMember 2017-12-31 0001126234 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001126234 us-gaap:TreasuryStockMember 2017-12-31 0001126234 us-gaap:RetainedEarningsMember 2017-12-31 0001126234 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001126234 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001126234 us-gaap:TreasuryStockMember 2018-01-01 2018-09-30 0001126234 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001126234 us-gaap:CommonStockMember 2018-09-30 0001126234 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001126234 us-gaap:TreasuryStockMember 2018-09-30 0001126234 2018-10-30 0001126234 us-gaap:RetainedEarningsMember 2018-09-30 0001126234 2016-12-31 0001126234 2017-09-30 0001126234 us-gaap:IPOMember 2011-01-01 2011-12-31 0001126234 nlnk:FollowOnOfferingMember 2013-01-01 2013-12-31 0001126234 nlnk:ATMOfferingMember 2015-01-01 2015-12-31 0001126234 nlnk:ATMOfferingMember 2017-01-01 2017-12-31 0001126234 nlnk:PublicOfferingMember 2017-10-01 2017-10-31 0001126234 2018-03-12 2018-03-12 0001126234 nlnk:ATMOfferingMember 2018-09-30 2018-09-30 0001126234 srt:MinimumMember us-gaap:ComputerEquipmentMember 2018-01-01 2018-09-30 0001126234 srt:MaximumMember us-gaap:ComputerEquipmentMember 2018-01-01 2018-09-30 0001126234 us-gaap:EquipmentMember 2018-01-01 2018-09-30 0001126234 nlnk:ContractManufacturingOrganizationEquipmentMember 2018-01-01 2018-09-30 0001126234 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 0001126234 2018-01-01 0001126234 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2017-12-31 0001126234 us-gaap:GrantMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-07-01 2018-09-30 0001126234 us-gaap:GrantMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-07-01 2018-09-30 0001126234 us-gaap:GrantMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-09-30 0001126234 2018-09-30 0001126234 us-gaap:GrantMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0001126234 us-gaap:LicenseAndServiceMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-07-01 2018-09-30 0001126234 us-gaap:LicenseAndServiceMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-07-01 2018-09-30 0001126234 us-gaap:LicenseAndServiceMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2017-01-01 2017-09-30 0001126234 us-gaap:LicenseAndServiceMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0001126234 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-07-01 2018-09-30 0001126234 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-07-01 2018-09-30 0001126234 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-09-30 0001126234 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0001126234 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2018-09-30 0001126234 2017-12-31 0001126234 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2017-12-31 0001126234 nlnk:GenentechInc.Member us-gaap:CollaborativeArrangementMember 2014-01-01 2014-12-31 0001126234 nlnk:GenentechInc.Member us-gaap:CollaborativeArrangementMember 2018-07-01 2018-09-30 0001126234 nlnk:GenentechInc.Member us-gaap:CollaborativeArrangementMember 2018-01-01 2018-09-30 0001126234 nlnk:GenentechInc.Member us-gaap:CollaborativeArrangementMember 2017-07-01 2017-09-30 0001126234 nlnk:GenentechInc.Member us-gaap:CollaborativeArrangementMember 2017-01-01 2017-09-30 0001126234 nlnk:MerckSharpeandDohmeCorpMember us-gaap:CollaborativeArrangementMember 2014-12-01 2014-12-31 0001126234 nlnk:MerckSharpeandDohmeCorpMember us-gaap:CollaborativeArrangementMember 2015-02-01 2015-02-28 0001126234 nlnk:MerckSharpeandDohmeCorpMember us-gaap:LicenseAndServiceMember us-gaap:CollaborativeArrangementMember 2018-07-01 2018-09-30 0001126234 nlnk:MerckSharpeandDohmeCorpMember us-gaap:LicenseAndServiceMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-09-30 0001126234 nlnk:MerckSharpeandDohmeCorpMember us-gaap:LicenseAndServiceMember us-gaap:CollaborativeArrangementMember 2017-07-01 2017-09-30 0001126234 nlnk:MerckSharpeandDohmeCorpMember us-gaap:LicenseAndServiceMember us-gaap:CollaborativeArrangementMember 2017-01-01 2017-09-30 0001126234 nlnk:A2009EquityIncentivePlanMember 2018-09-30 0001126234 nlnk:A2009EquityIncentivePlanMember 2010-05-15 2010-05-15 0001126234 nlnk:A2009EquityIncentivePlanMember 2011-01-07 2011-01-07 0001126234 nlnk:A2009EquityIncentivePlanMember 2013-01-01 2013-01-01 0001126234 nlnk:A2009EquityIncentivePlanMember 2014-01-01 2014-01-01 0001126234 nlnk:A2009EquityIncentivePlanMember 2015-01-01 2015-01-01 0001126234 nlnk:A2009EquityIncentivePlanMember 2016-01-01 2016-01-01 0001126234 nlnk:A2009EquityIncentivePlanMember 2017-01-01 2017-01-01 0001126234 us-gaap:GrantMember 2018-07-01 2018-09-30 0001126234 nlnk:A2009EquityIncentivePlanMember 2018-01-01 2018-01-01 0001126234 nlnk:A2009EquityIncentivePlanMember 2018-01-01 2018-09-30 0001126234 nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember 2011-11-10 0001126234 nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember 2013-05-09 2013-05-09 0001126234 nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember 2018-09-30 0001126234 nlnk:A2010EmployeeStockPurchasePlanMember 2011-11-10 0001126234 nlnk:A2010EmployeeStockPurchasePlanMember 2013-05-09 2013-05-09 0001126234 nlnk:A2010EmployeeStockPurchasePlanMember 2018-09-30 0001126234 us-gaap:EmployeeStockOptionMember 2018-09-30 0001126234 us-gaap:GrantMember 2017-07-01 2017-09-30 0001126234 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001126234 us-gaap:EmployeeStockOptionMember 2017-12-31 0001126234 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001126234 us-gaap:PerformanceSharesMember 2018-01-01 2018-09-30 0001126234 us-gaap:RestrictedStockMember 2017-12-31 0001126234 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001126234 us-gaap:RestrictedStockMember 2018-09-30 0001126234 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001126234 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001126234 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 shares iso4217:USD iso4217:USD shares pure NEWLINK GENETICS CORP 0001126234 Accelerated Filer 10-Q 2018-09-30 2018 Q3 false true false 37224606 --12-31 0.01 0.01 5000000 5000000 0 0 0 0 0.01 0.01 75000000 75000000 37305626 37168122 37216892 37109556 88734 58566 P3Y P3Y P5Y P5Y P5Y 0.026 0.029 0 0.762 0.792 P4Y P7Y10M24D 4.90 8371005 7314006 89053 181336 1300000 800000 500000 122061000 158708000 4920000 6226000 7398000 356000 700000 10176000 135079000 175466000 4096000 5091000 140000 140000 4236000 5231000 139315000 180697000 1238000 9256000 8736000 12467000 0 56000 84000 92000 74000 160000 10132000 22031000 6000000 6000000 59000 111000 929000 998000 6988000 7109000 17120000 29140000 0 0 373000 372000 403674000 389786000 1409000 1142000 -280443000 -237459000 122195000 151557000 139315000 180697000 0 5379000 11268000 18279000 120000 103000 1004000 334000 120000 5482000 12272000 18613000 7570000 18480000 39972000 52405000 7588000 7907000 23792000 25038000 15158000 26387000 63764000 77443000 -15038000 -20905000 -51492000 -58830000 -18000 12000 16000 -101000 664000 151000 1510000 353000 2000 3000 51000 116000 644000 160000 1475000 136000 -14394000 -20745000 -50017000 -58694000 -6991000 -119000 -6991000 -429000 -7403000 -20626000 -43026000 -58265000 -0.20 -0.69 -1.16 -1.98 37214363 29939823 37178542 29462226 37109556 372000 389786000 -1142000 -237459000 151557000 13620000 13620000 105393 1000 138000 139000 32111 130000 130000 30168 267000 267000 42000000 42000000 -43026000 -43026000 37216892 373000 403674000 -1409000 -280443000 122195000 -43026000 -58265000 13620000 14938000 901000 1064000 16000 -102000 -842000 -3220000 -9982000 -13856000 -11749000 -11500000 -7042000 5861000 -56000 -279000 78000 67000 -36622000 -31070000 7000 43000 118000 185000 111000 142000 269000 20585000 267000 260000 138000 185000 -136000 20140000 -36647000 -10788000 158708000 131490000 122061000 120702000 6000 11000 4000 -6261000 Description of Business<div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The accompanying condensed consolidated financial statements as of September 30, 2018 and for the three and nine months ended have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of $37.6 million from its initial public offering in 2011, completed a follow-on offering of its common stock raising net proceeds of $49.0 million in 2013, and raised an additional $58.7 million in net proceeds from an at the market (ATM) offering completed in 2015.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During 2017, the Company sold 1,940,656 shares of its common stock under an ATM offering, with aggregate net proceeds of $19.3 million after commissions of $398,000 paid to Cantor Fitzgerald &amp; Co. (Cantor) as the placement agent, and other costs of $163,000. In October 2017, the Company sold 5,750,000 of its shares of common stock in a public offering for aggregate net proceeds of $55.2 million after underwriters' discounts, commissions and other expenses of $3.7 million. On March 12, 2018, the Company entered into a new Sales Agreement with Cantor under which the Company may sell up to $60.0 million of its common stock in one or more placements at prevailing market prices in an ATM offering (the 2018 ATM Offering). As of September 30, 2018, no shares have been sold under the 2018 ATM Offering. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's cash and cash equivalents as of September 30, 2018 are expected to be adequate to satisfy the Company's liquidity requirements into the second half of 2021. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include selling additional shares of common stock, alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.</span></div> 37600000 49000000.0 58700000 1940656 19300000 398000 163000 5750000 55200000 3700000 60000000.0 0 Basis of Presentation<div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management’s opinion, reflect all adjustments necessary to present fairly the Company’s interim condensed financial information.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K. The financial results for any interim period are not necessarily indicative of financial results for the full year.</span></div> Significant Accounting Policies<div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The condensed consolidated financial statements include the financial statements of NewLink and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financial Instruments and Concentrations of Credit Risk</span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable and capital lease obligations was $133,000 and $271,000 as of September 30, 2018 and December 31, 2017, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain. </span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and equipment</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Property and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of $7.1 million and $6.6 million as of September 30, 2018 and December 31, 2017, respectively. Equipment under capital leases is stated at the present value of minimum lease payments. Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTU3Y2FiZTgzODRiYzU5Mzg3NTgwYzNlMDkxZWExL3NlYzo1MWE1N2NhYmU4Mzg0YmM1OTM4NzU4MGMzZTA5MWVhMV8xNjUvZnJhZzoxOWE5ZDdmNmI3NTY0ZTc1YTJjZGY3YTBhZWE5YTI4OC90ZXh0cmVnaW9uOjE5YTlkN2Y2Yjc1NjRlNzVhMmNkZjdhMGFlYTlhMjg4XzIzNjY_ef003c83-8235-4430-a2fb-e0feda765dd6">three</span> to five years, lab equipment has a useful life of five years and contract manufacturing organization equipment has a useful life of five years. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Issued Accounting Pronouncements not yet adopted</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In February 2016, the Financial Accounting Standards Board, or the FASB, issued ASU No. 2016-02, Leases, to improve financial reporting for leasing transactions. The new standard requires lessees to recognize on the balance sheet a right of use asset and related lease liability for all leases with terms greater than twelve months. The ASU also requires disclosures about the amount, timing, and uncertainty of cash flows arising from leases. The effective date for public entities is fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company does not currently have any material leases and therefore does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:22pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On May 28, 2014, the FASB issued ASU No. 2014-09 (Topic 606), Revenue from Contracts with Customers. Topic 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (Topic 605), and requires entities to recognize revenue when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted Topic 606 as of January 1, 2018 and as a result changed its accounting policy for revenue recognition, as discussed in Note 4.</span></div> <div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div> <div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The condensed consolidated financial statements include the financial statements of NewLink and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div> Financial Instruments and Concentrations of Credit RiskCash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable and capital lease obligations was $133,000 and $271,000 as of September 30, 2018 and December 31, 2017, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain. 133000 271000 Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds. Property and equipmentProperty and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of $7.1 million and $6.6 million as of September 30, 2018 and December 31, 2017, respectively. Equipment under capital leases is stated at the present value of minimum lease payments. Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTU3Y2FiZTgzODRiYzU5Mzg3NTgwYzNlMDkxZWExL3NlYzo1MWE1N2NhYmU4Mzg0YmM1OTM4NzU4MGMzZTA5MWVhMV8xNjUvZnJhZzoxOWE5ZDdmNmI3NTY0ZTc1YTJjZGY3YTBhZWE5YTI4OC90ZXh0cmVnaW9uOjE5YTlkN2Y2Yjc1NjRlNzVhMmNkZjdhMGFlYTlhMjg4XzIzNjY_ef003c83-8235-4430-a2fb-e0feda765dd6">three</span> to five years, lab equipment has a useful life of five years and contract manufacturing organization equipment has a useful life of five years. 7100000 6600000 P5Y P5Y P5Y <div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Issued Accounting Pronouncements not yet adopted</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In February 2016, the Financial Accounting Standards Board, or the FASB, issued ASU No. 2016-02, Leases, to improve financial reporting for leasing transactions. The new standard requires lessees to recognize on the balance sheet a right of use asset and related lease liability for all leases with terms greater than twelve months. The ASU also requires disclosures about the amount, timing, and uncertainty of cash flows arising from leases. The effective date for public entities is fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company does not currently have any material leases and therefore does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:22pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On May 28, 2014, the FASB issued ASU No. 2014-09 (Topic 606), Revenue from Contracts with Customers. Topic 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (Topic 605), and requires entities to recognize revenue when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted Topic 606 as of January 1, 2018 and as a result changed its accounting policy for revenue recognition, as discussed in Note 4.</span></div> Revenues <div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Adoption of ASC Topic 606, "Revenue from Contracts with Customers"</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On January 1, 2018, we adopted Topic 606 using the modified retrospective method by recognizing the cumulative effect of initially applying Topic 606 as an adjustment to the opening balance of equity as of January 1, 2018. Therefore results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting policy under Topic 605. The change in accounting policy from Topic 605 to Topic 606 impacted how the Company recognizes revenue from government grants, and did not impact license and collaboration revenues due to the nature of those services in the period leading up to and after the adoption of Topic 606. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company recorded an immaterial net reduction to the opening accumulated deficit within equity as of January 1, 2018 due to the cumulative impact of adopting Topic 606 with respect to grants from government entities which were not completed as of the date of adoption.  As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to accounts on the Condensed Consolidated Balance Sheet as of January 1, 2018 (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.514620%;"><tr><td style="width:1.0%;"/><td style="width:38.929535%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.389805%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.449175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.389805%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.449175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.992504%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported December 31, 2017 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted January 1, 2018 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,226 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(464)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,762 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other receivables </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10,176 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">506 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10,682 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">180,697 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">180,739 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(237,459)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(237,417)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders' equity </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">180,697 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">180,739 </span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The impact of adoption on the Company’s Condensed Consolidated Statement of Operating Loss for the three and nine months ended September 30, 2018 was as follows (in thousands):</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391813%;"><tr><td style="width:1.0%;"/><td style="width:22.071322%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542942%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542942%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542942%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542942%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542942%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">As Reported</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Adjustments</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Balance without Adoption of Topic 606</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">As Reported</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Adjustments</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Balance without Adoption of Topic 606</span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Statement of Operating Loss</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Grant Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,268 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">346 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,614 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Licensing and collaboration revenue </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">120 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">138 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,004 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">164 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,168 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and Development </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,570 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,588 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">39,972 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">468 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">40,440 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Loss </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,403)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,403)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,026)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,984)</span></td></tr></table></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The impact of adoption on the Company’s Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2018 was as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:35.829912%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.234604%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.234604%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.234604%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">As Reported</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Adjustments</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Balance without Adoption of Topic 606</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Net Loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,026)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,984)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Other receivables</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,982 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(492)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,490 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Accounts payable and accrued expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,749)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">450 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,299)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Net cash used in operating activities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,622)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,622)</span></td></tr></table></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Revenues are recognized under Topic 606 when control of the promised goods or services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company receives payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services, or HHS. These agreements provide the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues are recognized over time and measured using the input method. The Company uses labor costs and subcontractor fees as inputs to measure progress towards satisfying its performance obligations under these agreements. This is the most faithful depiction of the transfer of goods and services to the government entities due to the government entities’ control over the research and development activities. Under this method, the Company recognizes revenue generally in the period during which the related costs are incurred, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. </span></div>The Company had $320,000 and $9.3 million of receivables relating to the government contracts recorded in other receivables and zero and $465,000 of unbilled expenses relating to the government contracts recorded in prepaid expenses and other current assets on the balance sheet as of September 30, 2018 and December 31, 2017, respectively. The Company had $81,000 and $1.8 million of accrued expenses for subcontractor fees incurred under the government contracts as of September 30, 2018 and December 31, 2017, respectively. As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to accounts on the Condensed Consolidated Balance Sheet as of January 1, 2018 (in thousands):<div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.514620%;"><tr><td style="width:1.0%;"/><td style="width:38.929535%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.389805%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.449175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.389805%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.449175%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.992504%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported December 31, 2017 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted January 1, 2018 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,226 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(464)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,762 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other receivables </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10,176 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">506 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10,682 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">180,697 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">180,739 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(237,459)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(237,417)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders' equity </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">180,697 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">180,739 </span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The impact of adoption on the Company’s Condensed Consolidated Statement of Operating Loss for the three and nine months ended September 30, 2018 was as follows (in thousands):</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391813%;"><tr><td style="width:1.0%;"/><td style="width:22.071322%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542942%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542942%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542942%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542942%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542942%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.035661%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">As Reported</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Adjustments</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Balance without Adoption of Topic 606</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">As Reported</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Adjustments</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Balance without Adoption of Topic 606</span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Statement of Operating Loss</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Grant Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,268 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">346 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,614 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Licensing and collaboration revenue </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">120 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">138 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,004 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">164 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,168 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and Development </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,570 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,588 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">39,972 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">468 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">40,440 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Loss </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,403)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,403)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,026)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,984)</span></td></tr></table></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The impact of adoption on the Company’s Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2018 was as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:35.829912%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.234604%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.234604%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.234604%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">As Reported</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Adjustments</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Balance without Adoption of Topic 606</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Net Loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,026)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,984)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Other receivables</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,982 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(492)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,490 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Accounts payable and accrued expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,749)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">450 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,299)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Net cash used in operating activities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,622)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,622)</span></td></tr></table></div> 6226000 -464000 5762000 10176000 506000 10682000 180697000 42000 180739000 -237459000 42000 -237417000 180697000 42000 180739000 0 0 0 11268000 346000 11614000 120000 18000 138000 1004000 164000 1168000 7570000 18000 7588000 39972000 468000 40440000 -7403000 0 -7403000 -43026000 42000 -42984000 -43026000 42000 -42984000 -9982000 492000 -9490000 -11749000 450000 -11299000 -36622000 0 -36622000 Revenue Recognition Revenues are recognized under Topic 606 when control of the promised goods or services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company receives payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services, or HHS. These agreements provide the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues are recognized over time and measured using the input method. The Company uses labor costs and subcontractor fees as inputs to measure progress towards satisfying its performance obligations under these agreements. This is the most faithful depiction of the transfer of goods and services to the government entities due to the government entities’ control over the research and development activities. Under this method, the Company recognizes revenue generally in the period during which the related costs are incurred, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. 320000 9300000 0 465000 81000 1800000 License and Research Collaboration Agreements<div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Genentech, a Member of the Roche Group</span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In October 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Genentech, or the Genentech Agreement, for the development and commercialization of NLG919, one of the Company's clinical stage IDO pathway inhibitors and for the discovery of next generation IDO/TDO compounds to be developed and commercialized under this agreement. Under the terms of the Genentech Agreement, the Company received a nonrefundable upfront cash payment of $150.0 million from Genentech in 2014. On June 6, 2017, the Company received a formal notice of Genentech’s intent to terminate the Genentech Agreement with respect to NLG919. As part of the partial termination, worldwide rights to NLG919 reverted to us, and Genentech granted to us an exclusive, royalty-bearing license under certain Genentech intellectual property to develop and commercialize NLG919. If NLG919 is commercialized, we will be obligated to pay to Genentech royalties as a low single-digit percentage of net sales of NLG919.</span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Additionally, on May 9, 2018 the Company received formal notice that Genentech would not continue the collaboration with respect to next generation IDO/TDO inhibitors identified through the research program. The Genentech Agreement will terminate in its entirety no later than November 6, 2018. </span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For the three and nine months ended September 30, 2018, the Company recognized license and collaboration revenue under the Genentech Agreement of zero and $56,000, respectively, for providing an alliance manager. For the three and nine months ended September 30, 2017, the Company recognized license and collaboration revenue under the Genentech Agreement of $56,000 and $279,000, respectively, for providing an alliance manager. All of the deliverables identified within the collaboration and license agreement were completed in their entirety and all of the $150.0 million upfront payment was recognized as of March 31, 2018.</span></div><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merck Sharp &amp; Dohme Corp. </span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In November 2014, the Company entered into a licensing and collaboration agreement with Merck, or the Merck Agreement, to develop, manufacture and commercialize rVSV-ZEBOV GP, an Ebola vaccine the Company licensed from the Public Health Agency of Canada, or PHAC. Under the terms of the Merck Agreement, the Company granted Merck an exclusive, royalty bearing license to rVSV-ZEBOV GP and related technology. Under the Merck Agreement, the Company received a $30.0 million non-refundable, upfront payment in December 2014, and a one-time $20.0 million non-refundable milestone payment in February 2015 upon the initiation of the pivotal clinical trial using the current rVSV-ZEBOV GP vaccine product as one arm of the trial. In addition, the Company can receive escalating royalties on potential commercial sales by Merck of the current product candidate ranging from single digit to double digits on the rVSV-ZEBOV GP license agreement product sales and escalating royalties on potential commercial sales by Merck of products other than current products within the Company’s patent rights ranging from low to high single digit, on increasing levels of annual net sales worldwide. Merck will lead the development of rVSV-ZEBOV GP and any other rVSV-based viral hemorrhagic fever vaccine product candidates in order to create a marketable product safe for human use.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Merck Agreement was amended on December 5, 2017 in connection with our entry into an amended and restated PHAC license on December 5, 2017. The amended Merck Agreement absolves our subsidiary, BioProtection Systems Corporation, or BPS, from any future obligation to negotiate or amend the terms of the PHAC license, converts the scope of Merck's sublicense under PHAC’s intellectual property rights to be non-exclusive in the Ebola Sudan field of use, and requires Merck to reimburse us in certain circumstances where we may be obligated to pay royalties to PHAC as a result of Merck’s product sales but Merck would not otherwise be obligated to pay a royalty to us. On April 26, 2018 the Company entered into an agreement with Merck, DTRA and BARDA to transfer the government grants from BARDA and DTRA to Merck. The transfer was completed in June 2018 and Merck has replaced the Company as the prime contractor on all such grants. As a result grant revenues for the three and nine months ended September 30, 2018 have decreased as compared to the three and nine months ended September 30, 2017 and the Company does not expect to recognize additional revenue from government contracts for the development of the rVSV∆G-ZEBOV GP vaccine product candidate subsequent to September 30, 2018.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company completed all deliverables under the Merck Agreement in their entirety during the year ended December 31, 2016. For the three and nine months ended September 30, 2018, the Company recognized license and collaboration revenues under the Merck Agreement of $120,000 and $949,000, respectively, for the reimbursement of costs not covered under government contracts. For the three and nine months ended September 30, 2017, the company recognized license and collaboration revenue under the Merck Agreement of</span><span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> $48,000</span> and $55,000, respectively, for the reimbursement of costs not covered under government contracts. 150000000.0 0 56000 56000 279000 150000000.0 30000000.0 20000000.0 120000 949000 48000 55000 Common Stock Equity Incentive Plan<div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2009 Equity Incentive Plan</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In April 2000, the stockholders approved the Company's 2000 Equity Incentive Plan, or the 2000 Plan, and in July 2009, the stockholders approved the Company's 2009 Equity Incentive Plan, or the 2009 Plan. Following the approval of the 2009 Plan, all options outstanding under the 2000 Plan are effectively included under the 2009 Plan. Under the provisions of the 2009 Plan, the Company may grant the following types of common stock awards:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">• Incentive Stock Options</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">• Nonstatutory Stock Options</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">• Restricted Stock Awards</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">• Stock Appreciation Rights</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Awards under the 2009 Plan, as amended, may be made to officers, employees, members of the Board of Directors, advisors, and consultants to the Company. As of September 30, 2018, there were 11,722,602 shares of common stock authorized for the 2009 Plan and 1,489,402 shares remained available for issuance.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the authorized increases of common stock under the 2009 Plan:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:57.163743%;"><tr><td style="width:1.0%;"/><td style="width:40.199488%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.078772%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:54.521739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;font-weight:700;line-height:100%;">Date Authorized</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;font-weight:700;line-height:100%;">Authorized Shares Added</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2010</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,238,095 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">January 7, 2011</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">714,286 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2013</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">838,375 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2014</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,066,340 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2015</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,119,255 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,152,565 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,166,546 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,484,382 </span></td></tr></table></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The increases in the authorized shares of common stock under the 2009 Plan in 2010 and 2011 were approved by the Company’s stockholders. The increases in the authorized shares of common stock under the 2009 Plan in 2013 through 2018 were made pursuant to an “evergreen provision,” in accordance with which, on January 1 of each year, from 2013 to (and including) 2019, a number of shares of common stock in an amount equal to 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2010 Non-Employee Directors' Stock Award Plan</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Company’s 2010 Non-Employee Directors’ Stock Award Plan, or the Directors’ Plan, which became effective on November 10, 2011, 238,095 shares of common stock were reserved for future issuance. On May 9, 2013, an additional 161,905 shares of common stock were added to the shares reserved for future issuance under the Directors' Plan. As of September 30, 2018, no shares remained available for issuance under the Directors' Plan.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2010 Employee Stock Purchase Plan</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Company’s 2010 Employee Stock Purchase Plan, or the 2010 Purchase Plan, which became effective on November 10, 2011, 214,285 shares of common stock were reserved for future issuance. On May 9, 2013, an additional 185,715 shares of common stock were added to the shares reserved for future issuance under the 2010 Purchase Plan. As of September 30, 2018, 69,885 shares remained available for issuance under the 2010 Purchase Plan.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-based Compensation</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Share-based compensation expense for the three months ended September 30, 2018 and 2017 was $4.6 million and $4.4 million, respectively. Share-based compensation expense for the nine months ended September 30, 2018 and 2017 was $13.6 million and $14.9 million, respectively. Share-based compensation expense is allocated between research and development and general and administrative expenses within the condensed consolidated statements of operations. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of September 30, 2018, the total compensation cost related to nonvested option awards not yet recognized was $11.8 million and the weighted-average period over which it is expected to be recognized is 2.1 years.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options and Performance Stock Options</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the stock option activity, including options with market and performance conditions, for the nine months ended September 30, 2018:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.409357%;"><tr><td style="width:1.0%;"/><td style="width:39.090909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.709091%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.818182%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.709091%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.636364%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.709091%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.727273%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Number</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">of options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Weighted average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">remaining contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">term (years)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Outstanding at beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,202,221 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13.72 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Options granted</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,632,523 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.92 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Options exercised</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(32,946)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.24 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Options forfeited</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(317,359)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13.59 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Options expired</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(118,097)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21.96 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Outstanding at end of period</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,371,005 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12.32 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Options exercisable at end of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,264,767 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13.03 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8</span></td></tr></table></div><div style="text-indent:27pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company estimates the fair value of each stock option grant on the date of grant using a Black-Scholes option pricing model. For stock option grants issued with a market condition, the Company used a Monte Carlo simulation valuation model to determine the grant date fair value. </span></div><div style="text-indent:27pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the nine months ended September 30, 2018:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.865497%;"><tr><td style="width:1.0%;"/><td style="width:66.139535%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.962791%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:28.697674%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6% to 2.9% </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Expected dividend yield</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">—% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">76.2% to 79.2% </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Expected term (in years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0 to 7.9 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average grant-date fair value per share</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$4.90 </span></td></tr></table></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The intrinsic value of options exercised during the nine months ended September 30, 2018 was $77,788. The fair value of awards vested during the nine months ended September 30, 2018 was $10.2 million. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the nine months ended September 30, 2018, the Company’s Board of Directors approved and granted 466,750 shares of equity awards to certain executives with either market or performance conditions. The equity awards had a weighted-average grant date fair value per share of $5.33. The equity awards will vest upon the achievement of certain performance conditions. Certain performance conditions relating to the equity awards granted in 2018 and 2017 were met during the nine months ended September 30, 2018 and 213,725 shares were vested.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock and Performance Restricted Stock</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Restricted stock is common stock that is subject to restrictions, including risks of forfeiture, determined by the plan committee of the Board of Directors in its sole discretion, for as long as such common stock remains subject to any such restrictions. A holder of restricted stock has all rights of a stockholder with respect to such stock, including the right to vote and to receive dividends thereon, except as otherwise provided in the award agreement relating to such award. Restricted stock awards are classified as equity within the consolidated balance sheets. The fair value of each restricted stock grant is estimated on the date of grant using the closing price of the Company's common stock on the NASDAQ Stock Market on the date of grant.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at September 30, 2018 and changes during the nine months ended September 30, 2018 are as follows:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:64.473684%;"><tr><td style="width:1.0%;"/><td style="width:54.235828%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.954649%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.140590%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="height:27pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:27pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:27pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Number of restricted stock shares</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="height:27pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:27pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Weighted average grant date fair value</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Unvested at beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">168,221 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35.82 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Granted</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Vested</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(72,447)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35.40 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Forfeited/cancelled</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,721)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">40.99 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Unvested at end of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">89,053 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35.76 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of September 30, 2018, the total remaining unrecognized compensation cost related to restricted stock was approximately $1.6 million and is expected to be recognized over a weighted-average period of 1.0 years. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company does not have a formal policy regarding the source of shares issued upon exercise of stock options or issuance of restricted stock. The Company expects shares issued to be issued from treasury shares or new shares.</span></div> 11722602 1489402 The following table summarizes the authorized increases of common stock under the 2009 Plan: 1238095 714286 838375 1066340 1119255 1152565 1166546 1484382 0.04 238095 161905 0 214285 185715 69885 4600000 4400000 13600000 14900000 11800000 P2Y1M6D The following table summarizes the stock option activity, including options with market and performance conditions, for the nine months ended September 30, 2018: 7202221 13.72 P5Y3M18D 1632523 6.92 32946 4.24 317359 13.59 118097 21.96 8371005 12.32 P5Y1M6D 6264767 13.03 P3Y9M18D The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the nine months ended September 30, 2018: 77788 10200000 466750 5.33 213725 A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at September 30, 2018 and changes during the nine months ended September 30, 2018 are as follows: 168221 35.82 0 0 72447 35.40 6721 40.99 89053 35.76 1600000 P1Y Income Taxes<div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For the three and nine months ended September 30, 2018, the Company recorded a</span><span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> $7.0 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> income tax benefit. The income tax benefit for the three and nine months ended September 30, 2018 differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due a refund received as a result of amendments filed to change the allocation of income for certain states for the years ending December 31, 2014 and 2015. We received the full refund subsequent to September 30, 2018. For the nine months ended September 30, 2017, the Company recorded an income tax benefit of $429,000. For the three months ended September 30, 2017, the Company recorded $119,000. Additionally, the Company has a noncurrent income tax receivable as of September 30, 2018 for $140,000 which was recorded as an income tax benefit in 2017 and is for the receipt of AMT Credit carryovers. The Tax Cuts and Jobs Act of 2017, or the Tax Act, provides that the AMT credit carryovers are partially refundable beginning in 2018 as an offset to a tax liability. The Company expects the amount to be fully refunded by 2021.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected taxable income, and tax planning strategies in making this assessment. Valuation allowances have been established for the entire amount of the net deferred tax assets as of September 30, 2018 and December 31, 2017, respectively, due to the uncertainty of future recoverability.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company has a reserve for uncertain tax positions related to state tax matters of $653,000 as of September 30, 2018 recorded within Accrued Expenses in the condensed consolidated balance sheet, which includes the accrual of interest and penalties. The Company does not expect the amount to change significantly within the next 12 months.</span></div> -7000000.0 -429000 -119000 140000 653000 Net Loss per Common Share<div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Basic loss per share is based upon the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common stock equivalents during the period when the effect is dilutive.</span></div><div style="text-indent:22pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents the computation of basic and diluted loss per common share (in thousands, except share and per share data):</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.228070%;"><tr><td style="width:1.0%;"/><td style="width:46.076923%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820513%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.242308%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.217949%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.217949%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:21pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:21pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Loss attributable to common stockholders</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,403)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,626)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,026)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(58,265)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Basic and diluted weighted-average shares outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">37,214,363 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">29,939,823 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">37,178,542 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">29,462,226 </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Basic and diluted loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.20)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.69)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.16)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.98)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div>All common stock equivalents are excluded from the computation of diluted loss per share during periods in which losses are reported since the result would be anti-dilutive. As of September 30, 2018, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled 8,371,005 and 89,053, respectively. As of September 30, 2017, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled 7,314,006 and 181,336, respectively. The following table presents the computation of basic and diluted loss per common share (in thousands, except share and per share data): -7403000 -20626000 -43026000 -58265000 37214363 29939823 37178542 29462226 -0.20 -0.69 -1.16 -1.98 8371005 89053 7314006 181336 Restructuring Charges<div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee severance costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. The Company also records costs incurred with contract terminations associated with restructuring activities. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> In July 2018, the Company completed an organizational review of its clinical programs and reduced its headcount by approximately 30% as compared to June 30, 2018 and made several changes to senior leadership effective July 26, 2018 in order to conserve resources to further advance its clinical development programs. Restructuring charges of $1.3 million were recorded during the three and nine months ended September 30, 2018 of which $800,000 is included within general and administrative expenses and $500,000 is included within the research and development expenses in the condensed consolidated statement of operations.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company undertook an organizational realignment in July 2017 to refocus its clinical development efforts and align the Company's resources to focus on the Company's highest value opportunities. The Company's restructuring activities included a reduction of its workforce by approximately 50%, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus. The Company recorded total restructuring charges of $1.7 million during the nine months ended September 30, 2017 of which $1.1 million is included within general and administrative expenses and $600,000 is included within the research and development expenses in the condensed consolidated statement of operations.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table shows the amount accrued for restructuring activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet (in thousands):</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.426901%;"><tr><td style="width:1.0%;"/><td style="width:44.838407%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.205152%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:22.824356%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.205152%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:23.526932%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;font-weight:700;line-height:100%;">Employee Severance Cost</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;font-weight:700;line-height:100%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Balance as of December 31, 2017</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">207 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">207 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Expensed</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,323 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,323 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Cash Payments</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">511 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">511 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2018 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,019 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,019 </span></td></tr></table></div> 0.30 1300000 800000 500000 0.50 1700000 1100000 600000 The following table shows the amount accrued for restructuring activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet (in thousands): 207000 207000 1323000 1323000 511000 511000 1019000 1019000 Commitments and Contingencies <div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">From time to time, claims are asserted against the Company arising in the ordinary course of business. In the opinion of management, liabilities, if any, arising from existing claims are not expected to have a material effect on the Company's earnings, financial position, or liquidity.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York, or the Court, captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545, or the Securities Action.  Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick &amp; Foti, LLC as lead counsel in the Securities Action.  On October 31, 2016, the lead plaintiffs filed an amended complaint asserting claims under the federal securities laws against the Company, the Company’s Chief Executive Officer Charles J. Link, Jr., and the Company’s Chief Medical Officer and President Nicholas Vahanian, or collectively, the Defendants.  The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company’s investors. In particular, the lead plaintiffs allege that the Defendants made material</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L. The lead plaintiffs did not quantify any alleged damages in the amended complaint but, in addition to attorneys’ fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company’s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the amended complaint on July 14, 2017. The lead plaintiffs filed an opposition to the motion to dismiss on September 12, 2017. The Defendants filed a reply in support of the motion to dismiss on September 26, 2017. Oral argument was held on October 19, 2017, after which the Court reserved decision. On March 29, 2018, the Court dismissed the amended complaint for failure to state a claim, without prejudice, and gave the lead plaintiffs until May 4, 2018 to file any amended complaint attempting to remedy the defects in their claims.  On May 4, 2018, the lead plaintiffs filed a second amended complaint asserting claims under the federal securities laws against the Defendants. Like the first amended complaint, the second amended complaint alleges that the Defendants made material false and/or misleading statements or omissions relating to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L that caused losses to the Company’s investors. The lead plaintiffs did not quantify any alleged damages in the second amended complaint but, in addition to attorneys’ fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company’s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the second amended complaint on July 31, 2018. The lead plaintiffs filed an opposition to the motion to dismiss the second amended complaint on September 14, 2018. The Defendants filed a reply in support of the motion to dismiss the second amended complaint on October 9, 2018. Oral argument was held on October 19, 2018, after which the Court reserved decision. The Company intends to continue defending the Securities Action vigorously. </span></div><div style="text-indent:22pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company’s Chief Executive Officer Charles J. Link, Jr., the Company’s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth, or collectively, the Morrow Defendants, captioned Morrow v. Link., et al., Case 1:17-cv-03039, or the Morrow Action.  The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation of federal securities law.  The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.  The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company’s shareholders.  The language for such proposals is not specified in the complaint.  The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.  On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.  Also on May 19, 2017, plaintiffs’ counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.  The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.  By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise finally resolved.  Under the terms of the stay, the plaintiff in the Ely Action will be provided with any discovery that is provided in the Securities Action, and given an opportunity to participate in any mediation or settlement efforts in the Securities Action.  The Company disputes the claims in the Ely Action and intends to defend against them vigorously.</span></div> XML 18 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Oct. 30, 2018
Document and Entity Information [Abstract]    
Entity Registrant Name NEWLINK GENETICS CORP  
Entity Central Index Key 0001126234  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   37,224,606

XML 19 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 122,061 $ 158,708
Prepaid expenses and other current assets 4,920 6,226
Income tax receivable 7,398 356
Other receivables 700 10,176
Total current assets 135,079 175,466
Property and equipment, net 4,096 5,091
Income tax receivable 140 140
Total non-current assets 4,236 5,231
Total assets 139,315 180,697
Current liabilities:    
Accounts payable 1,238 9,256
Accrued expenses 8,736 12,467
Current portion of unearned revenue 0 56
Current portion of deferred rent 84 92
Current portion of notes payable and obligations under capital leases 74 160
Total current liabilities 10,132 22,031
Long-term liabilities:    
Royalty obligation payable to Iowa Economic Development Authority 6,000 6,000
Notes payable and obligations under capital leases 59 111
Deferred rent 929 998
Total long-term liabilities 6,988 7,109
Total liabilities 17,120 29,140
Stockholders' equity:    
Blank check preferred stock, $0.01 par value: Authorized shares — 5,000,000 at September 30, 2018 and December 31, 2017; issued and outstanding shares — 0 at September 30, 2018 and December 31, 2017 0 0
Common stock, $0.01 par value: Authorized shares — 75,000,000 at September 30, 2018 and December 31, 2017; issued 37,305,626 and 37,168,122 at September 30, 2018 and December 31, 2017, respectively, and outstanding 37,216,892 and 37,109,556 at September 30, 2018 and December 31, 2017, respectively 373 372
Additional paid-in capital 403,674 389,786
Treasury stock, at cost: 88,734 and 58,566 shares at September 30, 2018 and December 31, 2017, respectively (1,409) (1,142)
Accumulated deficit (280,443) (237,459)
Total stockholders' equity 122,195 151,557
Total liabilities and stockholders' equity $ 139,315 $ 180,697
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares
Sep. 30, 2018
Dec. 31, 2017
Stockholders' Equity:    
Blank check preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Blank check preferred stock, authorized shares 5,000,000 5,000,000
Blank check preferred stock, issued shares 0 0
Blank check preferred stock, outstanding shares 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares 75,000,000 75,000,000
Common stock, issued shares 37,305,626 37,168,122
Common stock, outstanding shares 37,216,892 37,109,556
Treasury stock, shares 88,734 58,566
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Total operating revenues $ 120 $ 5,482 $ 12,272 $ 18,613
Operating expenses:        
Research and development 7,570 18,480 39,972 52,405
General and administrative 7,588 7,907 23,792 25,038
Total operating expenses 15,158 26,387 63,764 77,443
Loss from operations (15,038) (20,905) (51,492) (58,830)
Other income and expense:        
Miscellaneous (expense) income (18) 12 16 (101)
Interest income 664 151 1,510 353
Interest expense (2) (3) (51) (116)
Other income, net 644 160 1,475 136
Net loss before taxes (14,394) (20,745) (50,017) (58,694)
Income tax benefit 6,991 119 6,991 429
Net loss $ (7,403) $ (20,626) $ (43,026) $ (58,265)
Basic and diluted loss per share (in dollars per share) $ (0.20) $ (0.69) $ (1.16) $ (1.98)
Basic and diluted average shares outstanding (in shares) 37,214,363 29,939,823 37,178,542 29,462,226
Grant revenue        
Revenues $ 0 $ 5,379 $ 11,268 $ 18,279
License and collaboration revenue        
Revenues $ 120 $ 103 $ 1,004 $ 334
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statement of Stockholders' Equity - 9 months ended Sep. 30, 2018 - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Balance at beginning of period at Dec. 31, 2017 $ 151,557 $ 372 $ 389,786 $ (1,142) $ (237,459)
Balance at beginning of period (shares) at Dec. 31, 2017 37,109,556 37,109,556      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation $ 13,620   13,620    
Exercise of stock options and restricted stock vested 139 $ 1 138    
Exercise of stock options and restricted stock vested (shares)   105,393      
Sales of shares under stock purchase plan 130   130    
Sales of shares under stock purchase plan (shares)   32,111      
Repurchase of common stock (267)     (267)  
Repurchase of common stock (shares)   (30,168)      
Cumulative effect of accounting change 42,000       42,000
Net loss (43,026)       (43,026)
Balance at end of period at Sep. 30, 2018 $ 122,195 $ 373 $ 403,674 $ (1,409) $ (280,443)
Balance at end of period (shares) at Sep. 30, 2018 37,216,892 37,216,892      
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash Flows From Operating Activities    
Net loss $ (43,026) $ (58,265)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 13,620 14,938
Depreciation and amortization 901 1,064
(Gain) Loss on sale of fixed assets (16) 102
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 842 3,220
Other receivables 9,982 13,856
Accounts payable and accrued expenses (11,749) (11,500)
Income taxes receivable (7,042) 5,861
Unearned revenue (56) (279)
Deferred rent (78) (67)
Net cash used in operating activities (36,622) (31,070)
Cash Flows From Investing Activities    
Purchase of equipment (7) (43)
Proceeds on sale of equipment 118 185
Net cash provided by investing activities 111 142
Cash Flows From Financing Activities    
Issuance of common stock, net of offering costs 269 20,585
Repurchase of common stock (267) (260)
Payments under capital lease obligations and principal payments on notes payable (138) (185)
Net cash (used in) provided by financing activities (136) 20,140
Net decrease in cash and cash equivalents (36,647) (10,788)
Cash and cash equivalents at beginning of period 158,708 131,490
Cash and cash equivalents at end of period 122,061 120,702
Supplemental disclosure of cash flows information:    
Cash paid for interest 6 11
Cash refunds received for taxes, net $ 4 $ (6,261)
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Description of Business
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business Description of Business
On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000.
NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs.
The accompanying condensed consolidated financial statements as of September 30, 2018 and for the three and nine months ended have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of $37.6 million from its initial public offering in 2011, completed a follow-on offering of its common stock raising net proceeds of $49.0 million in 2013, and raised an additional $58.7 million in net proceeds from an at the market (ATM) offering completed in 2015.
During 2017, the Company sold 1,940,656 shares of its common stock under an ATM offering, with aggregate net proceeds of $19.3 million after commissions of $398,000 paid to Cantor Fitzgerald & Co. (Cantor) as the placement agent, and other costs of $163,000. In October 2017, the Company sold 5,750,000 of its shares of common stock in a public offering for aggregate net proceeds of $55.2 million after underwriters' discounts, commissions and other expenses of $3.7 million. On March 12, 2018, the Company entered into a new Sales Agreement with Cantor under which the Company may sell up to $60.0 million of its common stock in one or more placements at prevailing market prices in an ATM offering (the 2018 ATM Offering). As of September 30, 2018, no shares have been sold under the 2018 ATM Offering.
The Company's cash and cash equivalents as of September 30, 2018 are expected to be adequate to satisfy the Company's liquidity requirements into the second half of 2021. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include selling additional shares of common stock, alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management’s opinion, reflect all adjustments necessary to present fairly the Company’s interim condensed financial information.
Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K. The financial results for any interim period are not necessarily indicative of financial results for the full year.
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Significant Accounting Policies Significant Accounting Policies
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Principles of Consolidation
The condensed consolidated financial statements include the financial statements of NewLink and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Financial Instruments and Concentrations of Credit Risk
Cash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable and capital lease obligations was $133,000 and $271,000 as of September 30, 2018 and December 31, 2017, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain. 
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.
Property and equipment
Property and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of $7.1 million and $6.6 million as of September 30, 2018 and December 31, 2017, respectively. Equipment under capital leases is stated at the present value of minimum lease payments. Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of three to five years, lab equipment has a useful life of five years and contract manufacturing organization equipment has a useful life of five years.
Recently Issued Accounting Pronouncements not yet adopted 
In February 2016, the Financial Accounting Standards Board, or the FASB, issued ASU No. 2016-02, Leases, to improve financial reporting for leasing transactions. The new standard requires lessees to recognize on the balance sheet a right of use asset and related lease liability for all leases with terms greater than twelve months. The ASU also requires disclosures about the amount, timing, and uncertainty of cash flows arising from leases. The effective date for public entities is fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company does not currently have any material leases and therefore does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures.
Recently Adopted Accounting Pronouncements

On May 28, 2014, the FASB issued ASU No. 2014-09 (Topic 606), Revenue from Contracts with Customers. Topic 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (Topic 605), and requires entities to recognize revenue when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted Topic 606 as of January 1, 2018 and as a result changed its accounting policy for revenue recognition, as discussed in Note 4.
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenues
 9 Months Ended
Sep. 30, 2018
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Adoption of ASC Topic 606, "Revenue from Contracts with Customers"
On January 1, 2018, we adopted Topic 606 using the modified retrospective method by recognizing the cumulative effect of initially applying Topic 606 as an adjustment to the opening balance of equity as of January 1, 2018. Therefore results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting policy under Topic 605. The change in accounting policy from Topic 605 to Topic 606 impacted how the Company recognizes revenue from government grants, and did not impact license and collaboration revenues due to the nature of those services in the period leading up to and after the adoption of Topic 606.
The Company recorded an immaterial net reduction to the opening accumulated deficit within equity as of January 1, 2018 due to the cumulative impact of adopting Topic 606 with respect to grants from government entities which were not completed as of the date of adoption.  As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to accounts on the Condensed Consolidated Balance Sheet as of January 1, 2018 (in thousands):
As Reported December 31, 2017 Adjustments Adjusted January 1, 2018 
Balance Sheet 
Assets: 
Prepaid expenses and other current assets $6,226 $(464)$5,762 
Other receivables $10,176 $506 $10,682 
Total assets $180,697 $42 $180,739 
Equity: 
Accumulated deficit $(237,459)$42 $(237,417)
Total liabilities and stockholders' equity $180,697 $42 $180,739 

The impact of adoption on the Company’s Condensed Consolidated Statement of Operating Loss for the three and nine months ended September 30, 2018 was as follows (in thousands):

Three Months Ended September 30, Nine Months Ended September 30, 
As Reported
Adjustments
Balance without Adoption of Topic 606
As Reported
Adjustments
Balance without Adoption of Topic 606
Statement of Operating Loss
Grant Revenues
$— $— $— $11,268 $346 $11,614 
Licensing and collaboration revenue $120 $18 $138 $1,004 $164 $1,168 
Research and Development $7,570 $18 $7,588 $39,972 $468 $40,440 
Net Loss $(7,403)$— $(7,403)$(43,026)$42 $(42,984)

The impact of adoption on the Company’s Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2018 was as follows (in thousands):
As Reported
Adjustments
Balance without Adoption of Topic 606
Statement of Cash Flows
Net Loss
$(43,026)$42 $(42,984)
Changes in operating assets and liabilities:
Other receivables
$9,982 $(492)$9,490 
Accounts payable and accrued expenses
$(11,749)$450 $(11,299)
Net cash used in operating activities
$(36,622)$— $(36,622)
Revenue Recognition
Revenues are recognized under Topic 606 when control of the promised goods or services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company receives payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services, or HHS. These agreements provide the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues are recognized over time and measured using the input method. The Company uses labor costs and subcontractor fees as inputs to measure progress towards satisfying its performance obligations under these agreements. This is the most faithful depiction of the transfer of goods and services to the government entities due to the government entities’ control over the research and development activities. Under this method, the Company recognizes revenue generally in the period during which the related costs are incurred, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.
The Company had $320,000 and $9.3 million of receivables relating to the government contracts recorded in other receivables and zero and $465,000 of unbilled expenses relating to the government contracts recorded in prepaid expenses and other current assets on the balance sheet as of September 30, 2018 and December 31, 2017, respectively. The Company had $81,000 and $1.8 million of accrued expenses for subcontractor fees incurred under the government contracts as of September 30, 2018 and December 31, 2017, respectively.
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
License and Research Collaboration Agreements
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
License and Research Collaboration Agreements License and Research Collaboration Agreements
Genentech, a Member of the Roche Group
In October 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Genentech, or the Genentech Agreement, for the development and commercialization of NLG919, one of the Company's clinical stage IDO pathway inhibitors and for the discovery of next generation IDO/TDO compounds to be developed and commercialized under this agreement. Under the terms of the Genentech Agreement, the Company received a nonrefundable upfront cash payment of $150.0 million from Genentech in 2014. On June 6, 2017, the Company received a formal notice of Genentech’s intent to terminate the Genentech Agreement with respect to NLG919. As part of the partial termination, worldwide rights to NLG919 reverted to us, and Genentech granted to us an exclusive, royalty-bearing license under certain Genentech intellectual property to develop and commercialize NLG919. If NLG919 is commercialized, we will be obligated to pay to Genentech royalties as a low single-digit percentage of net sales of NLG919.
Additionally, on May 9, 2018 the Company received formal notice that Genentech would not continue the collaboration with respect to next generation IDO/TDO inhibitors identified through the research program. The Genentech Agreement will terminate in its entirety no later than November 6, 2018.
For the three and nine months ended September 30, 2018, the Company recognized license and collaboration revenue under the Genentech Agreement of zero and $56,000, respectively, for providing an alliance manager. For the three and nine months ended September 30, 2017, the Company recognized license and collaboration revenue under the Genentech Agreement of $56,000 and $279,000, respectively, for providing an alliance manager. All of the deliverables identified within the collaboration and license agreement were completed in their entirety and all of the $150.0 million upfront payment was recognized as of March 31, 2018.
Merck Sharp & Dohme Corp.
In November 2014, the Company entered into a licensing and collaboration agreement with Merck, or the Merck Agreement, to develop, manufacture and commercialize rVSV-ZEBOV GP, an Ebola vaccine the Company licensed from the Public Health Agency of Canada, or PHAC. Under the terms of the Merck Agreement, the Company granted Merck an exclusive, royalty bearing license to rVSV-ZEBOV GP and related technology. Under the Merck Agreement, the Company received a $30.0 million non-refundable, upfront payment in December 2014, and a one-time $20.0 million non-refundable milestone payment in February 2015 upon the initiation of the pivotal clinical trial using the current rVSV-ZEBOV GP vaccine product as one arm of the trial. In addition, the Company can receive escalating royalties on potential commercial sales by Merck of the current product candidate ranging from single digit to double digits on the rVSV-ZEBOV GP license agreement product sales and escalating royalties on potential commercial sales by Merck of products other than current products within the Company’s patent rights ranging from low to high single digit, on increasing levels of annual net sales worldwide. Merck will lead the development of rVSV-ZEBOV GP and any other rVSV-based viral hemorrhagic fever vaccine product candidates in order to create a marketable product safe for human use.
The Merck Agreement was amended on December 5, 2017 in connection with our entry into an amended and restated PHAC license on December 5, 2017. The amended Merck Agreement absolves our subsidiary, BioProtection Systems Corporation, or BPS, from any future obligation to negotiate or amend the terms of the PHAC license, converts the scope of Merck's sublicense under PHAC’s intellectual property rights to be non-exclusive in the Ebola Sudan field of use, and requires Merck to reimburse us in certain circumstances where we may be obligated to pay royalties to PHAC as a result of Merck’s product sales but Merck would not otherwise be obligated to pay a royalty to us. On April 26, 2018 the Company entered into an agreement with Merck, DTRA and BARDA to transfer the government grants from BARDA and DTRA to Merck. The transfer was completed in June 2018 and Merck has replaced the Company as the prime contractor on all such grants. As a result grant revenues for the three and nine months ended September 30, 2018 have decreased as compared to the three and nine months ended September 30, 2017 and the Company does not expect to recognize additional revenue from government contracts for the development of the rVSV∆G-ZEBOV GP vaccine product candidate subsequent to September 30, 2018.
The Company completed all deliverables under the Merck Agreement in their entirety during the year ended December 31, 2016. For the three and nine months ended September 30, 2018, the Company recognized license and collaboration revenues under the Merck Agreement of $120,000 and $949,000, respectively, for the reimbursement of costs not covered under government contracts. For the three and nine months ended September 30, 2017, the company recognized license and collaboration revenue under the Merck Agreement of $48,000 and $55,000, respectively, for the reimbursement of costs not covered under government contracts.
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Equity Incentive Plan
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Common Stock Equity Incentive Plan Common Stock Equity Incentive Plan
2009 Equity Incentive Plan
In April 2000, the stockholders approved the Company's 2000 Equity Incentive Plan, or the 2000 Plan, and in July 2009, the stockholders approved the Company's 2009 Equity Incentive Plan, or the 2009 Plan. Following the approval of the 2009 Plan, all options outstanding under the 2000 Plan are effectively included under the 2009 Plan. Under the provisions of the 2009 Plan, the Company may grant the following types of common stock awards:
• Incentive Stock Options
• Nonstatutory Stock Options
• Restricted Stock Awards
• Stock Appreciation Rights
Awards under the 2009 Plan, as amended, may be made to officers, employees, members of the Board of Directors, advisors, and consultants to the Company. As of September 30, 2018, there were 11,722,602 shares of common stock authorized for the 2009 Plan and 1,489,402 shares remained available for issuance.
The following table summarizes the authorized increases of common stock under the 2009 Plan:
Date Authorized
Authorized Shares Added
May 15, 20101,238,095 
January 7, 2011714,286 
January 1, 2013838,375 
January 1, 20141,066,340 
January 1, 20151,119,255 
January 1, 20161,152,565 
January 1, 20171,166,546 
January 1, 20181,484,382 
The increases in the authorized shares of common stock under the 2009 Plan in 2010 and 2011 were approved by the Company’s stockholders. The increases in the authorized shares of common stock under the 2009 Plan in 2013 through 2018 were made pursuant to an “evergreen provision,” in accordance with which, on January 1 of each year, from 2013 to (and including) 2019, a number of shares of common stock in an amount equal to 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan.
2010 Non-Employee Directors' Stock Award Plan
Under the terms of the Company’s 2010 Non-Employee Directors’ Stock Award Plan, or the Directors’ Plan, which became effective on November 10, 2011, 238,095 shares of common stock were reserved for future issuance. On May 9, 2013, an additional 161,905 shares of common stock were added to the shares reserved for future issuance under the Directors' Plan. As of September 30, 2018, no shares remained available for issuance under the Directors' Plan.
2010 Employee Stock Purchase Plan
Under the terms of the Company’s 2010 Employee Stock Purchase Plan, or the 2010 Purchase Plan, which became effective on November 10, 2011, 214,285 shares of common stock were reserved for future issuance. On May 9, 2013, an additional 185,715 shares of common stock were added to the shares reserved for future issuance under the 2010 Purchase Plan. As of September 30, 2018, 69,885 shares remained available for issuance under the 2010 Purchase Plan.
Share-based Compensation
Share-based compensation expense for the three months ended September 30, 2018 and 2017 was $4.6 million and $4.4 million, respectively. Share-based compensation expense for the nine months ended September 30, 2018 and 2017 was $13.6 million and $14.9 million, respectively. Share-based compensation expense is allocated between research and development and general and administrative expenses within the condensed consolidated statements of operations.
As of September 30, 2018, the total compensation cost related to nonvested option awards not yet recognized was $11.8 million and the weighted-average period over which it is expected to be recognized is 2.1 years.
Stock Options and Performance Stock Options
The following table summarizes the stock option activity, including options with market and performance conditions, for the nine months ended September 30, 2018:
Number
of options
Weighted
average
exercise
price
Weighted average
remaining contractual
term (years)
Outstanding at beginning of period
7,202,221 $13.72 5.3
Options granted
1,632,523 6.92 
Options exercised
(32,946)4.24 
Options forfeited
(317,359)13.59 
Options expired
(118,097)21.96 
Outstanding at end of period
8,371,005 $12.32 5.1
Options exercisable at end of period
6,264,767 $13.03 3.8
The Company estimates the fair value of each stock option grant on the date of grant using a Black-Scholes option pricing model. For stock option grants issued with a market condition, the Company used a Monte Carlo simulation valuation model to determine the grant date fair value.
The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the nine months ended September 30, 2018:
Risk-free interest rate
2.6% to 2.9% 
Expected dividend yield
—%  
Expected volatility
76.2% to 79.2% 
Expected term (in years)
4.0 to 7.9 
Weighted-average grant-date fair value per share
$4.90 
The intrinsic value of options exercised during the nine months ended September 30, 2018 was $77,788. The fair value of awards vested during the nine months ended September 30, 2018 was $10.2 million.
During the nine months ended September 30, 2018, the Company’s Board of Directors approved and granted 466,750 shares of equity awards to certain executives with either market or performance conditions. The equity awards had a weighted-average grant date fair value per share of $5.33. The equity awards will vest upon the achievement of certain performance conditions. Certain performance conditions relating to the equity awards granted in 2018 and 2017 were met during the nine months ended September 30, 2018 and 213,725 shares were vested.
Restricted Stock and Performance Restricted Stock
Restricted stock is common stock that is subject to restrictions, including risks of forfeiture, determined by the plan committee of the Board of Directors in its sole discretion, for as long as such common stock remains subject to any such restrictions. A holder of restricted stock has all rights of a stockholder with respect to such stock, including the right to vote and to receive dividends thereon, except as otherwise provided in the award agreement relating to such award. Restricted stock awards are classified as equity within the consolidated balance sheets. The fair value of each restricted stock grant is estimated on the date of grant using the closing price of the Company's common stock on the NASDAQ Stock Market on the date of grant.
A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at September 30, 2018 and changes during the nine months ended September 30, 2018 are as follows:
Number of restricted stock shares
Weighted average grant date fair value
Unvested at beginning of period
168,221 $35.82 
Granted
— — 
Vested
(72,447)35.40 
Forfeited/cancelled
(6,721)40.99 
Unvested at end of period
89,053 $35.76 
As of September 30, 2018, the total remaining unrecognized compensation cost related to restricted stock was approximately $1.6 million and is expected to be recognized over a weighted-average period of 1.0 years.
The Company does not have a formal policy regarding the source of shares issued upon exercise of stock options or issuance of restricted stock. The Company expects shares issued to be issued from treasury shares or new shares.
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes
 9 Months Ended
Sep. 30, 2018
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
For the three and nine months ended September 30, 2018, the Company recorded a $7.0 million income tax benefit. The income tax benefit for the three and nine months ended September 30, 2018 differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due a refund received as a result of amendments filed to change the allocation of income for certain states for the years ending December 31, 2014 and 2015. We received the full refund subsequent to September 30, 2018. For the nine months ended September 30, 2017, the Company recorded an income tax benefit of $429,000. For the three months ended September 30, 2017, the Company recorded $119,000. Additionally, the Company has a noncurrent income tax receivable as of September 30, 2018 for $140,000 which was recorded as an income tax benefit in 2017 and is for the receipt of AMT Credit carryovers. The Tax Cuts and Jobs Act of 2017, or the Tax Act, provides that the AMT credit carryovers are partially refundable beginning in 2018 as an offset to a tax liability. The Company expects the amount to be fully refunded by 2021.
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected taxable income, and tax planning strategies in making this assessment. Valuation allowances have been established for the entire amount of the net deferred tax assets as of September 30, 2018 and December 31, 2017, respectively, due to the uncertainty of future recoverability.
The Company has a reserve for uncertain tax positions related to state tax matters of $653,000 as of September 30, 2018 recorded within Accrued Expenses in the condensed consolidated balance sheet, which includes the accrual of interest and penalties. The Company does not expect the amount to change significantly within the next 12 months.
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss per Common Share
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Net Loss per Common Share Net Loss per Common Share
Basic loss per share is based upon the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common stock equivalents during the period when the effect is dilutive.

The following table presents the computation of basic and diluted loss per common share (in thousands, except share and per share data):
 
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Loss attributable to common stockholders
$(7,403)$(20,626)$(43,026)$(58,265)
Basic and diluted weighted-average shares outstanding
37,214,363 29,939,823 37,178,542 29,462,226 
Basic and diluted loss per share
$(0.20)$(0.69)$(1.16)$(1.98)
All common stock equivalents are excluded from the computation of diluted loss per share during periods in which losses are reported since the result would be anti-dilutive. As of September 30, 2018, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled 8,371,005 and 89,053, respectively. As of September 30, 2017, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled 7,314,006 and 181,336, respectively.
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring Charges
 9 Months Ended
Sep. 30, 2018
Restructuring and Related Activities [Abstract]  
Restructuring Charges Restructuring Charges
The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee severance costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. The Company also records costs incurred with contract terminations associated with restructuring activities.
In July 2018, the Company completed an organizational review of its clinical programs and reduced its headcount by approximately 30% as compared to June 30, 2018 and made several changes to senior leadership effective July 26, 2018 in order to conserve resources to further advance its clinical development programs. Restructuring charges of $1.3 million were recorded during the three and nine months ended September 30, 2018 of which $800,000 is included within general and administrative expenses and $500,000 is included within the research and development expenses in the condensed consolidated statement of operations.
The Company undertook an organizational realignment in July 2017 to refocus its clinical development efforts and align the Company's resources to focus on the Company's highest value opportunities. The Company's restructuring activities included a reduction of its workforce by approximately 50%, which consisted primarily of clinical and research and development staff, as well as stopping additional research on the Zika virus. The Company recorded total restructuring charges of $1.7 million during the nine months ended September 30, 2017 of which $1.1 million is included within general and administrative expenses and $600,000 is included within the research and development expenses in the condensed consolidated statement of operations.
The following table shows the amount accrued for restructuring activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet (in thousands):
Employee Severance Cost
Total
Balance as of December 31, 2017
207 207 
Expensed
1,323 1,323 
Cash Payments
511 511 
Balance as of September 30, 2018 1,019 1,019 
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure Commitments and Contingencies
From time to time, claims are asserted against the Company arising in the ordinary course of business. In the opinion of management, liabilities, if any, arising from existing claims are not expected to have a material effect on the Company's earnings, financial position, or liquidity.

On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York, or the Court, captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545, or the Securities Action.  Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick & Foti, LLC as lead counsel in the Securities Action.  On October 31, 2016, the lead plaintiffs filed an amended complaint asserting claims under the federal securities laws against the Company, the Company’s Chief Executive Officer Charles J. Link, Jr., and the Company’s Chief Medical Officer and President Nicholas Vahanian, or collectively, the Defendants.  The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company’s investors. In particular, the lead plaintiffs allege that the Defendants made material
misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L. The lead plaintiffs did not quantify any alleged damages in the amended complaint but, in addition to attorneys’ fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company’s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the amended complaint on July 14, 2017. The lead plaintiffs filed an opposition to the motion to dismiss on September 12, 2017. The Defendants filed a reply in support of the motion to dismiss on September 26, 2017. Oral argument was held on October 19, 2017, after which the Court reserved decision. On March 29, 2018, the Court dismissed the amended complaint for failure to state a claim, without prejudice, and gave the lead plaintiffs until May 4, 2018 to file any amended complaint attempting to remedy the defects in their claims.  On May 4, 2018, the lead plaintiffs filed a second amended complaint asserting claims under the federal securities laws against the Defendants. Like the first amended complaint, the second amended complaint alleges that the Defendants made material false and/or misleading statements or omissions relating to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L that caused losses to the Company’s investors. The lead plaintiffs did not quantify any alleged damages in the second amended complaint but, in addition to attorneys’ fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company’s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the second amended complaint on July 31, 2018. The lead plaintiffs filed an opposition to the motion to dismiss the second amended complaint on September 14, 2018. The Defendants filed a reply in support of the motion to dismiss the second amended complaint on October 9, 2018. Oral argument was held on October 19, 2018, after which the Court reserved decision. The Company intends to continue defending the Securities Action vigorously.

On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company’s Chief Executive Officer Charles J. Link, Jr., the Company’s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth, or collectively, the Morrow Defendants, captioned Morrow v. Link., et al., Case 1:17-cv-03039, or the Morrow Action.  The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation of federal securities law.  The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.  The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company’s shareholders.  The language for such proposals is not specified in the complaint.  The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.  On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.  Also on May 19, 2017, plaintiffs’ counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.  The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.  By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise finally resolved.  Under the terms of the stay, the plaintiff in the Ely Action will be provided with any discovery that is provided in the Securities Action, and given an opportunity to participate in any mediation or settlement efforts in the Securities Action.  The Company disputes the claims in the Ely Action and intends to defend against them vigorously.
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Use of Estimates
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Principles of Consolidation
Principles of Consolidation
The condensed consolidated financial statements include the financial statements of NewLink and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Financial Instruments Financial Instruments and Concentrations of Credit RiskCash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable and capital lease obligations was $133,000 and $271,000 as of September 30, 2018 and December 31, 2017, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain.
Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.
Property and equipment Property and equipmentProperty and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of $7.1 million and $6.6 million as of September 30, 2018 and December 31, 2017, respectively. Equipment under capital leases is stated at the present value of minimum lease payments. Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of three to five years, lab equipment has a useful life of five years and contract manufacturing organization equipment has a useful life of five years.
Recent Accounting Pronouncements
Recently Issued Accounting Pronouncements not yet adopted 
In February 2016, the Financial Accounting Standards Board, or the FASB, issued ASU No. 2016-02, Leases, to improve financial reporting for leasing transactions. The new standard requires lessees to recognize on the balance sheet a right of use asset and related lease liability for all leases with terms greater than twelve months. The ASU also requires disclosures about the amount, timing, and uncertainty of cash flows arising from leases. The effective date for public entities is fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted for all entities. The Company does not currently have any material leases and therefore does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures.
Recently Adopted Accounting Pronouncements

On May 28, 2014, the FASB issued ASU No. 2014-09 (Topic 606), Revenue from Contracts with Customers. Topic 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (Topic 605), and requires entities to recognize revenue when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted Topic 606 as of January 1, 2018 and as a result changed its accounting policy for revenue recognition, as discussed in Note 4.
Revenue Recognition Revenue Recognition Revenues are recognized under Topic 606 when control of the promised goods or services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company receives payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services, or HHS. These agreements provide the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues are recognized over time and measured using the input method. The Company uses labor costs and subcontractor fees as inputs to measure progress towards satisfying its performance obligations under these agreements. This is the most faithful depiction of the transfer of goods and services to the government entities due to the government entities’ control over the research and development activities. Under this method, the Company recognizes revenue generally in the period during which the related costs are incurred, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenues (Tables)
 9 Months Ended
Sep. 30, 2018
Revenue from Contract with Customer [Abstract]  
Schedule of New Accounting Pronouncements As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to accounts on the Condensed Consolidated Balance Sheet as of January 1, 2018 (in thousands):
As Reported December 31, 2017 Adjustments Adjusted January 1, 2018 
Balance Sheet 
Assets: 
Prepaid expenses and other current assets $6,226 $(464)$5,762 
Other receivables $10,176 $506 $10,682 
Total assets $180,697 $42 $180,739 
Equity: 
Accumulated deficit $(237,459)$42 $(237,417)
Total liabilities and stockholders' equity $180,697 $42 $180,739 

The impact of adoption on the Company’s Condensed Consolidated Statement of Operating Loss for the three and nine months ended September 30, 2018 was as follows (in thousands):

Three Months Ended September 30, Nine Months Ended September 30, 
As Reported
Adjustments
Balance without Adoption of Topic 606
As Reported
Adjustments
Balance without Adoption of Topic 606
Statement of Operating Loss
Grant Revenues
$— $— $— $11,268 $346 $11,614 
Licensing and collaboration revenue $120 $18 $138 $1,004 $164 $1,168 
Research and Development $7,570 $18 $7,588 $39,972 $468 $40,440 
Net Loss $(7,403)$— $(7,403)$(43,026)$42 $(42,984)

The impact of adoption on the Company’s Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2018 was as follows (in thousands):
As Reported
Adjustments
Balance without Adoption of Topic 606
Statement of Cash Flows
Net Loss
$(43,026)$42 $(42,984)
Changes in operating assets and liabilities:
Other receivables
$9,982 $(492)$9,490 
Accounts payable and accrued expenses
$(11,749)$450 $(11,299)
Net cash used in operating activities
$(36,622)$— $(36,622)
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Equity Incentive Plan (Tables)
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Authorized Increases of Common Stock under the 2009 Plan The following table summarizes the authorized increases of common stock under the 2009 Plan:
Stock Option Activity The following table summarizes the stock option activity, including options with market and performance conditions, for the nine months ended September 30, 2018:
Assumptions Used in Black-Scholes Pricing Model for New Grants The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the nine months ended September 30, 2018:
Restricted Stock Activity A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at September 30, 2018 and changes during the nine months ended September 30, 2018 are as follows:
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss per Common Share (Tables)
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Basic and Diluted Net Loss per Common Share The following table presents the computation of basic and diluted loss per common share (in thousands, except share and per share data):
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring Charges (Tables)
 9 Months Ended
Sep. 30, 2018
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs The following table shows the amount accrued for restructuring activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet (in thousands):
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Description of Business (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 30, 2018
Mar. 12, 2018
Oct. 31, 2017
Dec. 31, 2017
Dec. 31, 2015
Dec. 31, 2013
Dec. 31, 2011
Financings              
Maximum available under ATM offering   $ 60,000          
IPO              
Financings              
FInancing proceeds             $ 37,600
Follow-on Offering              
Financings              
FInancing proceeds           $ 49,000  
ATM Offering              
Financings              
FInancing proceeds       $ 19,300 $ 58,700    
Number of shares of common stock sold 0     1,940,656      
Commissions paid       $ 398      
Other costs       $ 163      
Public Offering              
Financings              
FInancing proceeds     $ 55,200        
Number of shares issued     5,750,000        
Fees and commissions     $ 3,700        
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Dec. 31, 2017
Accounting Policies [Abstract]    
Fair Value Disclosure of notes payable and capital lease obligations $ 133 $ 271
Accumulated depreciation $ 7,100 $ 6,600
Computer Equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Useful life 3 years  
Computer Equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Useful life 5 years  
Lab Equipment    
Property, Plant and Equipment [Line Items]    
Useful life 5 years  
Contract Manufacturing Organization Equipment    
Property, Plant and Equipment [Line Items]    
Useful life 5 years  
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenues (Narrative) (Details) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]    
Government contract receivable $ 320,000 $ 9,300,000
Accrued expenses for subcontractor fees 81,000 1,800,000
Prepaid Expenses and Other Current Assets    
Disaggregation of Revenue [Line Items]    
Unbilled contracts receivable $ 0 $ 465,000
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenues (Effects of New Accounting Pronouncements) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Jan. 01, 2018
Dec. 31, 2017
Assets:            
Prepaid expenses and other current assets $ 4,920   $ 4,920   $ 5,762 $ 6,226
Other receivables 700   700   10,682 10,176
Total assets 139,315   139,315   180,739 180,697
Stockholders' equity:            
Accumulated deficit (280,443)   (280,443)   (237,417) (237,459)
Total liabilities and stockholders' equity 139,315   139,315   180,739 180,697
Research and development 7,570 $ 18,480 39,972 $ 52,405    
Net loss (7,403) (20,626) (43,026) (58,265)    
Other receivables     9,982 13,856    
Accounts payable and accrued expenses     (11,749) (11,500)    
Net cash used in operating activities     (36,622) (31,070)    
Balance without Adoption of Topic 606            
Stockholders' equity:            
Research and development 7,588   40,440      
Net loss (7,403)   (42,984)      
Other receivables     9,490      
Accounts payable and accrued expenses     (11,299)      
Net cash used in operating activities     (36,622)      
Adjustments            
Assets:            
Prepaid expenses and other current assets         (464)  
Other receivables           506
Total assets           $ 42
Stockholders' equity:            
Accumulated deficit         42  
Total liabilities and stockholders' equity         $ 42  
Adjustments | Accounting Standards Update 2014-09            
Stockholders' equity:            
Research and development 18   468      
Net loss 0   42      
Other receivables     (492)      
Accounts payable and accrued expenses     450      
Net cash used in operating activities     0      
Grant revenue            
Stockholders' equity:            
Revenues 0 5,379 11,268 18,279    
Grant revenue | Balance without Adoption of Topic 606            
Stockholders' equity:            
Revenues 0   11,614      
Grant revenue | Adjustments | Accounting Standards Update 2014-09            
Stockholders' equity:            
Revenues 0   346      
License and collaboration revenue            
Stockholders' equity:            
Revenues 120 $ 103 1,004 334    
License and collaboration revenue | Balance without Adoption of Topic 606            
Stockholders' equity:            
Revenues 138   $ 1,168      
License and collaboration revenue | Adjustments | Accounting Standards Update 2014-09            
Stockholders' equity:            
Revenues $ 18     $ 164    
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
License and Research Collaboration Agreements (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2015
Dec. 31, 2014
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2014
License and collaboration revenue              
Deferred Revenue Arrangement [Line Items]              
Grant revenue     $ 120 $ 103 $ 1,004 $ 334  
License and Collaborative Arrangement | Genentech              
Deferred Revenue Arrangement [Line Items]              
Upfront cash payments             $ 150,000
Alliance manager     0 56 56 279  
License and Collaborative Arrangement | Merck              
Deferred Revenue Arrangement [Line Items]              
Upfront cash payments $ 20,000 $ 30,000          
License and Collaborative Arrangement | Merck | License and collaboration revenue              
Deferred Revenue Arrangement [Line Items]              
Grant revenue     $ 120 $ 48 $ 949 $ 55  
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Equity Incentive Plan (Narrative) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jan. 01, 2018
Jan. 01, 2017
Jan. 01, 2016
Jan. 01, 2015
Jan. 01, 2014
May 09, 2013
Jan. 01, 2013
Jan. 07, 2011
May 15, 2010
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Nov. 10, 2011
Share-based Compensation Arrangement by Share-based Payment Award                            
Share-based compensation expense                   $ 4,600,000 $ 4,400,000 $ 13,600,000 $ 14,900,000  
Granted (in shares)                       0    
Options exercisable at end of period (in shares)                       72,447    
2009 Equity Incentive Plan                            
Share-based Compensation Arrangement by Share-based Payment Award                            
Number of shares authorized                   11,722,602   11,722,602    
Number of shares remained available for issuance                   1,489,402   1,489,402    
Increase in number of shares authorized 1,484,382 1,166,546 1,152,565 1,119,255 1,066,340   838,375 714,286 1,238,095          
Evergreen increase (percent)                       4.00%    
2010 Non-Employee Directors' Stock Option Plan                            
Share-based Compensation Arrangement by Share-based Payment Award                            
Number of shares authorized                           238,095
Number of shares remained available for issuance                   0   0    
Increase in number of shares authorized           161,905                
2010 Employee Stock Purchase Plan                            
Share-based Compensation Arrangement by Share-based Payment Award                            
Number of shares authorized                           214,285
Number of shares remained available for issuance                   69,885   69,885    
Increase in number of shares authorized           185,715                
Stock Option                            
Share-based Compensation Arrangement by Share-based Payment Award                            
Total compensation cost related to non-vested option awards                   $ 11,800,000   $ 11,800,000    
Weighted average vesting period for non-vested option awards, in years                       2 years 1 month 6 days    
Intrinsic value of options exercised                       $ 77,788    
Fair value of awards vested                       $ 10,200,000    
Performance Stock                            
Share-based Compensation Arrangement by Share-based Payment Award                            
Granted (in shares)                       466,750    
Weighted average grant-date fair value per share (in dollars per share)                       $ 5.33    
Options exercisable at end of period (in shares)                       213,725    
Restricted Stock                            
Share-based Compensation Arrangement by Share-based Payment Award                            
Weighted average vesting period for non-vested option awards, in years                       1 year    
Weighted average grant-date fair value per share (in dollars per share)                       $ 0    
Unrecognized compensation cost                   $ 1,600,000   $ 1,600,000    
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details) - shares
Jan. 01, 2018
Jan. 01, 2017
Jan. 01, 2016
Jan. 01, 2015
Jan. 01, 2014
Jan. 01, 2013
Jan. 07, 2011
May 15, 2010
2009 Equity Incentive Plan                
Share-based Compensation Arrangement by Share-based Payment Award                
Authorized Shares Added 1,484,382 1,166,546 1,152,565 1,119,255 1,066,340 838,375 714,286 1,238,095
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Equity Incentive Plan (Stock Option Activity) (Details) - Stock Option - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2018
Dec. 31, 2017
Number of options    
Outstanding at beginning of period (in shares) 7,202,221  
Options granted (in shares) 1,632,523  
Options exercised (in shares) (32,946)  
Options forfeited (in shares) (317,359)  
Options expired (in shares) (118,097)  
Outstanding at end of period (in shares) 8,371,005 7,202,221
Weighted average exercise price    
Outstanding, weighted average exercise price at beginning of period (in dollars per share) $ 13.72  
Granted, weighted average exercise price (in dollars per share) 6.92  
Exercised, weighted average exercise price (in dollars per share) 4.24  
Forfeitured, weighted average exercise price (in dollars per share) 13.59  
Expired, weighted average exercise price (in dollars per share) 21.96  
Outstanding, weighted average exercise price at end of period (in dollars per share) $ 12.32 $ 13.72
Options exercisable at end of period (in shares) 6,264,767  
Exercisable, weighted average exercise price (in dollars per share) $ 13.03  
Outstanding, weighted average remaining contractual term, in years 5 years 1 month 6 days 5 years 3 months 18 days
Exercisable, weighted average remaining contractual term, in years 3 years 9 months 18 days  
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details) - Stock Option
 9 Months Ended
Sep. 30, 2018
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award  
Risk-free interest rate, minimum (percent) 2.60%
Risk free interest rate, maximum (percent) 2.90%
Expected dividend rate (percent) 0.00%
Volatility rate, minimum (percent) 76.20%
Volatility rate, maximum (percent) 79.20%
Weighted average grant-date fair value per share (in dollars per share) $ 4.90
Minimum  
Share-based Compensation Arrangement by Share-based Payment Award  
Expected Term (in years) 4 years
Maximum  
Share-based Compensation Arrangement by Share-based Payment Award  
Expected Term (in years) 7 years 10 months 24 days
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)
 9 Months Ended
Sep. 30, 2018
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]  
Granted (in shares) | shares 0
Vested (in shares) | shares (72,447)
Forfeited / cancelled (in shares) | shares (6,721)
Restricted Stock  
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]  
Unvested at beginning of period (in shares) | shares 168,221
Unvested at end of period (in shares) | shares 89,053
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Weighted average grant date fair value at beginning of period (in dollars per share) | $ / shares $ 35.82
Weighted average grant-date fair value per share (in dollars per share) | $ / shares 0
Vested, weighted average grant date fair value (in dollars per share) | $ / shares 35.40
Forfeited/cancelled, weighted average grant date fair value (in dollars per share) | $ / shares 40.99
Weighted average grant date fair value at end of period (in dollars per share) | $ / shares $ 35.76
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Tax Disclosure [Abstract]        
Income tax benefit $ 6,991,000 $ 119,000 $ 6,991,000 $ 429,000
Income tax benefit from Tax Act     (140,000)  
Uncertain tax positions $ 653,000   $ 653,000  
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss per Common Share (Net Loss Per Share Computation) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Earnings Per Share [Abstract]        
Loss attributable to common stockholders $ (7,403) $ (20,626) $ (43,026) $ (58,265)
Basic and diluted weighted-average shares (in shares) 37,214,363 29,939,823 37,178,542 29,462,226
Basic and diluted loss per share (in dollars per share) $ (0.20) $ (0.69) $ (1.16) $ (1.98)
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss per Common Share (Antidilutive Securities) (Details) - shares
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Stock Option    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 8,371,005 7,314,006
Restricted Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 89,053 181,336
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring Charges (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 31, 2018
Jul. 31, 2017
Sep. 30, 2018
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Restructuring Charges            
Percentage reduction in force 30.00% 50.00%        
Restructuring Reserve [Roll Forward]            
Balance at beginning of period       $ 207    
Expensed     $ 1,300 1,323   $ 1,700
Cash Payments       511    
Balance at end of period     1,019 1,019   207
General and Administrative Expense            
Restructuring Reserve [Roll Forward]            
Expensed     800 800 $ 1,100  
Research and Development Expense            
Restructuring Reserve [Roll Forward]            
Expensed     500 500 $ 600  
Employee Severance Cost            
Restructuring Reserve [Roll Forward]            
Balance at beginning of period       207    
Expensed       1,323    
Cash Payments       511    
Balance at end of period     $ 1,019 $ 1,019   $ 207
EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 110 175 1 false 33 0 false 4 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://www.linkp.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.linkp.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statement of Stockholders' Equity Sheet http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101101 - Disclosure - Description of Business Sheet http://www.linkp.com/role/DescriptionofBusiness Description of Business Notes 7 false false R8.htm 2103102 - Disclosure - Basis of Presentation Sheet http://www.linkp.com/role/BasisofPresentation Basis of Presentation Notes 8 false false R9.htm 2104103 - Disclosure - Significant Accounting Policies Sheet http://www.linkp.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 2107104 - Disclosure - Revenues Sheet http://www.linkp.com/role/Revenues Revenues Notes 10 false false R11.htm 2111105 - Disclosure - License and Research Collaboration Agreements Sheet http://www.linkp.com/role/LicenseandResearchCollaborationAgreements License and Research Collaboration Agreements Notes 11 false false R12.htm 2113106 - Disclosure - Common Stock Equity Incentive Plan Sheet http://www.linkp.com/role/CommonStockEquityIncentivePlan Common Stock Equity Incentive Plan Notes 12 false false R13.htm 2120107 - Disclosure - Income Taxes Sheet http://www.linkp.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 2122108 - Disclosure - Net Loss per Common Share Sheet http://www.linkp.com/role/NetLossperCommonShare Net Loss per Common Share Notes 14 false false R15.htm 2126109 - Disclosure - Restructuring Charges Sheet http://www.linkp.com/role/RestructuringCharges Restructuring Charges Notes 15 false false R16.htm 2129110 - Disclosure - Commitments and Contingencies Sheet http://www.linkp.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 2205201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.linkp.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.linkp.com/role/SignificantAccountingPolicies 17 false false R18.htm 2308301 - Disclosure - Revenues (Tables) Sheet http://www.linkp.com/role/RevenuesTables Revenues (Tables) Tables http://www.linkp.com/role/Revenues 18 false false R19.htm 2314302 - Disclosure - Common Stock Equity Incentive Plan (Tables) Sheet http://www.linkp.com/role/CommonStockEquityIncentivePlanTables Common Stock Equity Incentive Plan (Tables) Tables http://www.linkp.com/role/CommonStockEquityIncentivePlan 19 false false R20.htm 2323303 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.linkp.com/role/NetLossperCommonShareTables Net Loss per Common Share (Tables) Tables http://www.linkp.com/role/NetLossperCommonShare 20 false false R21.htm 2327304 - Disclosure - Restructuring Charges (Tables) Sheet http://www.linkp.com/role/RestructuringChargesTables Restructuring Charges (Tables) Tables http://www.linkp.com/role/RestructuringCharges 21 false false R22.htm 2402401 - Disclosure - Description of Business (Details) Sheet http://www.linkp.com/role/DescriptionofBusinessDetails Description of Business (Details) Details http://www.linkp.com/role/DescriptionofBusiness 22 false false R23.htm 2406402 - Disclosure - Significant Accounting Policies (Details) Sheet http://www.linkp.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://www.linkp.com/role/SignificantAccountingPoliciesPolicies 23 false false R24.htm 2409403 - Disclosure - Revenues (Narrative) (Details) Sheet http://www.linkp.com/role/RevenuesNarrativeDetails Revenues (Narrative) (Details) Details http://www.linkp.com/role/RevenuesTables 24 false false R25.htm 2410404 - Disclosure - Revenues (Effects of New Accounting Pronouncements) (Details) Sheet http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails Revenues (Effects of New Accounting Pronouncements) (Details) Details http://www.linkp.com/role/RevenuesTables 25 false false R26.htm 2412405 - Disclosure - License and Research Collaboration Agreements (Details) Sheet http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails License and Research Collaboration Agreements (Details) Details http://www.linkp.com/role/LicenseandResearchCollaborationAgreements 26 false false R27.htm 2415406 - Disclosure - Common Stock Equity Incentive Plan (Narrative) (Details) Sheet http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails Common Stock Equity Incentive Plan (Narrative) (Details) Details http://www.linkp.com/role/CommonStockEquityIncentivePlanTables 27 false false R28.htm 2416407 - Disclosure - Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details) Sheet http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details) Details http://www.linkp.com/role/CommonStockEquityIncentivePlanTables 28 false false R29.htm 2417408 - Disclosure - Common Stock Equity Incentive Plan (Stock Option Activity) (Details) Sheet http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails Common Stock Equity Incentive Plan (Stock Option Activity) (Details) Details http://www.linkp.com/role/CommonStockEquityIncentivePlanTables 29 false false R30.htm 2418409 - Disclosure - Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details) Sheet http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details) Details http://www.linkp.com/role/CommonStockEquityIncentivePlanTables 30 false false R31.htm 2419410 - Disclosure - Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details) Sheet http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details) Details http://www.linkp.com/role/CommonStockEquityIncentivePlanTables 31 false false R32.htm 2421411 - Disclosure - Income Taxes (Details) Sheet http://www.linkp.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.linkp.com/role/IncomeTaxes 32 false false R33.htm 2424412 - Disclosure - Net Loss per Common Share (Net Loss Per Share Computation) (Details) Sheet http://www.linkp.com/role/NetLossperCommonShareNetLossPerShareComputationDetails Net Loss per Common Share (Net Loss Per Share Computation) (Details) Details http://www.linkp.com/role/NetLossperCommonShareTables 33 false false R34.htm 2425413 - Disclosure - Net Loss per Common Share (Antidilutive Securities) (Details) Sheet http://www.linkp.com/role/NetLossperCommonShareAntidilutiveSecuritiesDetails Net Loss per Common Share (Antidilutive Securities) (Details) Details http://www.linkp.com/role/NetLossperCommonShareTables 34 false false R35.htm 2428414 - Disclosure - Restructuring Charges (Details) Sheet http://www.linkp.com/role/RestructuringChargesDetails Restructuring Charges (Details) Details http://www.linkp.com/role/RestructuringChargesTables 35 false false All Reports Book All Reports nlnk-20180930.htm nlnk-20180930.xsd nlnk-20180930_cal.xml nlnk-20180930_def.xml nlnk-20180930_lab.xml nlnk-20180930_pre.xml nlnk-2018930x10qxex101.htm nlnk-2018930x10qxex102.htm nlnk-2018930x10qxex103.htm nlnk-2018930x10qxex104.htm nlnk-2018930x10qxex105.htm nlnk-2018930x10qxex311.htm nlnk-2018930x10qxex312.htm nlnk-2018930x10qxex321.htm http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nlnk-20180930.htm": { "axisCustom": 0, "axisStandard": 15, "contextCount": 110, "dts": { "calculationLink": { "local": [ "nlnk-20180930_cal.xml" ] }, "definitionLink": { "local": [ "nlnk-20180930_def.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml" ] }, "inline": { "local": [ "nlnk-20180930.htm" ] }, "labelLink": { "local": [ "nlnk-20180930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "nlnk-20180930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "nlnk-20180930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" ] } }, "elementCount": 286, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 38, "http://xbrl.sec.gov/dei/2018-01-31": 12, "total": 50 }, "keyCustom": 6, "keyStandard": 169, "memberCustom": 9, "memberStandard": 22, "nsprefix": "nlnk", "nsuri": "http://www.linkp.com/20180930", "report": { "R1": { "firstAnchor": null, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://www.linkp.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": null }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107104 - Disclosure - Revenues", "role": "http://www.linkp.com/role/Revenues", "shortName": "Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111105 - Disclosure - License and Research Collaboration Agreements", "role": "http://www.linkp.com/role/LicenseandResearchCollaborationAgreements", "shortName": "License and Research Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113106 - Disclosure - Common Stock Equity Incentive Plan", "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlan", "shortName": "Common Stock Equity Incentive Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120107 - Disclosure - Income Taxes", "role": "http://www.linkp.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122108 - Disclosure - Net Loss per Common Share", "role": "http://www.linkp.com/role/NetLossperCommonShare", "shortName": "Net Loss per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126109 - Disclosure - Restructuring Charges", "role": "http://www.linkp.com/role/RestructuringCharges", "shortName": "Restructuring Charges", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129110 - Disclosure - Commitments and Contingencies", "role": "http://www.linkp.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2205201 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Revenues (Tables)", "role": "http://www.linkp.com/role/RevenuesTables", "shortName": "Revenues (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314302 - Disclosure - Common Stock Equity Incentive Plan (Tables)", "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanTables", "shortName": "Common Stock Equity Incentive Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i22c14dc2a6aa417f8ebdb91ca8430f36_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i22c14dc2a6aa417f8ebdb91ca8430f36_I20180930", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeTaxesReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323303 - Disclosure - Net Loss per Common Share (Tables)", "role": "http://www.linkp.com/role/NetLossperCommonShareTables", "shortName": "Net Loss per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327304 - Disclosure - Restructuring Charges (Tables)", "role": "http://www.linkp.com/role/RestructuringChargesTables", "shortName": "Restructuring Charges (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "iee5016500ace4971b6e19786913d254d_D20180312-20180312", "decimals": "-5", "first": true, "lang": null, "name": "nlnk:MaximumAvailableUnderATMOffering", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Description of Business (Details)", "role": "http://www.linkp.com/role/DescriptionofBusinessDetails", "shortName": "Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "iee5016500ace4971b6e19786913d254d_D20180312-20180312", "decimals": "-5", "first": true, "lang": null, "name": "nlnk:MaximumAvailableUnderATMOffering", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i22c14dc2a6aa417f8ebdb91ca8430f36_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Significant Accounting Policies (Details)", "role": "http://www.linkp.com/role/SignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i22c14dc2a6aa417f8ebdb91ca8430f36_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "contextRef": "i22c14dc2a6aa417f8ebdb91ca8430f36_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GovernmentContractReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Revenues (Narrative) (Details)", "role": "http://www.linkp.com/role/RevenuesNarrativeDetails", "shortName": "Revenues (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "contextRef": "i22c14dc2a6aa417f8ebdb91ca8430f36_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GovernmentContractReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i22c14dc2a6aa417f8ebdb91ca8430f36_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Revenues (Effects of New Accounting Pronouncements) (Details)", "role": "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails", "shortName": "Revenues (Effects of New Accounting Pronouncements) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "ic311cc9110a54eb3a2e75218fb884cbb_I20180101", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i35097d095c5047cbbc42920aabc376d4_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - License and Research Collaboration Agreements (Details)", "role": "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails", "shortName": "License and Research Collaboration Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "idd59aab77d76435cbbfe62e039c5953b_D20140101-20141231", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i7d0ed0cd01ea4c659f583c1adf3c1da4_D20180701-20180930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Common Stock Equity Incentive Plan (Narrative) (Details)", "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "shortName": "Common Stock Equity Incentive Plan (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i7d0ed0cd01ea4c659f583c1adf3c1da4_D20180701-20180930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "contextRef": "i09f1a5d848f14ed0bfafd2a8df609090_D20180101-20180101", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details)", "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails", "shortName": "Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "contextRef": "ic26ca64bd56741b1b079c865d7f230ae_I20171231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - Common Stock Equity Incentive Plan (Stock Option Activity) (Details)", "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails", "shortName": "Common Stock Equity Incentive Plan (Stock Option Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "contextRef": "i33c6b7fb51ec4913b2da783c3944191f_D20180101-20180930", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "role": "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details)", "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails", "shortName": "Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)", "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails", "shortName": "Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i7d0ed0cd01ea4c659f583c1adf3c1da4_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Income Taxes (Details)", "role": "http://www.linkp.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": "0", "lang": null, "name": "nlnk:TaxCutsandJobsActof2017IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i7d0ed0cd01ea4c659f583c1adf3c1da4_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424412 - Disclosure - Net Loss per Common Share (Net Loss Per Share Computation) (Details)", "role": "http://www.linkp.com/role/NetLossperCommonShareNetLossPerShareComputationDetails", "shortName": "Net Loss per Common Share (Net Loss Per Share Computation) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "contextRef": "ib132481d6a8648f294033a9d2649c54a_D20170101-20170930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425413 - Disclosure - Net Loss per Common Share (Antidilutive Securities) (Details)", "role": "http://www.linkp.com/role/NetLossperCommonShareAntidilutiveSecuritiesDetails", "shortName": "Net Loss per Common Share (Antidilutive Securities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "contextRef": "ib132481d6a8648f294033a9d2649c54a_D20170101-20170930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i64c73651bfc448bb9734aa3676e06dbc_D20180701-20180731", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428414 - Disclosure - Restructuring Charges (Details)", "role": "http://www.linkp.com/role/RestructuringChargesDetails", "shortName": "Restructuring Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i64c73651bfc448bb9734aa3676e06dbc_D20180701-20180731", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i7d0ed0cd01ea4c659f583c1adf3c1da4_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i7d0ed0cd01ea4c659f583c1adf3c1da4_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ia6cf8082800e4fed952e9695c576b60b_I20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statement of Stockholders' Equity", "role": "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity", "shortName": "Condensed Consolidated Statement of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ic0d1e12c7ac8448895ac289ffd70a5c5_I20171231", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Description of Business", "role": "http://www.linkp.com/role/DescriptionofBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Basis of Presentation", "role": "http://www.linkp.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104103 - Disclosure - Significant Accounting Policies", "role": "http://www.linkp.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "ic769bca855e54102b774a350e532101c_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 33, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.linkp.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "nlnk_A2009EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "A2009EquityIncentivePlanMember", "terseLabel": "2009 Equity Incentive Plan" } } }, "localname": "A2009EquityIncentivePlanMember", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "nlnk_A2010EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "A2010EmployeeStockPurchasePlanMember", "terseLabel": "2010 Employee Stock Purchase Plan" } } }, "localname": "A2010EmployeeStockPurchasePlanMember", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "A2010NonEmployeeDirectorsStockOptionPlanMember", "terseLabel": "2010 Non-Employee Directors' Stock Option Plan" } } }, "localname": "A2010NonEmployeeDirectorsStockOptionPlanMember", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "nlnk_ATMOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ATMOfferingMember", "terseLabel": "ATM Offering" } } }, "localname": "ATMOfferingMember", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "nlnk_ContractManufacturingOrganizationEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ContractManufacturingOrganizationEquipmentMember", "terseLabel": "Contract Manufacturing Organization Equipment" } } }, "localname": "ContractManufacturingOrganizationEquipmentMember", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nlnk_DeferredGovernmentGrantsObligationsNoncurrent": { "auth_ref": [], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "label": "DeferredGovernmentGrantsObligationsNoncurrent", "terseLabel": "Royalty obligation payable to Iowa Economic Development Authority" } } }, "localname": "DeferredGovernmentGrantsObligationsNoncurrent", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "nlnk_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.linkp.com/20180930", "xbrltype": "stringItemType" }, "nlnk_FinancingsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Financings [Table]", "label": "Financings [Line Items]", "terseLabel": "Financings" } } }, "localname": "FinancingsLineItems", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "nlnk_FinancingsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financings [Table]", "label": "Financings [Table]", "terseLabel": "Schedule of Financing Rounds" } } }, "localname": "FinancingsTable", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "nlnk_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "FollowOnOfferingMember", "terseLabel": "Follow-on Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "nlnk_GenentechInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "GenentechInc.Member", "terseLabel": "Genentech" } } }, "localname": "GenentechInc.Member", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails" ], "xbrltype": "domainItemType" }, "nlnk_GovernmentContractAccruedSubcontractorFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "GovernmentContractAccruedSubcontractorFees", "terseLabel": "Accrued expenses for subcontractor fees" } } }, "localname": "GovernmentContractAccruedSubcontractorFees", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/RevenuesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nlnk_LicenseRevenueManagerLabor": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "LicenseRevenueManagerLabor", "terseLabel": "Alliance manager" } } }, "localname": "LicenseRevenueManagerLabor", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "nlnk_MaximumAvailableUnderATMOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "MaximumAvailableUnderATMOffering", "terseLabel": "Maximum available under ATM offering" } } }, "localname": "MaximumAvailableUnderATMOffering", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "nlnk_MerckSharpeandDohmeCorpMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "MerckSharpeandDohmeCorpMember", "terseLabel": "Merck" } } }, "localname": "MerckSharpeandDohmeCorpMember", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails" ], "xbrltype": "domainItemType" }, "nlnk_PublicOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "PublicOfferingMember", "terseLabel": "Public Offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "nlnk_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum", "terseLabel": "Evergreen increase (percent)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageofAuthorizedStockMaximum", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "percentItemType" }, "nlnk_TaxCutsandJobsActof2017IncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "TaxCutsandJobsActof2017IncomeTaxExpenseBenefit", "negatedLabel": "Income tax benefit from Tax Act" } } }, "localname": "TaxCutsandJobsActof2017IncomeTaxExpenseBenefit", "nsuri": "http://www.linkp.com/20180930", "presentation": [ "http://www.linkp.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r38", "r68" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "verboseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails", "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails", "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r100", "r125", "r126", "r193" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations", "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations", "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]", "verboseLabel": "Range" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails", "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]", "verboseLabel": "Range" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails", "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r28", "r103" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r70" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of adjustment to stockholders' equity associated with an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.", "label": "Adjustments Related to Tax Withholding for Share-based Compensation", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r130", "r132", "r158", "r159" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r132", "r153", "r157" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r76" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/NetLossperCommonShareAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r76" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/NetLossperCommonShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/NetLossperCommonShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r76" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/NetLossperCommonShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.", "label": "Arrangements and Non-arrangement Transactions [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r98", "r178", "r186" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r1", "r2", "r37" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r7", "r8", "r9", "r10", "r11", "r12", "r13", "r14" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r133", "r155" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r169", "r170" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r69" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Calculated under guidance for revenue recognition in effect prior to change to new guidance for revenue from contract with customer when using transition method for cumulative effect in period including initial date of application.", "label": "Calculated under Revenue Guidance in Effect before Topic 606 [Member]", "terseLabel": "Balance without Adoption of Topic 606" } } }, "localname": "CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r26", "r62" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets", "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "terseLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "License and Research Collaboration Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "License and Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r116", "r117" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies Disclosure" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized shares" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued shares" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r118" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance at end of period (shares)", "periodStartLabel": "Balance at beginning of period (shares)", "verboseLabel": "Common stock, outstanding shares" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals", "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r18" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, $0.01 par value: Authorized shares \u2014 75,000,000 at September 30, 2018 and December 31, 2017; issued 37,305,626 and 37,168,122 at September 30, 2018 and December 31, 2017, respectively, and outstanding 37,216,892 and 37,109,556 at September 30, 2018 and December 31, 2017, respectively" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r85", "r184" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r65", "r166", "r167", "r168" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1": { "auth_ref": [ "r74" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the cumulative effect on retained earnings net of related income tax effect.", "label": "Cumulative Effect on Retained Earnings, Net of Tax", "terseLabel": "Cumulative effect of accounting change" } } }, "localname": "CumulativeEffectOnRetainedEarningsNetOfTax1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCreditCurrent": { "auth_ref": [ "r31", "r175" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.", "label": "Deferred Rent Credit, Current", "terseLabel": "Current portion of deferred rent" } } }, "localname": "DeferredRentCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCreditNoncurrent": { "auth_ref": [ "r33", "r175" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.", "label": "Deferred Rent Credit, Noncurrent", "terseLabel": "Deferred rent" } } }, "localname": "DeferredRentCreditNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementByTypeTable": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Deferred Revenue Arrangement, by Type [Table]", "terseLabel": "Deferred Revenue Arrangement, by Type [Table]" } } }, "localname": "DeferredRevenueArrangementByTypeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Revenue Arrangement [Line Items]", "terseLabel": "Deferred Revenue Arrangement [Line Items]" } } }, "localname": "DeferredRevenueArrangementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r3" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.", "label": "Deferred Revenue, Current", "terseLabel": "Current portion of unearned revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r60", "r96" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Adjustments" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails", "http://www.linkp.com/role/RevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails", "http://www.linkp.com/role/RevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r122", "r160" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Common Stock Equity Incentive Plan" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r133", "r155" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Authorized Increases of Common Stock under the 2009 Plan" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r75" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted loss per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations", "http://www.linkp.com/role/NetLossperCommonShareNetLossPerShareComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/NetLossperCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average vesting period for non-vested option awards, in years" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r154" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r154" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested options awarded to employees as compensation.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Total compensation cost related to non-vested option awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Severance Cost" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails", "http://www.linkp.com/role/NetLossperCommonShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Lab Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r65", "r171", "r172" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "(Gain) Loss on sale of fixed assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GovernmentContractReceivable": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of receivables that are derived from government contracts.", "label": "Government Contract Receivable", "verboseLabel": "Government contract receivable" } } }, "localname": "GovernmentContractReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GovernmentContractReceivableUnbilledAmounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unbilled amounts (net of unliquidated progress payments) of government contract receivables.", "label": "Government Contract Receivable, Unbilled Amounts", "terseLabel": "Unbilled contracts receivable" } } }, "localname": "GovernmentContractReceivableUnbilledAmounts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]", "terseLabel": "Grant revenue" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r42", "r71", "r177", "r181", "r192" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r105" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r67", "r97", "r162" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations", "http://www.linkp.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash refunds received for taxes, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r36", "r180", "r190" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income tax receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivableNoncurrent": { "auth_ref": [ "r14", "r185" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Noncurrent", "terseLabel": "Income tax receivable" } } }, "localname": "IncomeTaxesReceivableNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r59" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes receivable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCharges": { "auth_ref": [ "r59" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.", "label": "Increase (Decrease) in Deferred Charges", "negatedLabel": "Deferred rent" } } }, "localname": "IncreaseDecreaseInDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r59" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Unearned revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r59" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Increase (Decrease) in Other Receivables", "negatedTerseLabel": "Other receivables" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r59" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r41", "r95", "r173", "r174", "r183" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r47", "r94" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r30" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r179", "r188" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "terseLabel": "Total liabilities and stockholders' equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r4", "r5", "r6", "r15", "r16" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUncertainTaxPositionsCurrent": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for uncertainty in income taxes classified as current.", "label": "Liability for Uncertainty in Income Taxes, Current", "terseLabel": "Uncertain tax positions" } } }, "localname": "LiabilityForUncertainTaxPositionsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicenseAndServiceMember": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License and Service [Member]", "terseLabel": "License and collaboration revenue" } } }, "localname": "LicenseAndServiceMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations", "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r15" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt and Capital Lease Obligations", "terseLabel": "Notes payable and obligations under capital leases" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.", "label": "Long-term Debt and Capital Lease Obligations, Current", "terseLabel": "Current portion of notes payable and obligations under capital leases" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligations including current maturities.", "label": "Long-term Debt and Capital Lease Obligations, Including Current Maturities", "terseLabel": "Fair Value Disclosure of notes payable and capital lease obligations" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r82", "r91" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Description of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/DescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r56" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows From Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r56" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows From Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r56", "r58", "r61" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r39", "r40", "r43", "r61", "r77", "r182", "r191" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Loss attributable to common stockholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity", "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations", "http://www.linkp.com/role/NetLossperCommonShareNetLossPerShareComputationDetails", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income and expense:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Restricted Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r49" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Miscellaneous (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForBrokerageFees": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for brokerage fees during the current period. This element is intended to represent the brokerage fees paid by and between financial industry participants.", "label": "Payments for Brokerage Fees", "terseLabel": "Fees and commissions" } } }, "localname": "PaymentsForBrokerageFees", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForCommissions": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for commissions during the current period.", "label": "Payments for Commissions", "terseLabel": "Commissions paid" } } }, "localname": "PaymentsForCommissions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r53" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r55", "r107" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "terseLabel": "Cash Payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Other costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r51" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchase of equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares or units awarded to employees for meeting certain performance targets.", "label": "Performance Shares [Member]", "verboseLabel": "Performance Stock" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r133", "r155" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Blank check preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Blank check preferred stock, authorized shares" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Blank check preferred stock, issued shares" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Blank check preferred stock, outstanding shares" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r17" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred Stock, Value, Outstanding", "terseLabel": "Blank check preferred stock, $0.01 par value: Authorized shares \u2014 5,000,000 at September 30, 2018 and December 31, 2017; issued and outstanding shares \u2014 0 at September 30, 2018 and December 31, 2017" } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r1", "r24", "r25" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r52" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Issuance of common stock, net of offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r50" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds on sale of equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r28", "r104" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r104", "r189" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r27", "r65", "r104" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r10", "r102" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.", "label": "Repayments of Debt and Capital Lease Obligations", "negatedTerseLabel": "Payments under capital lease obligations and principal payments on notes payable" } } }, "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r161", "r194" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r76" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "verboseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails", "http://www.linkp.com/role/NetLossperCommonShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringCharges" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Percentage reduction in force" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r60", "r106", "r110", "r114" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Expensed" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r107", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r119", "r187" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r123", "r124", "r125" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Grant revenue", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations", "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails", "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r69", "r129" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/Revenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of consideration recognized during the period for the milestone or milestones.", "label": "Revenue Recognition, Milestone Method, Revenue Recognized", "terseLabel": "Upfront cash payments" } } }, "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r64", "r65", "r66" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r45", "r92", "r93", "r99" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total operating revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "FInancing proceeds" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r76" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Common Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/NetLossperCommonShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Basic and Diluted Net Loss per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/NetLossperCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r70", "r72", "r73", "r79", "r80", "r81" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Schedule of New Accounting Pronouncements" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r28", "r104" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r108", "r109", "r112" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring Charges" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r107", "r113" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Restructuring and Related Costs" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r133", "r155" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions Used in Black-Scholes Pricing Model for New Grants" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in stock options.", "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "terseLabel": "Stock Option Activity" } } }, "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r59" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited / cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited/cancelled, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value per share (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested at end of period (in shares)", "periodStartLabel": "Unvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average grant date fair value at end of period (in dollars per share)", "periodStartLabel": "Weighted average grant date fair value at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "terseLabel": "Options exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend rate (percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Volatility rate, maximum (percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Volatility rate, minimum (percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk free interest rate, maximum (percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum (percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of additional shares authorized for issuance under an established share-based compensation plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase in number of shares authorized", "verboseLabel": "Authorized Shares Added" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares remained available for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Options expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value per share (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r138", "r155" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, weighted average exercise price at end of period (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r131", "r135" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails", "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeitured, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r151", "r156" ], "lang": { "en-US": { "role": { "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable, weighted average remaining contractual term, in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding, weighted average remaining contractual term, in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r136" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of awards vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.", "label": "Shares Paid for Tax Withholding for Share Based Compensation", "negatedTerseLabel": "Repurchase of common stock (shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r35", "r118" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity", "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity", "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r17", "r18", "r118", "r119" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Sales of shares under stock purchase plan (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r118", "r119" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of shares of common stock sold" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r118", "r119", "r140" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (in shares)", "terseLabel": "Exercise of stock options and restricted stock vested (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails", "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r17", "r18", "r118", "r119" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Sales of shares under stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r35", "r118", "r119" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Exercise of stock options and restricted stock vested" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r21", "r22", "r101" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets", "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flows information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r34", "r120" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r34", "r120" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r34", "r120", "r121" ], "calculation": { "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost: 88,734 and 58,566 shares at September 30, 2018 and December 31, 2017, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RevenuesEffectsofNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/RestructuringChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r83", "r84", "r86", "r87", "r88", "r89", "r90" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted average shares outstanding (in shares)", "verboseLabel": "Basic and diluted weighted-average shares (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations", "http://www.linkp.com/role/NetLossperCommonShareNetLossPerShareComputationDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=68054760&loc=d3e55295-109406" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5)(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r195": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.26(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" } }, "version": "2.0" } ZIP 60 0001126234-18-000140-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001126234-18-000140-xbrl.zip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end

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�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